<html><body><h1>Case: Messages In KBs</h1>

<p><b>Numeric Data Values:</b></p>
<table>
<tr><td width="200">Diabetes Testing</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HbA1C</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Glycosylated_Hemoglobin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;PPG</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Blood Chemistry</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;Chem7</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sodium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potassium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chloride</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bicarbonate</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BUN</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Creatinine</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;eGFR</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Glucose</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;Lipid Panel</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HDL_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LDL_Cholesterol</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calculated_LDL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Direct_Measure_LDL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Triglycerides</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Liver panel</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Albumin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alkaline_phosphatase</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SGOT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SGPT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total_Bilirubin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Chemistry panel misc</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Calcium</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Creatine_Phosphokinase_CPK_or_CK</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phosphorus</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uric_Acid</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B 12</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Urine chemistry</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Creatinine_Clearance</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Microalbumin</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">CHF tests</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;BNP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;NT_proBNP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Hematology</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;AGN</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;CBC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HCT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HGB</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;PLT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;WBC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Microbiology_Tests</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Hepatitis_B_Surface_Antigen</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Hepatitis_C_Status</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;HIV_Test</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Pulmonary_Function_Studies</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;DCL</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;DLCO</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;FEV1</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;FVC</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">respiratory gas exchange</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">target_HBA1c</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Urinalysis</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Urine_Alb/creat_Ratio_24h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Urine_ALB/CREAT_RATIO_spot</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineAlbumin_24H</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineAlbumin_SPOT</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_12h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_24h</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_Qualitative</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;UrineProtein_Spot</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">Vital_Signs</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Diastolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment_Diastolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DB_Diastolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Systolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment_Systolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DB_Systolic_BP</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;BMI</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Height</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;High_Cardiovascular_Risk</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Metabolic_Syndrome</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Pulse</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200">&nbsp;&nbsp;&nbsp;&nbsp;Weight</td><td width="200"></td><td width="200"><td></tr>
<tr><td width="200"><p>Others:</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> </p><table>
<tr><td width="200">Session_Time</td><td width="200">2015-02-17</td><td width="200">2015-2-17</td></tr>
</table><p>
<h1 align="center">Print Messages Guideline</h1>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Do All Guidelines
<p><b>Action Choices</b>
<ul>
<li><b>Select Guideline</b><br>
<ul>
<li><b>Lipid <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<li><b>HF <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<li><b>CKD <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<li><b>HTN <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<li><b>Glycemic Control <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
</ul>
<li><b>HF</b><br>
<ul>
<li><b>HF Dashboard Algorithm Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_HF_Class110353$*--><b>-   PM rec add AA and using ACE</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE inhibitor. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$ATHENA_HF_Class110388$*--><b>-   age > 70, dose adjustments may be necessary</b>  <i>Recommendation</i> : %#For patients older than 70 years be alert of the possible need for dose adjustment based on eGFR.#% </p><p><!--Message$ATHENA_HF_Class110823$*--><b>-   Combined use ACEI, ARB and aldosterone antagonist not rec</b>  <i>Primary_Recommendation</i> : %#Routine combined use of an ACEI, ARB, and aldosterone antagonist is NOT RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class170004$*--><b>-   Use of drugs adversely affect HF status Astronaut</b>  <i>Primary_Recommendation</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs (not aspirin), most antiarrhythmic drugs,  most
calcium channel blocking drugs (except amlodipine) and thiazolidinediones). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class230001$*--><b>-   ICD primary prev rec Stage C Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class230003$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class230005$*--><b>-   CRT when LVEF<=35% and QRS>=0.15s and LBBB Astronaut II</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class371546$*--><b>-   PM ARB (add or on) and pregnancy warning</b>  <i>Primary_Recommendation</i> : %#Angiotensin receptor blocker is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$ATHENA_HF_Class380470$*--><b>-   PM Rec BB stage C HF and on other BB</b>  <i>Recommendation</i> : %#Patient already has active prescription for a different beta blocker. Consider appropriateness of change to the recommended beta blocker.#% </p><p><!--Message$ATHENA_HF_Class390000$*--><b>-   PM Active prescription for ACEi and 80<=SBP<110</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP is between 80 and 110, evaluate continuing prescription for ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390004$*--><b>-   .PM active prescription ACE inhibitor and SBP<80</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP<80, consider STOPPING ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390605$*--><b>-   Add hydralazine SBP<110</b>  <i>Primary_Recommendation</i> : %#Would recommend add hydralazine but SBP is less than 110mmHg. Evaluate clinical significance#% </p><p><!--Message$ATHENA_HF_Class401993$*--><b>-   PM CKD stage 4 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 4. Evaluate clinical significance.#% </p><p><!--Message$KB_150996_Class0$*--><b>-   Rec add AA suppressed no NYHA or DM</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because 
patient is missing values for NYHA Class symptoms or presence of DM.#% </p><p><!--Message$KB_155357_Class35$*--><b>-   PM rec add AA and using ARB</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for angiotensin receptor blocker. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$KB_155357_Class59$*--><b>-   deleting nitrates because prescription for phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Should stop nitrates but continue hydralazine. Need to stop either nitrates or the phosphodiesterase inhibitors#% </p><p><!--Message$KB_155357_Class69$*--><b>-   PM on other BB rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Patient already has active prescription for a different beta blocker.  Consider appropriateness of change to the recommended beta blocker#% </p><p><!--Message$KB_155357_Class72$*--><b>-   PM on sotalol rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Note that patient has prescription for sotalol. Consider discussion with cardiology before changing beta blockers#% </p><p><!--Message$KB_222371_Class1$*--><b>-   Rec add AA suppressed K</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because patient is missing values for potassium#% </p><p><!--Message$KB_222371_Class3$*--><b>-   rec add hydralazine or nitrates suppressed no symptoms</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralaine and/or nitrates was not evaluated because patient is missing data for NYHA Class symptoms.#% </p><p><!--Message$KB_222371_Class4$*--><b>-   rec add AA suppressed no BNP</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist when patient has NYHA Class II symptoms was not evaluated because patient is missing values for BNP#% </p><p><!--Message$KB_222371_Class6$*--><b>-   rec add hydralazine and nitrates suppressed no Race</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralazine and/or isosobide dinitrates  to African Americans was not evaluated because patient is missing values for race#% </p><p><!--Message$KB_313397_Class14$*--><b>-   PM rec add ACEi CKD stage5 or eGFR>15</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class16$*--><b>-   PM Rec add ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor. Use caution if prescribing.#% </p><p><!--Message$KB_313397_Class18$*--><b>-   PM add ACEi and 20 percent increase creatinine after starting ACEi</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class22$*--><b>-   PM Rec add ACEi and active prescription for Aliskerin</b>  <i>Recommendation</i> : %#Patient has a prescription for aliskerin; evaluate clinical significance and impact of prescription for ACE inhibitor#% </p><p><!--Message$KB_313397_Class23$*--><b>-   PM Rec add ACE and presence K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_335875_Class22$*--><b>-   PM CKD stage 5 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 5. Evaluate clinical significance.#% </p><p><!--Message$KB_335875_Class8$*--><b>-   PM SBP<110 and (rec add BB or rec add AA)</b>  <i>Primary_Recommendation</i> : %#Most recent SBP less than 110mmHg. Evaluate clinical significance and therapeutic implications.#% </p><p><!--Message$KB_486502_Class0$*--><b>-   PM 20% increase of creatinine after starting ACE inhibitor</b>  <i>Recommendation</i> : %#Patient had an increase of more than 20% of creatinine (comparing pre ACE inhibitor value with peak value within 3m after starting ACE inhibitor) after starting ACE inhibitor.#% </p><p><!--Message$KB_486502_Class2$*--><b>-   PM Rec ADD ARB and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59; evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class3$*--><b>-   PM  hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_486502_Class6$*--><b>-   PM Rec ADD ACEi and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ACE inhibitor and frequency of monitoring labs.#% </p><p><!--Message$KB_502940_Class6$*--><b>-   PM Pregancy warning (add ACEi or on ACEi)</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status#% </p><p><!--Message$KB_243202_Class1$*--><b>-   Out of scope message</b>  <i>Primary_Recommendation</i> : %#HF patients with preserved EJ function, LVEF>40) or without an LVEF value are out of scope of this CDS.#% </p><p><!--Message$KB_261275_Class13$*--><b>-   BB substitution</b>  <i>Recommendation</i> : %#Patient is taking a beta blocker that is not one of the recommeded beta blockers for heart failure patients. Evaluate susbtitution with carvedilol, bisoprolol or sustained release metoprolol succinate.#% </p></li><li>[Parameterized Messages]  <p><!--Parameterized_Message$ATHENA_HF_Class390610$*--><b>-   most recent SBP<110 and on hydralazine</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of hydralazine.#%</p>    <p><!--Parameterized_Message$ATHENA_HF_Class440007$*--><b>-   SBP<80 and on ARB</b>%#Patient's most recent SBP (date ?date) was less than 80mmHg. Consider evaluating dose of angiotensin receptor blocker.#%</p>    <p><!--Parameterized_Message$KB_155357_Class13$*--><b>-   most recent K >5 and on ARB</b>%#Patient's most recent potassium (date ?date) was greater than 5; consider discontinuing angiotensin receptor blocker or other drugs contributing to hyperkalemia. Evaluate clinical significance.#%</p>    <p><!--Parameterized_Message$KB_155357_Class16$*--><b>-   SBP<110 and on ARB</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of angiotensin receptor blocker.#%</p>    <p><!--Parameterized_Message$KB_155357_Class21$*--><b>-   Female, most recent creatinine >=2.3, on ACE</b>%#Patient has active prescription for ACE inhibitorand most recent creatinine (date ?date) is greater than 2.2.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class28$*--><b>-   Male, most recent creatinine >=2.5, on ACE</b>%#Patient has active prescription for ACE inhibitor and most recent creatinine (date ?date) is greater than 2.4.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class31$*--><b>-   Female, most recent creatinine >=2.3, on ARB</b>%#Patient has active prescription for angiotensin receptor blocker and most recent creatinine (date ?date) is greater than 2.2.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class34$*--><b>-   Male, most recent creatinine >=2.5, on ARB</b>%#Patient has active prescription for an angiotensin receptor blocker and most recent creatinine (date ?date) is greater than 2.4.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class7$*--><b>-   most recent K>5 and on ACE inhibitor</b>%#Patient's most recent potassium (date ?date) was greater than 5; consider discontinuing ACE inhibitor or other drugs contributing to hyperkalemia. Evaluate clinical significance.#%</p>    <p><!--Parameterized_Message$KB_212231_Class2$*--><b>-   SBP<110 and on ACE inhibitor</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of ACE inhibitor.#%</p>    <p><!--Parameterized_Message$KB_335875_Class14$*--><b>-   Most recent eGFR<30 and on ACE</b>%#Patient has active prescription for ACE inhibitor and most recent eGFR (date ?date) is less than 30.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_335875_Class21$*--><b>-   Most recent eGFR<30 and on ARB</b>%#Patient has active prescription for an angiotensin receptor blocker and most recent eGFR (date ?date) is less than 30.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_783525_Class3$*--><b>-   ?label</b>%#Patient is taking ?harmful_HF_drug that may be harmful to those with HF.#%</p>   </li></ul>
<li><b>HF Dashboard Consultation Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_HF_Class380817$*--><b>-   PM on nitrates and  hydralazine and phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Patient has active prescriptions for hydralazine, a nitrate and a phosphodiesterase inhibitor. Must discontinue either nitrate or phsophodiesterase inhibitor.#% </p><p><!--Message$ATHENA_HF_Class440002$*--><b>-   PM: most recent K >5</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE Inhibitor and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class440004$*--><b>-   PM: On ARB and K>5</b>  <i>Recommendation</i> : %#Patient has active prescription for and ARB and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$KB_313397_Class11$*--><b>-   PM On ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor.#% </p><p><!--Message$KB_313397_Class19$*--><b>-   PM on ACEi and 20 percent increase in creatinine after starting ACEi or ARB</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class20$*--><b>-   PM on ACE and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class24$*--><b>-   PM On ACEi and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class7$*--><b>-   PM on ACEi and CKD stage 3 or 4 or 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class9$*--><b>-   PM on ace and ckd stage 5 or eGFR<15</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_486502_Class10$*--><b>-   PM On ARB and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class12$*--><b>-   PM on ARB and 20 percent increase in creatinine after starting ARB or ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for aldosterone antagonist blocker.#% </p><p><!--Message$KB_486502_Class15$*--><b>-   PM on ARB and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class17$*--><b>-   PM On ARB and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class5$*--><b>-   PM On ARB and CKD stage 3/4 OR 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class8$*--><b>-   PM on ARB and (CKD stage 5 OR most recent  eGFR<15)</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_234689_Class0$*--><b>-   diuretcs out of scope</b>  <i>Primary_Recommendation</i> : %#HF with reduced EF with fluid retention is an indication for diuretic therapy, but is beyond the scope of this project recommendations.#% </p></li><li>[Parameterized Messages] </li></ul>
<li><b>HF Dashboard collateral messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_HF_Class170020$*--><b>-   Presence of NSAID HF collateral message Astronaut</b>  <i>Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class401702$*--><b>-   add nitrates age>=70</b>  <i>Recommendation</i> : %#Isosorbide dinitrate  may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401845$*--><b>-   add hydralazine age>=70</b>  <i>Recommendation</i> : %#Hidralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class110380$*--><b>-   monitoring renal function and K for ACEI</b>  <i>Recommendation</i> : %#Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with preexisting hypotension, hyponatremia, diabetes
mellitus, or azotemia or in those taking potassium
supplements.#% </p><p><!--Message$ATHENA_HF_Class240016$*--><b>-   rec add hyralazine_nitrates Astronaut II</b>  <i>Class I</i> : %#The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III or IIV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70167$*--><b>-   Aldosterone antagonist warning</b>  <i>Recommendation</i> : %#Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.#% </p><p><!--Message$KB_899077_Class2$*--><b>-   rec add ACE-I dose based on 2013 ACCF/AHA Guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific ACE-I starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.#% </p><p><!--Message$KB_899077_Class4$*--><b>-   rec add ARB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below)  for specific ARB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
candesartan starting dose 4-8 mg/once; max dose 32 mg once
losartan starting dose 25-50 once; max dose 50-150 mg once
valsartan 20-40 mg twice; max dose 160 mg twice#% </p><p><!--Message$KB_899077_Class5$*--><b>-   rec add AA based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific AA starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
spironolactone starting dose 12.5 0 25.0 once; max dose 25 mg once or twice
eplerenone starting dose 25 mg once; max dose 50 mg once#% </p><p><!--Message$KB_899077_Class6$*--><b>-   rec add BB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
bisoprolol starting dose 1.25 mg once; max dose 10 mg once
carvedilol starting dose 3.125 mg twice; max dose 50 mg twice
carvedilol CR starting dose 10 mg once; max dose 80 mg once
metoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once#% </p><p><!--Message$KB_899077_Class7$*--><b>-   rec add hydralazine and nitrates based on 2013 ACCF/AHA guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific hydraline and nitrates starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
fixed dose combination starting dose 37.5 mg hydralazine + 20 mg isosorbide dintrate/ 3x; max dose 75 mg hydralazine + 40 mg isosorbide dinitrate 3x dialy
hydralazine and isosorbide dinitrate sstarting dose hydralazine 25-50 mg 3 or 4 x daily and isosorbide dintrate 20 to 30 mg 3 or 4 x dialy; max dose hydralazine 300 mg daily in divided doses and isosorbide dintrate 120 mg daily in divided doses#% </p></li><li>[Parameterized Messages] </li></ul>
</ul>
<li><b>Lipid</b><br>
<ul>
<li><b>Lipid Dashboard Consultation Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$Lipid_dashboard_Class300000$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age related changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$Lipid_dashboard_Class110003$*--><b>-   Women ages 18-50:  pregnant women</b>  <i>Primary_Recommendation</i> : %#Pregnant women and nursing mothers are out of scope for this CDS.#% </p><p><!--Message$Lipid_dashboard_Class110008$*--><b>-   Treat hi TG mgs</b>  <i>Primary_Recommendation</i> : %#Triglycerides are >=500 mg/dL.  Evaluate and treat.#% </p><p><!--Message$Lipid_dashboard_Class110011$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Consider therapeutic life style changes <link to TLC>#% </p><p><!--Message$Lipid_dashboard_Class120001$*--><b>-   Order baseline CK?</b>  <i>Recommendation</i> : %#Baseline measurement of creatinine kinase (CK) is reasonable for those individuals believed to be at increased risk for adverse muscle events based upon personal or family history of statin intolerance or muscle disease or concomitant drug therapy that might increase the risk for myopathy.#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p></li><li>[Parameterized Messages]  <p><!--Parameterized_Message$library_Class160004$*--><b>-   Give warning when There exists medication whose daily dose is greater than the upper limit of maximum recommended dose range</b>%#The daily dose of medications ?meds is above the maximum recommended dose. Please review.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class120004$*--><b>-   ?label</b>%#Patient is on ?LDL_elevating_drug that may elevate LDL-C. Evaluate and treat.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class130005$*--><b>-   ?label</b>%#Patient has a diagnosis of ?LDL_elevating_dx that may elevate LDL-C. Evaluate and treat.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class340005$*--><b>-   Duplicate drug message</b>%#The patient has more than one prescription for ?dup_drug..  Foreach of the drugs mentioned, dosages were summed for the purposes of these recommendations#%</p>   </li></ul>
<li><b>Lipid Dashboard Algorithm Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$Lipid_dashboard_Class250022$*--><b>-   Cannot tolerate formulary statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate formulary statin, consider non-formulary statin#% </p><p><!--Message$Lipid_dashboard_Class280020$*--><b>-   Pres niacin > 1gm/day and Pres statin</b>  <i>Primary_Recommendation</i> : %#Patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class280021$*--><b>-   Pres fibrate and Pres statin</b>  <i>Recommendation</i> : %#Patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class100010$*--><b>-   Pres hem stroke msg, risk/benefit of increasing dose</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke but is not at goal..  Consider risk/benefit of increasing statin dose or intensity.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100011$*--><b>-   Increase dose to moderate intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has DM.  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class100012$*--><b>-   Increase dose to high intensity msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider increasing dose to high intensity dose.#% </p><p><!--Message$Lipid_dashboard_Class100013$*--><b>-   Substitute high intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider substituting high intensity atorvastatin or rosuvastatin in place of existing statin#% </p><p><!--Message$Lipid_dashboard_Class100014$*--><b>-   Intolerance to increase statin dose msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of statns, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>#% </p><p><!--Message$Lipid_dashboard_Class180005$*--><b>-   Goals achieved</b>  <i>Primary_Recommendation</i> : %#Patient is on moderate or high dose statin or LDL<100.  Goal achieved#% </p><p><!--Message$Lipid_dashboard_Class230001$*--><b>-   No statin rec for add statin</b>  <i>Primary_Recommendation</i> : %#No statin can be recommended..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class240017$*--><b>-   Absence of DM and ASDVD out of scope msg</b>  <i>Primary_Recommendation</i> : %#Patient does not have DM or ASCVD and is out of scope of this CDS.#% </p><p><!--Message$Lipid_dashboard_Class240022$*--><b>-   > 1 statin cannot generate recommendations msg</b>  <i>Primary_Recommendation</i> : %#We are unable to generate recommendations because patient is taking more than 1 statin, which is generally not recommended.#% </p><p><!--Message$Lipid_dashboard_Class250010$*--><b>-   Follow up in 4-12 weeks</b>  <i>Recommendation</i> : %#Follow up in 4-12 weeks#% </p><p><!--Message$Lipid_dashboard_Class250023$*--><b>-   Rsik/benefit msg for frail, abnormal liver/renal, Asian</b>  <i>Primary_Recommendation</i> : %#Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p><p><!--Message$Lipid_dashboard_Class260010$*--><b>-   Stop contraindicated statin</b>  <i>Primary_Recommendation</i> : %#Presence of contraindication to statin.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class270009$*--><b>-   Intolerance to increase high intensity statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of atrovastatin or rosuvastatin statns, consider  <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class300117$*--><b>-   Prim msg:  statin DDI pres of statin</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about continuing use of statin or increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class330001$*--><b>-   Increase dose to moderate intensity ASCVD</b>  <i>Primary_Recommendation</i> : %#Patient has ASCVD and is over age 75..  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.  If patient cannot tolerate increaseing dose, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>..#% </p><p><!--Message$Lipid_dashboard_Class420000$*--><b>-   Statin rec DM patients if not 40<=age<=75</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75  (inclusinve) derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range.
Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian.#% </p><p><!--Message$Lipid_dashboard_Class430000$*--><b>-   Substitute high intensity statin for low dose statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity statns (atorvastatin>=40mg, rosuvastatin>=20mg), consider increasing dose to moderate intensity (atorvastatin >=10mg, rosuvastatin >=5 mg, simvastatin >=20 mg, lovastatin >=40 mg, fluvastatin >=80 mg.)  or<a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class70046$*--><b>-   Patient on drug that interacts w statin</b>  <i>Primary_Recommendation</i> : %#Patient is on a 
<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>  that increases the risk of myopathy; please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class70047$*--><b>-   Patient refuses statin</b>  <i>Recommendation</i> : %#If patient refuses statin or cannot tolerate statin, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p></li><li>[Parameterized Messages] </li></ul>
<li><b>Lipid Dashboard collateral messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$Lipid_dashboard_Class160013$*--><b>-   Presence of fibric acid msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking a fibric acid (fenofibrate, gemfibrozil or clofibrate) which increases risk of myopathy.  Consider switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class160023$*--><b>-   Presence of niacin >1gm/day msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class230022$*--><b>-   ASCVD Prim message moderate intensity statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease with history of hemorrhagic stroke oris over age.75. Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class30052$*--><b>-   DM Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has diabetes without atherosclerotic cardiovascular disease and 40<=age<=75.  Moderate intensity statins are recommended. Formulary moderate intensity statin are atorvastatin 10 mg simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg.  Non formulary moderate intensity statins are rosuvastatin 5 mg, fluvastatin 40 mg.#% </p><p><!--Message$Lipid_dashboard_Class360002$*--><b>-   Blocked add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class360003$*--><b>-   Blocked add statin missing eGFR past 3 mo</b>  <i>Recommendation</i> : %#We would normaly recommend adding a statin, but we are missing eGFR in the past 3 months..#% </p><p><!--Message$Lipid_dashboard_Class360006$*--><b>-   Blocked incr dose missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend increasing dose of a statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class410212$*--><b>-   ASCVD Prim Msg to start high dose statin (not conditional)</b>  <i>Primary_Recommendation</i> : %#High intensity statins are recommended for patients with atherosclerotic cardiovascular disease.   Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p></li><li>[Parameterized Messages] </li></ul>
</ul>
<li><b>HTN</b><br>
<ul>
<li><b>HTN Dashboard Algorithm Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p></li><li>[Parameterized Messages] </li></ul>
<li><b>HTN Dashboard Consultation Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_HTN_Dashboard_Class10035$*--><b>-   Ischemic Heart disease and DBP<60 and BP at target</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90004$*--><b>-   PM: K>5 and active prescription for ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an ACE Inhibitor and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90006$*--><b>-   PM: K>5 and active prescription for ARB</b>  <i>Recommendation</i> : %#Patient has an active prescription for an ARB and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10048$*--><b>-   Above Dashboard Target below JNC8 Target</b>  <i>Primary_Recommendation</i> : %#NEED TO DECIDE WHAT MESSAGE TO GIVE....

NEED TO DECIDE IF WILL DO SUBSTITUTIONS#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80010$*--><b>-   >4 active anti-hypertensive meds (broad) AND BP<220/110 AND absence IIHD AND DBP>=60</b>  <i>Recommendation</i> : %#Patient on more than 4 antihypertensive drugs. Refer to hypertension specialist.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80017$*--><b>-   BP below Dashboard and JNC target</b>  <i>Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_372688$*--><b>-   Ischemic Heart disease and DBP<60 and BP not at target</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_43301$*--><b>-   SBP>=220 or DBP>=115, urgent attention</b>  <i>Primary_Recommendation</i> : %#SBP>220 or DBP>115 so treatment recommendations are beyond the scope of this program. If MARKED BP ELEVATION is confirmed, then the patient needs further TREATMENT and EARLY FOLLOW-UP to MONITOR THERAPEUTIC EFFICACY. #% </p></li><li>[Parameterized Messages] </li></ul>
<li><b>HTN Dashboard collateral messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_CKD_Class100006$*--><b>-   PTH elevated, not normal Ca or phosphate or vitamin D labs</b>  <i>Primary_Recommendation</i> : %#PTH is elevated and Ca or phosphate or vitamin D labs are not within normal range.  Please assess.#% </p><p><!--Message$ATHENA_CKD_Class10016$*--><b>-   ACR<30 and BP>140/90</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal of <=140/90 when ACR<30.#% </p><p><!--Message$ATHENA_CKD_Class10018$*--><b>-   ACR>=30 and BP>130/80</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal of <=130/80 when ACR>=30.#% </p><p><!--Message$ATHENA_CKD_Class110001$*--><b>-   Msg to order vitamin D lab when PTH elevated</b>  <i>Recommendation</i> : %#PTH is elevated and vitamin D levels need to be assessed but lab is missing.  Please order vitamin D lab.#% </p><p><!--Message$ATHENA_CKD_Class140002$*--><b>-   blocked msg to add K</b>  <i>Recommendation</i> : %#We would normally be ordering ACE/ARB, but cannot do so because we are missing K in the past month.#% </p><p><!--Message$ATHENA_CKD_Class140005$*--><b>-   blocked message to measure BP</b>  <i>Recommendation</i> : %#We would normally be recommending ACE/ARB, but cannot do so because we are missing BP measurements in the past month#% </p><p><!--Message$ATHENA_CKD_Class170261$*--><b>-   ACR>300 refer</b>  <i>Primary_Recommendation</i> : %#ACR>300.  Please refer to nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40030$*--><b>-   Pres of ASCVD msg to consider antiplatelet</b>  <i>Recommendation</i> : %#Consider antiplatelet therapy for patients with CKD and atherosclerotic vascular disease.#% </p><p><!--Message$ATHENA_CKD_Class40032$*--><b>-   Pres JNC8 BP meds msg</b>  <i>Recommendation</i> : %#Patients with CKD and on BP medications need to be aware of the possiblity of postural hypotension/#% </p><p><!--Message$ATHENA_CKD_Class40034$*--><b>-   Age>75 warning msg</b>  <i>Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_CKD_Class60014$*--><b>-   ALERT:  Calcium outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Calcium level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60016$*--><b>-   ALERT:  Phosphate outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Phosphate level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60018$*--><b>-   ALERT: Alk Phos outside normal range</b>  <i>Recommendation</i> : %#ALERT: Alkaline Phosphatase level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class70011$*--><b>-   Msg to order HGB annually</b>  <i>Recommendation</i> : %#Patients with CKD and 30<=eGFR<60 are recommended to have their HGB checked annually.#% </p><p><!--Message$ATHENA_CKD_Class70012$*--><b>-   Msg to order HGB lab as clinically appropriate</b>  <i>Recommendation</i> : %#Missing HGB lab.  Order as clinically appropriate for CKD patients with eGFR>=60.#% </p><p><!--Message$ATHENA_CKD_Class70016$*--><b>-   Dx of anemia</b>  <i>Primary_Recommendation</i> : %#ALERT:  Patient has anemia:   HGB<13 (male) or HGB<12 (femiale).#% </p><p><!--Message$ATHENA_CKD_Class90000$*--><b>-   ALERT:  bicarb outside normal range</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate values (CO2) are outside the normal range#% </p><p><!--Message$ATHENA_CKD_Class90006$*--><b>-   ALERT:  PTH values outside normal range</b>  <i>Recommendation</i> : %#ALERT:  PTH  level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Instance_50037$*--><b>-   Please complete mALB/creatinine ratio screening</b>  <i>Recommendation</i> : %#Please complete urine screening for CKD#% </p><p><!--Message$ATHENA_CKD_Instance_50038$*--><b>-   Please complete creatinine screening</b>  <i>Recommendation</i> : %#Please complete creatinine screening#% </p><p><!--Message$ATHENA_GlycemicControl_Class150033$*--><b>-   On metformin check serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class160003$*--><b>-   On metformin check CBC</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have CBC measured  at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class210400$*--><b>-   Check serum creatiine if on metformin</b>  <i>Recommendation</i> : %#Check serum creatinine yearly if on metformin#% </p><p><!--Message$ATHENA_GlycemicControl_Class230026$*--><b>-   Start insulin msg in presence of SU</b>  <i>Recommendation</i> : %#If adding Insulin in the presence of SU, titrate SU down while titrating insulin up.#% </p><p><!--Message$ATHENA_GlycemicControl_Class290002$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_GlycemicControl_Class300002$*--><b>-   Glyburide serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Glyburide have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class310002$*--><b>-   Msg to order HbA1c</b>  <i>Recommendation</i> : %#HbA1c is either missing or older than 1 year; CDS cannot give recommendations.  Please order HbA1c.#% </p><p><!--Message$ATHENA_GlycemicControl_Class350001$*--><b>-   Disclaimer Insulin</b>  <i>Primary_Recommendation</i> : %#Patient is on Insulin; management of insulin is outside the scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class360002$*--><b>-   Disclaimer HbA1c btwn 6 and 9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class430001$*--><b>-   ALERT:  30<eGFR<60 or creatinine 1.5- 2.5 male etc</b>  <i>Primary_Recommendation</i> : %#Patient's renal function is impaired, it is extremely important to monitor renal function and potassium#% </p><p><!--Message$ATHENA_GlycemicControl_Class440011$*--><b>-   collateral msg 30<eGFR<60 or 1.5<creatinine<2.5 male or 1.3<creatinine<2.3 female</b>  <i>Recommendation</i> : %#We are recommending use of ACE/ARB, but be reminded to obtain new labs within 1-2 weeks#% </p><p><!--Message$ATHENA_GlycemicControl_Class440018$*--><b>-   collateral msage eGFR>=60, low creatinine</b>  <i>Recommendation</i> : %#We are recommending use of ACE/ARB, but be reminded to obtain new labs within 1-2 weeks#% </p><p><!--Message$ATHENA_GlycemicControl_Class480007$*--><b>-   Absence in past month eGFR and creat and K and SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR, K and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480008$*--><b>-   Absence in past month eGFR and creat and K and Presence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR and K within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480009$*--><b>-   Absence in past month eGFR and creat and SBP and Presence K</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480010$*--><b>-   Absence in past month  K and SBP and Presence of eGFR</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:   K and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480011$*--><b>-   Absence in past month eGFR and creat and Presence K and SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:   eGFR within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480012$*--><b>-   Presence in past month eGFR or creat and K and Absence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals: BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480013$*--><b>-   Presence in past month eGFR or creat and Absence K and Presence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:. K within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class500000$*--><b>-   Absence of eGFR cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR and creatinine labs within past month are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class50002$*--><b>-   On Metformin check serum B12 level</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum B12 checked at least every 2 years.#% </p><p><!--Message$ATHENA_GlycemicControl_Class540025$*--><b>-   Follow up in 3 months if rec add drug</b>  <i>Recommendation</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class550037$*--><b>-   Absence of bicarb cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because bicarb within past year is missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550038$*--><b>-   Absence of SGOT and SGOT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because SGOT and SGPT  labs within past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550039$*--><b>-   Absence of eGFR and bicarb cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and bicarb labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550041$*--><b>-   Absence of eGFR and SGOT/SGPT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550043$*--><b>-   Absence of bicarb and SGOT/SGPT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because bicarb and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550045$*--><b>-   Absence of eGFR, bicarb, SGOT/SGPT</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and bicarb and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60001$*--><b>-   add chlorpropamide elderly</b>  <i>Recommendation</i> : %#100mg/day-125mg/day for elderly patients.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60002$*--><b>-   add chlorpropamide middle aged</b>  <i>Recommendation</i> : %#250mg/day in the mild-to-moderately severe, middle aged, stable patient#% </p><p><!--Message$ATHENA_GlycemicControl_Class60005$*--><b>-   add tolazamide age>=65</b>  <i>Recommendation</i> : %#100mg/day for elderly patients#% </p><p><!--Message$ATHENA_GlycemicControl_Class60006$*--><b>-   add tolazamide age<65</b>  <i>Recommendation</i> : %#100mg/day-250mg/day in the mild-to-moderately severe patient#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class730029$*--><b>-   Missing creatinine past year and age>65</b>  <i>Recommendation</i> : %#We would normally increase the dose of gliburide, but patient's agie is >=65 and creatinine lab within the past year is missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class850006$*--><b>-   Presence of gemfibrozil and thiazolidinedione bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking gemfibrozil and thiazolidinedione, which are contraindciated.  Please evaluate#% </p><p><!--Message$ATHENA_GlycemicControl_Class850007$*--><b>-   Presence of SGLT2 inhibitor and UGT2 inducer bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking an SGLT2 inhibitor (canaglifozin or empaflifozin) and a UDG2 inducer which are contraindciated.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_HF_Class100014$*--><b>-   Fluid management if using diuretics</b>  <i>Class I</i> : %#Continue to manage diuretics and salt restriction for optimal volume control.  (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class100015$*--><b>-   fluid management NOT on diuretics</b>  <i>Class I</i> : %#Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class100847$*--><b>-   rec cardiac resynchronization therapy</b>  <i>Class I</i> : %#Patients with LVEF of less than or equal to 35%, sinus rhythm, and NYHA functional class III ambulatory class IV symptoms
despite recommended optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive cardiac resynchronization therapy, with or without an ICD, unless contraindicated (203–218). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class110348$*--><b>-   LVEF<30</b>  <i>Recommendation</i> : %#Most recent LVEF <30, patient should have a cardiac evaluation.#% </p><p><!--Message$ATHENA_HF_Class110350$*--><b>-   30<=LVEF<40</b>  <i>Recommendation</i> : %#Patient has a low LVEF, consider cardiac evaluation or repeat left ventricular ejection fraction in about 3 months.#% </p><p><!--Message$ATHENA_HF_Class110353$*--><b>-   PM rec add AA and using ACE</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE inhibitor. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$ATHENA_HF_Class110361$*--><b>-   add bb before inc dose ace</b>  <i>Recommendation</i> : %#In clinical trial, adding a beta blocker showed greater improvement in heart failure symptoms and outcomes versus increasing dose of ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class110363$*--><b>-   ICD info to discuss with patient</b>  <i>Recommendation</i> : %#Discussion should clarify in simple words exactly what an ICD does and doesn’t do.
Of every 100 patients like yourself, during the next 5 years 7-8 will live longer because of device but:    
- 28-30 will die anyway
- Most (>50%) will never use their device but we have no sure way to know who they are
- 8-10 will have an inappropriate shock which may increase the risk of dying 
- 4-10 will have other complications, some of which will be fatal
- Your heart failure is more likely to worsen
- Someday you may wish to have the defibrillation feature inactivated#% </p><p><!--Message$ATHENA_HF_Class110366$*--><b>-   expectation of survival</b>  <i>Recommendation</i> : %#When evaluating expectation of survival with a good functional status, it is important that this estimation be based on non-cardiac survival.#% </p><p><!--Message$ATHENA_HF_Class110368$*--><b>-   order ecg</b>  <i>Recommendation</i> : %#Order ECG to determine QRS duration and candidacy for a CRT.#% </p><p><!--Message$ATHENA_HF_Class110371$*--><b>-   inital dose recommendation digoxin when age>70, egfr<30 or lean body mass.</b>  <i>Recommendation</i> : %#Initial recommended dose of digoxin is 0.125mcg daily (or every other day).#% </p><p><!--Message$ATHENA_HF_Class110388$*--><b>-   age > 70, dose adjustments may be necessary</b>  <i>Recommendation</i> : %#For patients older than 70 years be alert of the possible need for dose adjustment based on eGFR.#% </p><p><!--Message$ATHENA_HF_Class110823$*--><b>-   Combined use ACEI, ARB and aldosterone antagonist not rec</b>  <i>Primary_Recommendation</i> : %#Routine combined use of an ACEI, ARB, and aldosterone antagonist is NOT RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class120883$*--><b>-   Acute MI, use contemporary guidelines</b>  <i>Class I</i> : %#Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).#% </p><p><!--Message$ATHENA_HF_Class124168$*--><b>-   Use of drugs adversely affect HF status</b>  <i>Class I</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most
calcium channel blocking drugs). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class160001$*--><b>-   CRT NYHA classification Astronaut</b>  <i>Recommendation</i> : %#Functional Capacity .....................................................Objective Assessment
Class I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class160002$*--><b>-   NYHA classification</b>  <i>Recommendation</i> : %#NYHA Class I...............................Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	/A. No objective evidence of cardiovascular disease.

NYHA Class II............................. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	/	B. Objective evidence of minimal cardiovascular disease.

NYHA Class III. .............................Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	/C. Objective evidence of moderately severe cardiovascular disease.

NYHA Class IV. ...........................Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.		/D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class160433$*--><b>-   ICD primary prev rec Stage C Astronaut</b>  <i>Class I</i> : %#Class I:  Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and ASSUMING NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.#% </p><p><!--Message$ATHENA_HF_Class170004$*--><b>-   Use of drugs adversely affect HF status Astronaut</b>  <i>Primary_Recommendation</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs (not aspirin), most antiarrhythmic drugs,  most
calcium channel blocking drugs (except amlodipine) and thiazolidinediones). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class170011$*--><b>-   Use of ACE inhibitor and NSAID Astronaut</b>  <i>Primary_Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170016$*--><b>-   Add ACE inhibitor while on NSAID not aspirin primary message</b>  <i>Primary_Recommendation</i> : %#Presence of NSAID detected.  Warning:  Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170020$*--><b>-   Presence of NSAID HF collateral message Astronaut</b>  <i>Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170336$*--><b>-   CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation Astronaut</b>  <i>Class II a</i> : %#Class IIa:  For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of those patients with NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.#% </p><p><!--Message$ATHENA_HF_Class230001$*--><b>-   ICD primary prev rec Stage C Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class230003$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class230005$*--><b>-   CRT when LVEF<=35% and QRS>=0.15s and LBBB Astronaut II</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class371546$*--><b>-   PM ARB (add or on) and pregnancy warning</b>  <i>Primary_Recommendation</i> : %#Angiotensin receptor blocker is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$ATHENA_HF_Class380470$*--><b>-   PM Rec BB stage C HF and on other BB</b>  <i>Recommendation</i> : %#Patient already has active prescription for a different beta blocker. Consider appropriateness of change to the recommended beta blocker.#% </p><p><!--Message$ATHENA_HF_Class380817$*--><b>-   PM on nitrates and  hydralazine and phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Patient has active prescriptions for hydralazine, a nitrate and a phosphodiesterase inhibitor. Must discontinue either nitrate or phsophodiesterase inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390000$*--><b>-   PM Active prescription for ACEi and 80<=SBP<110</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP is between 80 and 110, evaluate continuing prescription for ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390004$*--><b>-   .PM active prescription ACE inhibitor and SBP<80</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP<80, consider STOPPING ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390015$*--><b>-   Absence labs will not rec ACEi</b>  <i>Recommendation</i> : %#Patient does not have creatinine, eGFR and/or potassium in past year. ACE could have been recommended if labs existed. Please order labs.#% </p><p><!--Message$ATHENA_HF_Class390605$*--><b>-   Add hydralazine SBP<110</b>  <i>Primary_Recommendation</i> : %#Would recommend add hydralazine but SBP is less than 110mmHg. Evaluate clinical significance#% </p><p><!--Message$ATHENA_HF_Class401702$*--><b>-   add nitrates age>=70</b>  <i>Recommendation</i> : %#Isosorbide dinitrate  may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401845$*--><b>-   add hydralazine age>=70</b>  <i>Recommendation</i> : %#Hidralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401993$*--><b>-   PM CKD stage 4 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 4. Evaluate clinical significance.#% </p><p><!--Message$ATHENA_HF_Class440002$*--><b>-   PM: most recent K >5</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE Inhibitor and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class440004$*--><b>-   PM: On ARB and K>5</b>  <i>Recommendation</i> : %#Patient has active prescription for and ARB and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class50052$*--><b>-   Refer cardiology for ICD (ischemic cardiomyopathy)</b>  <i>Class II a</i> : %#Placement of an ICD is reasonable in patients with ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of 30% or less, are NYHA functional class I on chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. 
If this is the case, refer to cardiology.#% </p><p><!--Message$ATHENA_HF_Class50058$*--><b>-   Refer cardiology for ICD (non-ischemic cardiomyopathy)</b>  <i>Class II b</i> : %#Placement of an ICD might be considered in patients without HF who have nonischemic cardiomyopathy and an LVEF less than or equal to 30% who are in NYHA functional class I with chronic optimal medical therapy and have a reasonable expectation of survival with good functional status for more than 1 year.
If this is the case refer to cardiology.#% </p><p><!--Message$ATHENA_HF_Class50062$*--><b>-   valvular disease</b>  <i>Class I</i> : %#Valve replacement or repair should be recommended for patients with hemodynamically significant valvular stenosis or regurgitation and no symptoms of HF in accordance with contemporary guidelines.#% </p><p><!--Message$ATHENA_HF_Class50065$*--><b>-   coronary revascularization</b>  <i>Class I</i> : %#Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).#% </p><p><!--Message$ATHENA_HF_Class50099$*--><b>-   ICD secondary prevention</b>  <i>Recommendation</i> : %#Patient has an indication for an implantable cardioverter-defibrillator, refer to cardiology.
 (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70139$*--><b>-   ICD secondary prev rec Stage C</b>  <i>Class I</i> : %#An implantable cardioverter-defibrillator is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of HF and reduced LVEF who have a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70140$*--><b>-   ICD primary prev rec Stage C</b>  <i>Class I</i> : %#Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70170$*--><b>-   atrial fibrillation and HF</b>  <i>Class II a</i> : %#It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70188$*--><b>-   CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation</b>  <i>Class II a</i> : %#For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70193$*--><b>-   CRT  frequent dependence ventricular pacing</b>  <i>Class II a</i> : %#For patients with LVEF of less than or equal to 35% with NYHA functional class III or ambulatory class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable (2). (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70197$*--><b>-   nutritional supplements and stage C</b>  <i>Class III</i> : %#Use of NUTRITIONAL SUPPLEMENTS as treatment for HF is NOT INDICATED in patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70199$*--><b>-   hormonal therapies and stage C</b>  <i>Class III</i> : %#HORMONAL THERAPIES other than to replete deficiencies are NOT RECOMMENDED and may be harmful to patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$KB_150996_Class0$*--><b>-   Rec add AA suppressed no NYHA or DM</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because 
patient is missing values for NYHA Class symptoms or presence of DM.#% </p><p><!--Message$KB_155357_Class35$*--><b>-   PM rec add AA and using ARB</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for angiotensin receptor blocker. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$KB_155357_Class52$*--><b>-   Age >=70, add hydralazine</b>  <i>Recommendation</i> : %#Hydralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$KB_155357_Class59$*--><b>-   deleting nitrates because prescription for phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Should stop nitrates but continue hydralazine. Need to stop either nitrates or the phosphodiesterase inhibitors#% </p><p><!--Message$KB_155357_Class69$*--><b>-   PM on other BB rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Patient already has active prescription for a different beta blocker.  Consider appropriateness of change to the recommended beta blocker#% </p><p><!--Message$KB_155357_Class72$*--><b>-   PM on sotalol rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Note that patient has prescription for sotalol. Consider discussion with cardiology before changing beta blockers#% </p><p><!--Message$KB_222371_Class1$*--><b>-   Rec add AA suppressed K</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because patient is missing values for potassium#% </p><p><!--Message$KB_222371_Class3$*--><b>-   rec add hydralazine or nitrates suppressed no symptoms</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralaine and/or nitrates was not evaluated because patient is missing data for NYHA Class symptoms.#% </p><p><!--Message$KB_222371_Class4$*--><b>-   rec add AA suppressed no BNP</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist when patient has NYHA Class II symptoms was not evaluated because patient is missing values for BNP#% </p><p><!--Message$KB_222371_Class6$*--><b>-   rec add hydralazine and nitrates suppressed no Race</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralazine and/or isosobide dinitrates  to African Americans was not evaluated because patient is missing values for race#% </p><p><!--Message$KB_313397_Class11$*--><b>-   PM On ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor.#% </p><p><!--Message$KB_313397_Class14$*--><b>-   PM rec add ACEi CKD stage5 or eGFR>15</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class16$*--><b>-   PM Rec add ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor. Use caution if prescribing.#% </p><p><!--Message$KB_313397_Class18$*--><b>-   PM add ACEi and 20 percent increase creatinine after starting ACEi</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class19$*--><b>-   PM on ACEi and 20 percent increase in creatinine after starting ACEi or ARB</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class2$*--><b>-   PM rec add ACEi CKD stage3 or 4 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class20$*--><b>-   PM on ACE and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class22$*--><b>-   PM Rec add ACEi and active prescription for Aliskerin</b>  <i>Recommendation</i> : %#Patient has a prescription for aliskerin; evaluate clinical significance and impact of prescription for ACE inhibitor#% </p><p><!--Message$KB_313397_Class23$*--><b>-   PM Rec add ACE and presence K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class24$*--><b>-   PM On ACEi and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class7$*--><b>-   PM on ACEi and CKD stage 3 or 4 or 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class9$*--><b>-   PM on ace and ckd stage 5 or eGFR<15</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_335875_Class22$*--><b>-   PM CKD stage 5 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 5. Evaluate clinical significance.#% </p><p><!--Message$KB_335875_Class25$*--><b>-   Delete</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_335875_Class8$*--><b>-   PM SBP<110 and (rec add BB or rec add AA)</b>  <i>Primary_Recommendation</i> : %#Most recent SBP less than 110mmHg. Evaluate clinical significance and therapeutic implications.#% </p><p><!--Message$KB_486502_Class0$*--><b>-   PM 20% increase of creatinine after starting ACE inhibitor</b>  <i>Recommendation</i> : %#Patient had an increase of more than 20% of creatinine (comparing pre ACE inhibitor value with peak value within 3m after starting ACE inhibitor) after starting ACE inhibitor.#% </p><p><!--Message$KB_486502_Class10$*--><b>-   PM On ARB and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class12$*--><b>-   PM on ARB and 20 percent increase in creatinine after starting ARB or ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for aldosterone antagonist blocker.#% </p><p><!--Message$KB_486502_Class15$*--><b>-   PM on ARB and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class17$*--><b>-   PM On ARB and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class19$*--><b>-   DELETE  PM rec ADD ACE inhibitor and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#?messagebody#% </p><p><!--Message$KB_486502_Class2$*--><b>-   PM Rec ADD ARB and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59; evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class3$*--><b>-   PM  hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_486502_Class5$*--><b>-   PM On ARB and CKD stage 3/4 OR 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class6$*--><b>-   PM Rec ADD ACEi and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ACE inhibitor and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class8$*--><b>-   PM on ARB and (CKD stage 5 OR most recent  eGFR<15)</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_502940_Class0$*--><b>-   PM Pregnancy message</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$KB_502940_Class6$*--><b>-   PM Pregancy warning (add ACEi or on ACEi)</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status#% </p><p><!--Message$KB_810954_Class14$*--><b>-   PM Angioedema as a reaction to ACEi</b>  <i>Recommendation</i> : %#Patient has angioedema as a recorded allergy to ACE inhibitor. Evaluate clinical significance.#% </p><p><!--Message$KB_982939_Class0$*--><b>-   PM Angioedema as a reaction to ARB</b>  <i>Primary_Recommendation</i> : %#Patient has angioedema as a recorded allergy to angiotensin receptor blocker. Evaluate clinical significance.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10035$*--><b>-   Ischemic Heart disease and DBP<60 and BP at target</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60001$*--><b>-   DM rec based expert opinion</b>  <i>Recommendation</i> : %#This is not JNC8 recommendation but is based on expert opinion.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60002$*--><b>-   CKD rec add ACE age>75</b>  <i>Recommendation</i> : %#Per JNC8 there is lack of evidence to support use of ACE Inhibitor for patients with CKD and age>75 years. Evaluate clinical benefit.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60028$*--><b>-   CKD JNC8 and age>75</b>  <i>Recommendation</i> : %#Per JNC8 there is lack of evidence to support use of ARB for patients with CKD and age>75 years. Evaluate clinical benefit.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class70443$*--><b>-   BP above target JNC8</b>  <i>Recommendation</i> : %#BP above target. Evaluate clinical significance. Follow up in a month.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90004$*--><b>-   PM: K>5 and active prescription for ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an ACE Inhibitor and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90006$*--><b>-   PM: K>5 and active prescription for ARB</b>  <i>Recommendation</i> : %#Patient has an active prescription for an ARB and most recent K >5. Monitor closely.#% </p><p><!--Message$athena_hypertension_03650$*--><b>-   DHP add and Angina</b>  <i>Recommendation</i> : %#Felodipine is not FDA-Approved for the indication of angina, but by VA guidelines it is the DHP calcium channel antagonist of choice.#% </p><p><!--Message$athena_hypertension_03659$*--><b>-   Add Beta Blocker and Diltiazem</b>  <i>Recommendation</i> : %#Use caution if combining a beta blocker with diltiazem because of the risk of heart block or myocardial depression. Use of a dihydropyridine calcium channel blocker (eg. felodipine) in conjunction with beta blocker may be more appropriate to avoid this interaction.#% </p><p><!--Message$athena_hypertension_03661$*--><b>-   Add Beta blocker and DM</b>  <i>Recommendation</i> : %#Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.#% </p><p><!--Message$athena_hypertension_03663$*--><b>-   Add Beta blocker and PVD</b>  <i>Recommendation</i> : %#Beta blockers may exacerbate symptoms of peripheral vascular disease (PVD). It is important to follow the effect on your individual patient.#% </p><p><!--Message$athena_hypertension_03665$*--><b>-   Add Beta blockers and Verapamil</b>  <i>Recommendation</i> : %#Patient has strong indication for beta blocker and beta blockers should not be used concurrently with verapamil. Consider titrating off verapamil to allow beta blocker.#% </p><p><!--Message$athena_hypertension_03667$*--><b>-   Add Beta blocker and Depression</b>  <i>Recommendation</i> : %#Use caution as beta blockers may cause or exacerbate symptoms of depression; however, many patients tolerate them without difficulty.#% </p><p><!--Message$athena_hypertension_03669$*--><b>-   Beta blocker secondary prevention</b>  <i>Recommendation</i> : %#Beta blockers reduce the risk for subsequent MI and sudden cardiac death and should be considered for this patient apart from their use as a antihypertensive.#% </p><p><!--Message$athena_hypertension_04779$*--><b>-   Furosemide without CHF or RF</b>  <i>Recommendation</i> : %#Patient is taking furosemide and appears to have neither CHF nor renal failure. Hydrochlorothiazide is generally the more efficacious diuretic in the management of hypertension.#% </p><p><!--Message$athena_hypertension_04821$*--><b>-   ISH MESSAGE</b>  <i>Recommendation</i> : %#Both thiazide diuretics and dihydropyridine calcium channel blockers are effective in lowering the risk of stroke in ISH,  but there have been no head to head comparisons. Thiazides are far less expensive.#% </p><p><!--Message$athena_hypertension_05571$*--><b>-   add beta blocker delete clonidine</b>  <i>Recommendation</i> : %#Use caution when discontinuing clonidine. Gradual dosage reduction may be necessary to avoid serious rebound hypertension.  Add beta adrenoreceptor antagonist only after discontinuing clonidine.#% </p><p><!--Message$athena_hypertension_07645$*--><b>-   delete CCB, no CAD </b>  <i>Recommendation</i> : %#If indicated, the patient should be warned about the possibility of chest pain after discontinuing a calcium channel blocker. Some patients experience angina that is 'unmasked' when a calcium channel blocker is discontinued.#% </p><p><!--Message$athena_hypertension_104230$*--><b>-   Add HCTZ/BB diabetes, ACE compellingly indicated if proteinuria</b>  <i>Recommendation</i> : %#If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.#% </p><p><!--Message$athena_hypertension_11566$*--><b>-   ON HCTZ and gout complicated</b>  <i>Recommendation</i> : %#Complicated gout is a strong contraindication for use of thiazides, although some patients tolerate and therefore benefit from this drug therapy. Consider the possibility of gout complications, particularly if you increase the dose of hydrochlorothiazide.#% </p><p><!--Message$athena_hypertension_11567$*--><b>-   Hypokalemia and on thiazide</b>  <i>Recommendation</i> : %#Hypokalemia is a strong contraindication for use of thiazide diuretics. Discontinue use of thiazide diuretics. #% </p><p><!--Message$athena_hypertension_11568$*--><b>-   Hyponatremia and ON HCTZ</b>  <i>Recommendation</i> : %#Hyponatremia is a strong contraindication for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_118523$*--><b>-   MI and SBP<100</b>  <i>Recommendation</i> : %#Most recent Systolic BP in database is less than 100. Use your clinical judgment about safety of  adding, substituting, or maintaining drug regimen.#% </p><p><!--Message$athena_hypertension_12824$*--><b>-   ON ARB, Hyperkalemia</b>  <i>Recommendation</i> : %#Hyperkalemia is a strong contraindication for Angiotensin II receptor blockers (ARB). May need to discontinue ARB.#% </p><p><!--Message$athena_hypertension_143079$*--><b>-   Gout, UA < 6.9</b>  <i>Recommendation</i> : %#When uric acid level is 'normal', thiazides may be used if gout is well controlled, that is, there have been no gouty attacks in the past year. However, additional hypouricemic treatment may be needed.#% </p><p><!--Message$athena_hypertension_143086$*--><b>-   gout and ua >6.8</b>  <i>Recommendation</i> : %#Thiazides should be avoided in patients with diagnosis of gout and elevated uric acid.#% </p><p><!--Message$athena_hypertension_150674$*--><b>-   Adding drug, DBP<100 and SBP<160, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_150676$*--><b>-   Adding drug, SBP>=160 or DBP>=100</b>  <i>Primary_Recommendation</i> : %#ADD antihypertensive medication: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_154823$*--><b>-   ISH, using non DHP and add DHP</b>  <i>Recommendation</i> : %#Evidence for benefit of calcium channel blockers in isolated systolic hypertension is for dihydropiridine calcium channel blockers.#% </p><p><!--Message$athena_hypertension_160432$*--><b>-   BB and diltiazen and MI</b>  <i>Recommendation</i> : %#Patient has an indication for beta blocker. Use caution if combining a beta blocker with diltiazem because of the risk of heart block or myocardial depression. Consider replacing diltiazen with a beta blocker if clinically warranted.#% </p><p><!--Message$athena_hypertension_174212$*--><b>-   Urinary incontinence and ADD HCTZ</b>  <i>Recommendation</i> : %#There is little information about the likelihood that introduction of low-dose thiazides will adversely affect bladder function.  Follow individual patient response to treatment.#% </p><p><!--Message$athena_hypertension_189162$*--><b>-   Primary: Secondary Prevention BP controlled add ACEI/BB</b>  <i>Primary_Recommendation</i> : %#Patient may benefit from the addition of a drug for secondary prevention.#% </p><p><!--Message$athena_hypertension_192999$*--><b>-   Add ACE inhibitor and dx of renal disease</b>  <i>Recommendation</i> : %#ACE inhibitors can cause hyperkalemia and the risk in this patient needs to be evaluated carefully as the pt has an ICD9 code for renal disease.
#% </p><p><!--Message$athena_hypertension_207030$*--><b>-   sinoatrial node dysfunction + pacemaker+ diltiazem/verapamil</b>  <i>Recommendation</i> : %#Diltiazem or verapamil may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.#% </p><p><!--Message$athena_hypertension_207035$*--><b>-   sinoatrial node dysfunction and pacemaker BB</b>  <i>Recommendation</i> : %#Beta adrenergic receptor antagonists may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.#% </p><p><!--Message$athena_hypertension_210254$*--><b>-   alpha blocker monotherapy</b>  <i>Recommendation</i> : %#Blood pressure is adequately controlled based on the most recent BP, however alpha blocker MONOTHERAPY is currently not recommended.#% </p><p><!--Message$athena_hypertension_213176$*--><b>-   sinoatrial node dysfunction and no pacemaker</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction and no pacemaker, exercise caution if adding diltiazem or verapamil.#% </p><p><!--Message$athena_hypertension_213178$*--><b>-   BB, sinoatrial node dysfunction, no pacemaker</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction and no pacemaker, exercise caution if adding a beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_21662$*--><b>-   SBP<100</b>  <i>Recommendation</i> : %#Most recent Systolic BP in database is less than 100. Use your clinical judgment about safety of  adding, substituting, or maintaining drug regimen.#% </p><p><!--Message$athena_hypertension_223056$*--><b>-   Substituting verapamil with metoprolol</b>  <i>Recommendation</i> : %#This patient will benefit from metoprolol (secondary prevention of MI). Recheck BP in 4-6 weeks.#% </p><p><!--Message$athena_hypertension_224126$*--><b>-   felodipine less myocardial effects</b>  <i>Recommendation</i> : %#Felodipine is the preferred calcium channel blocker because it has less myocardial effects than diltiazem.#% </p><p><!--Message$athena_hypertension_224834$*--><b>-   pulse<65 add BB</b>  <i>Recommendation</i> : %#Patient has a relatively slow heart rate. Beta adrenergic receptor antagonists may lower heart rate further.#% </p><p><!--Message$athena_hypertension_228843$*--><b>-   ADR ACE I cross reactivity</b>  <i>Recommendation</i> : %#Angiotensin II receptor blockers (ARBs) are recommended if the patient develops cough during use of ACE inhibitor.  There is a risk of cross-reactivity between ACE Inhibitors and ARBs; for some ADEs other than cough, ARBs may also be contraindicated.#% </p><p><!--Message$athena_hypertension_229056$*--><b>-   Amiodarone add diltiazem</b>  <i>Recommendation</i> : %#'Concurrent use of amiodarone and diltiazem may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_238977$*--><b>-   BPH, add HCTZ</b>  <i>Recommendation</i> : %#Thiazide diuretics may worsen urinary symptoms of benign prostatic hyperplasia.#% </p><p><!--Message$athena_hypertension_23967$*--><b>-   Increase dose ACE, on K sparing diuretics</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_23970$*--><b>-   increase dose K sparing diuretic, on ACE inhibitor</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_244812$*--><b>-   amiodarone add beta blocker</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and beta adrenergic receptor antagonist may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_26264$*--><b>-   presence of angina, deleting NDHP CCB</b>  <i>Recommendation</i> : %#This patient has a diagnosis of ANGINA, and also has compelling indications for other antihypertensive agents. Use clinical judgement to evaluate benefit/harm of substituting away from diltiazem.#% </p><p><!--Message$athena_hypertension_26265$*--><b>-   2nd/3rd degree heart block, no pacemaker on BB</b>  <i>Recommendation</i> : %#Second or 3rd degree heart block without presence of a pacemaker is a strong contraindication for use of beta adrenergic receptor antagonists, but therapy must be individualized. Consider consultation.#% </p><p><!--Message$athena_hypertension_262653$*--><b>-   high K when rec increase dose ACE</b>  <i>Recommendation</i> : %#Serum K+ is high based on most recent value in database, please recheck. If HYPERKALEMIA is confirmed consider decreasing dose of ACE inhibitor or adding a diuretic.#% </p><p><!--Message$athena_hypertension_263505$*--><b>-   Uric acid >6.8</b>  <i>Recommendation</i> : %#The risk of gout with thiazides is increased when uric acid is above normal.#% </p><p><!--Message$athena_hypertension_269217$*--><b>-   hyperkalemia, delete ACE, absence of triamterene</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ACE-I should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_269267$*--><b>-   add metoprolol, adjust dose other drugs</b>  <i>Recommendation</i> : %#When adding metoprolol to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269270$*--><b>-   add ACE(2ary prevention HF), dose adjustment </b>  <i>Recommendation</i> : %#When adding ACE inhibitor to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269274$*--><b>-   Add ACE +Diabetes AND proteinuria/renal manifestations- dose adjustment</b>  <i>Recommendation</i> : %#When adding ACE inhibitor to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269593$*--><b>-   ISH on thiazide</b>  <i>Recommendation</i> : %#Beta receptor antagonists may have added benefit in decreasing the risk of stroke in patients with ISH who are taking thiazides.  Alternatively, a dihydropyridine, nitrendipine, has been shown to be effective in ISH as compared to placebo.  However, dihydropiridines available in the U.S., such as felodipine, have not been studied as an addition to thiazide in this setting. Very little is known about the added benefits from particular drug combinations.#% </p><p><!--Message$athena_hypertension_270092$*--><b>-   heart failure and ndhp</b>  <i>Recommendation</i> : %#Patient has heart failure which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.#% </p><p><!--Message$athena_hypertension_270094$*--><b>-   heart block and add ndhp</b>  <i>Recommendation</i> : %#Patient has heart block which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.#% </p><p><!--Message$athena_hypertension_270098$*--><b>-   add beta blocker, obstructive pulmonary disease</b>  <i>Recommendation</i> : %#Cardiovascular benefits of beta blocker therapy may outweigh the increased risk of bronchospasm in this patient.#% </p><p><!--Message$athena_hypertension_273237$*--><b>-   HF + MI consider felodipine</b>  <i>Recommendation</i> : %#Felodipine is the preferred CCB because it has less myocardial effects than diltiazen.#% </p><p><!--Message$athena_hypertension_284058$*--><b>-   triamterene or amiloride, high K and ACE Inhibitor</b>  <i>Recommendation</i> : %#A potassium sparing diuretic (triamterene or amiloride) is not indicated in light of this patient's hyperkalemia.#% </p><p><!--Message$athena_hypertension_288910$*--><b>-   Rec substituting away from furosemide</b>  <i>Recommendation</i> : %#Consider replacing the loop diuretic with HCTZ. Patient is taking a loop diuretic and appears to have neither CHF nor renal insufficiency. HCTZ, while a low efficacy diuretic in comparison to furosemide, may have greater efficacy in controlling hypertension.#% </p><p><!--Message$athena_hypertension_288914$*--><b>-   Add HCTZ, delete Loop diuretic, Cr>2</b>  <i>Recommendation</i> : %#This patient has a creatinine greater than 2.0. Thiazide diuretics may be
effective antihypertensives with creatinine up to 2.5; if the BP does not
respond, furosemide is an alternative. If you use furosemide, note that
twice daily dosing is preferred over once daily.#% </p><p><!--Message$athena_hypertension_29650$*--><b>-   ISH treatment benefits</b>  <i>Recommendation</i> : %#In a meta-analysis, isolated systolic hypertension and wide pulse pressure in elderly persons increased the risk for all cause mortality, cardiovascular events and stroke. Treatment reduced the risk by 13% for all cause mortality, 30% for stroke and 26% for cardiovascular events in 3.8 years.#% </p><p><!--Message$athena_hypertension_301093$*--><b>-   PM 5<K<5.4 and rec increase dose  ACE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; caution and close monitoring are recommended if ACE inhibitor dose is increased.#% </p><p><!--Message$athena_hypertension_301094$*--><b>-   PM 5.0<K<5.4  and using ace, no rec dose increase</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; close monitoring recommended if ACE inhibitor continued.#% </p><p><!--Message$athena_hypertension_303336$*--><b>-   using sotalol & presence bronchospasm</b>  <i>Primary_Recommendation</i> : %#Patient has history of BRONCHOSPASM which may be contraindication to beta blocker sotalol; assess tolerance. Sotalol may be essential for arrhythmia.#% </p><p><!--Message$athena_hypertension_303337$*--><b>-   using sotalol & presence heart block/no pacemaker</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of heart block without a pacemaker which may be contraindication to beta blocker sotalol; however, sotalol may be essential for arrhythmia. Consider cardiology consultation.#% </p><p><!--Message$athena_hypertension_303338$*--><b>-   using sotalol & presence unpecified heart block/no pacemaker</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of unspecified heart block without a pacemaker which may be contraindication to beta blocker sotalol; however, sotalol may be essential for arrhythmia. Consider cardiology consultation.#% </p><p><!--Message$athena_hypertension_303341$*--><b>-   5<K<=5.4 and using ARB, rec INCREASE DOSE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; caution and close monitoring are recommended if ARB dose is increased.#% </p><p><!--Message$athena_hypertension_303343$*--><b>-   5<K<=5.4 and using ARB, NOT rec INCREASE DOSE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; close monitoring recommended if ARB continued.#% </p><p><!--Message$athena_hypertension_305971$*--><b>-   PM using triamterene and ACE I, not rec increase dose ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescriptions for both potassium sparing diuretic (triamterene) and ACEi: caution re risk of hyperkalemia#% </p><p><!--Message$athena_hypertension_305972$*--><b>-   PM: using triamterene and ARB, not rec increase dose ARB</b>  <i>Primary_Recommendation</i> : %#Patient has prescriptions for both potassium sparing diuretic (triamterene) and ARB: caution re risk of hyperkalemia#% </p><p><!--Message$athena_hypertension_305974$*--><b>-   PM using triamterene and ACE I, rec increase dose ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if increasing dose ACEi, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305976$*--><b>-   PM using triamterene , rec ADD ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if adding ACEi, consider discontinuing triamterene to avoid hyperkalemia.
#% </p><p><!--Message$athena_hypertension_305977$*--><b>-   PM using triamterene and ARB, rec increase dose</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if increasing dose ARB, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305978$*--><b>-   PM using triamterene , rec ADD ARB</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if adding ARB, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305983$*--><b>-   Precaution: hyperkalemia, on ACE and absence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ACE inhibitor should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305984$*--><b>-   hyperkalemia, delete ACE primary msg, presence of triamterene</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305985$*--><b>-   Precaution: hyperkalemia, on ACEi and on triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305986$*--><b>-   PRIMARY: hyperkalemia, on ARB , absence of triamterence</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ARB should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305987$*--><b>-   precaution: hyperkalemia, on ARB, absence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ARB should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305988$*--><b>-   PRIMARY: hyperkalemia, on ARB , presence of triamterence</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305989$*--><b>-   precaution: hyperkalemia, on ARB, presence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_306255$*--><b>-   hypokalemia, increase dose diuretics</b>  <i>Recommendation</i> : %#This patient has a prescription for a diuretic, and the most recent K+ is below normal limits.  Use caution and recheck potassium before increasing thiazide dosage.#% </p><p><!--Message$athena_hypertension_31098$*--><b>-   HCTZ dosing message and creatinine<=2.0</b>  <i>Recommendation</i> : %#HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_hypertension_31100$*--><b>-   HCTZ dosing message and CR>2.0</b>  <i>Recommendation</i> : %#While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.#% </p><p><!--Message$athena_hypertension_31109$*--><b>-   Unspecified heart block, absence 1st, 2nd or 3rd degree heart block</b>  <i>Recommendation</i> : %#This patient has a diagnosis of unspecified heart block. Second or third degree heart block without presence of a pacemaker is a strong contraindication for use of beta adrenergic receptor antagonists, but therapy must be individualized. Consider consultation and update problem list.#% </p><p><!--Message$athena_hypertension_312849$*--><b>-   Gout, no uric acid</b>  <i>Recommendation</i> : %#Thiazides may be used if gout is well controlled, however thiazides may worsen symptoms of gout if uric acid is elevated.#% </p><p><!--Message$athena_hypertension_314611$*--><b>-   Check K and creatinine when increasing dose, [Cr<=1.5(male) or Cr<=1.3(female)]</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_314614$*--><b>-   Check K and creatinine when increasing dose, Cr>1.5 (male)</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors. When considering frequency of follow up, please note that this patient's last creatinine was >1.5.#% </p><p><!--Message$athena_hypertension_314618$*--><b>-   adding ace inhibitor, check Cr and K, [Cr<=1.5(male) or Cr<=1.3(female)] and K<5.6</b>  <i>Recommendation</i> : %#Check the patient's creatinine and potassium concentrations when prescribing  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_314621$*--><b>-   adding ACE inhibitor, creatinine message if K>5.5</b>  <i>Recommendation</i> : %#Check the patient's creatinine when prescribing or increasing dose of  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_32504$*--><b>-   on BB presence of bronchospasm primary msg</b>  <i>Primary_Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Please evaluate carefully if maintaining patient on beta adrenergic receptor antagonist or increasing the dose.#% </p><p><!--Message$athena_hypertension_327119$*--><b>-   ISH definition</b>  <i>Recommendation</i> : %#Strictly speaking, ISH is defined as pre-treatment SBP >= 140 and DBP < 90.#% </p><p><!--Message$athena_hypertension_327120$*--><b>-   consult message on thiazides target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP ELEVATED despite high doses of 4 antihypertensives.#% </p><p><!--Message$athena_hypertension_328273$*--><b>-   verapamil and HF, increase dose</b>  <i>Recommendation</i> : %#Verapamil can have potent negative inotropic effect.  Apparently this patient with heart failure is already tolerating it; however, use caution if you decide to increase dose.#% </p><p><!--Message$athena_hypertension_330345$*--><b>-   ACE inhibitor and HF</b>  <i>Recommendation</i> : %#Use of ACE inhibitors in patients with heart failure and ejection fraction <0.35 significantly reduces overall mortality and hospital admissions.  For patients with ejection fraction >=0.35 ACE inhibitors may be beneficial but this is not established.#% </p><p><!--Message$athena_hypertension_33188$*--><b>-   pulse<65, increase dose BB</b>  <i>Recommendation</i> : %#Patient has a relatively slow heart rate. Increasing dose of beta adrenergic receptor antagonists may lower heart rate further.#% </p><p><!--Message$athena_hypertension_334164$*--><b>-   add ACE inhibitor, Diabetes AND proteinuria/renal manifestations</b>  <i>Recommendation</i> : %#Use of ACE inhibitors in patients with diabetes and proteinuria significantly reduces risk of myocardial infarction, stroke, overt nephropathy and cardiovascular death.#% </p><p><!--Message$athena_hypertension_350271$*--><b>-   increase dose ARB, High K</b>  <i>Recommendation</i> : %#Serum K+ is high based on most recent value in database, please recheck. If HYPERKALEMIA is confirmed consider decreasing dose of ARB or adding a diuretic.#% </p><p><!--Message$athena_hypertension_35597$*--><b>-   Zero daily dose in non-contraindicated drug warning</b>  <i>Primary_Recommendation</i> : %#DRUG DOSE information from pharmacy database is MISSING for an antihypertensive drug. Evaluate if dose increase is appropriate.#% </p><p><!--Message$athena_hypertension_360318$*--><b>-   add ace and "race black on thiazides"</b>  <i>Recommendation</i> : %#In the ALLHAT trial, ACEi was less effective in lowering BP in Afr-Amer than diuretics & CCB.  The differences were abolished when ACEi was combined with thiazides.#% </p><p><!--Message$athena_hypertension_361684$*--><b>-   marginally elevated BP, Target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_361691$*--><b>-   Adding drug, marginally elevated BP Target 140/90</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_362750$*--><b>-   ISH thiazides</b>  <i>Recommendation</i> : %#Thiazide diuretics reduce risk of stroke, cardiovascular events, and mortality in patients with isolated systolic hypertension.#% </p><p><!--Message$athena_hypertension_37158$*--><b>-   ADR ACE I beyond scope of program</b>  <i>Recommendation</i> : %#An adverse drug event (ADE) has been listed for ACE inhibitor.  Analyzing the nature or significance of the ADE is beyond the scope of this program. #% </p><p><!--Message$athena_hypertension_379470$*--><b>-   intensify message, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_39003$*--><b>-   ISH BP Target, SBP>=180</b>  <i>Recommendation</i> : %#For an elderly patient with marked systolic hypertension (SBP>=180), initial target is SBP below 160 mmHg.#% </p><p><!--Message$athena_hypertension_39007$*--><b>-   ISH target, 140<=SBP<180- age >60 years</b>  <i>Recommendation</i> : %#For an elderly patient with isolated systolic hypertension and SBP between 160 and 180mmHg, initial target is to lower SBP by 20 mmHg.#% </p><p><!--Message$athena_hypertension_391779$*--><b>-   MI (ACE) and JNC7 rec aldosterone antagonists</b>  <i>Recommendation</i> : %#ACE Inhibitor is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.#% </p><p><!--Message$athena_hypertension_391783$*--><b>-   MI (BB)  and JNC7 rec aldosterone antag</b>  <i>Recommendation</i> : %#Beta Adrenergic Receptor Antagonist is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.#% </p><p><!--Message$athena_hypertension_405292$*--><b>-   High Postural hypotension risk- age</b>  <i>Primary_Recommendation</i> : %#Older persons are at higher risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405293$*--><b>-   High Postural hypotension risk- DM</b>  <i>Primary_Recommendation</i> : %#Diabetic patients are at higher risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405294$*--><b>-   High Postural hypotension risk- diuretic</b>  <i>Primary_Recommendation</i> : %#Active prescription for a  diuretic increases risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405296$*--><b>-   High Postural hypotension risk-  cerebral vascular disease</b>  <i>Primary_Recommendation</i> : %#Cerebral vascular disease increases risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_407883$*--><b>-   add ACE and presence of cerebrovascular disease</b>  <i>Recommendation</i> : %#With respect to the prevention of recurrent stroke,PROGRESS demonstrated that addition of the diuretic, indapamide, to the ACEI, perindopril,caused a 43 percent reduction in stroke occurence.#% </p><p><!--Message$athena_hypertension_407884$*--><b>-   PM: Stroke and BP control</b>  <i>Primary_Recommendation</i> : %#BP control extremely important to prevent further cardiovascular events.#% </p><p><!--Message$athena_hypertension_408418$*--><b>-   DHP and migraine</b>  <i>Recommendation</i> : %#Calcium channel antagonists may have a favorable effect on migraine. There is very little evidence to guide the choice of drug for this indication.#% </p><p><!--Message$athena_hypertension_412565$*--><b>-   on 4 drugs, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION.#% </p><p><!--Message$athena_hypertension_413512$*--><b>-   on 4 drugs, absence thiazides, not marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_413763$*--><b>-   Adding drug, marginally elevated BP, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_414890$*--><b>-   marginally elevated BP, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_419564$*--><b>-   Adding drug, DBP<100 and SBP<160, target 130/85</b>  <i>Primary_Recommendation</i> : %#Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_427221$*--><b>-   intensify message, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP.#% </p><p><!--Message$athena_hypertension_428368$*--><b>-   intensify message, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_429435$*--><b>-   Primary: use ARB and ACE for non diabetic renal disease</b>  <i>Recommendation</i> : %#Patient has a diagnosis of non diabetic kidney disease, use of combined therapy with ARB and ACE may offer more renal protection than either alone.#% </p><p><!--Message$athena_hypertension_432951$*--><b>-   Add ACE/ARB & CKD; alert creatinine rise</b>  <i>Recommendation</i> : %#A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.#% </p><p><!--Message$athena_hypertension_434555$*--><b>-   On 1 drug, BP >= 160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_435003$*--><b>-   On 2 or 3 drugs, BP >=160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_436122$*--><b>-   Ischemic Heart disease and DBP<60 and BP not controlled</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_436124$*--><b>-   ischemic heart disease, dbp<60 and BP controlled</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$athena_hypertension_436463$*--><b>-   on 4 drugs, absence thiazides, BP > =160/100</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_436668$*--><b>-   on 4 drugs, presence thiazides, BP >= 160/100</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_437283$*--><b>-   on 4 drugs, not max dose, bp >=160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_437493$*--><b>-   on 4 drugs, not max dose, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_437494$*--><b>-   on 4 drugs, bp not marginally elevated, < 160/100, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_438122$*--><b>-   on 4 drugs, bp marginally elevated, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_438123$*--><b>-   on 4 drugs, bp not marginally elevated, bp < 160/100, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.
#% </p><p><!--Message$athena_hypertension_439133$*--><b>-   On thiazides, sodium < 125 alert</b>  <i>Primary_Recommendation</i> : %#ALERT!  Patient has active prescription for thiazide diuretics and HYPONATREMIA.#% </p><p><!--Message$athena_hypertension_439556$*--><b>-   on thiazides, K<3.5 alert</b>  <i>Primary_Recommendation</i> : %#ALERT!  Patient has active prescription for thiazide diuretics and HYPOKALEMIA.#% </p><p><!--Message$athena_hypertension_441551$*--><b>-   on 4 drugs, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_453682$*--><b>-   4 drugs, marginally elevated BP, target 130/85, presence of dm,chf,ri consult message</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION#% </p><p><!--Message$athena_hypertension_453683$*--><b>-   On 4 drugs, absence of thiazide, not marginally elevated, target 130/85</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_458684$*--><b>-   Adding drug, marginally elevated BP, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_458690$*--><b>-   Adding drug, DBP < 100 and SBP < 160, target 140/80</b>  <i>Primary_Recommendation</i> : %#Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458697$*--><b>-   marginally elevated BP, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_458700$*--><b>-   intensify message, target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458701$*--><b>-   on 4 drugs, bp not marginally elevated, bp < 160/100, target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458702$*--><b>-   on 4 drugs, bp marginally elevated, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_458703$*--><b>-   4 drugs, marginally elevated BP, target 140/80, presence of dm,consult message</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION#% </p><p><!--Message$athena_hypertension_458704$*--><b>-   On 4 drugs, absence of thiazide, not marginally elevated, target 140/80</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_458706$*--><b>-   consult message on hctz target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_462726$*--><b>-   add ACE and Creatinine>1.5 (male)</b>  <i>Recommendation</i> : %#ACE inhibitor is recommended because most recent creatinine is above 1.5mg/dl, disregard if renal insufficiency is acute. Recheck creatinine and potassium concentration after starting ACE inhibitor therapy.#% </p><p><!--Message$athena_hypertension_465027$*--><b>-   Check K and creatinine when increasing dose, Cr>1.3 (female)</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors. When considering frequency of follow up, please note that this patient's last creatinine was >1.3.#% </p><p><!--Message$athena_hypertension_465029$*--><b>-   add ACE and Creatinine>1.3 (female)</b>  <i>Recommendation</i> : %#ACE inhibitor is recommended because most recent creatinine is above 1.3mg/dl (upper normal limit for females), disregard if renal insufficiency is acute. Recheck creatinine and potassium concentration after starting ACE inhibitor therapy.#% </p><p><!--Message$athena_hypertension_469429$*--><b>-   consult message on hctz target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_469832$*--><b>-   BP controlled, HCTZ>25mg</b>  <i>Primary_Recommendation</i> : %#HCTZ dose above 25mg has no added antihypertensive effect for most patients, and increases risk of adverse effects. Consider adjusting the dose to 25mg.#% </p><p><!--Message$athena_hypertension_469833$*--><b>-   SBP>=100, BP controlled, HCTZ absent or <=25mg</b>  <i>Primary_Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_484963$*--><b>-   primary: rec add ARB and presence of cough as ADR ACE</b>  <i>Primary_Recommendation</i> : %#Patient has cough as an ADR to ACE and there is no record of angioedema, please exclude possibility of other serious adverse reactions before prescribing ARB.#% </p><p><!--Message$athena_hypertension_491109$*--><b>-   Atrial fibrillation and add NDHP orBB</b>  <i>Recommendation</i> : %#Management of  arrythmia is complex and may require consultation with specialist.#% </p><p><!--Message$athena_hypertension_501754$*--><b>-   bronchospasm</b>  <i>Recommendation</i> : %#Bronchospasm is a strong contraindication for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_506843$*--><b>-   Hyponatremia in the past</b>  <i>Recommendation</i> : %#Patient had severe hyponatremia in the past, monitor introduction of thiazide therapy closely.#% </p><p><!--Message$athena_hypertension_510458$*--><b>-   Taking 2 bbs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 beta adrenergic receptor antagonists. Please evaluate.#% </p><p><!--Message$athena_hypertension_510459$*--><b>-   Taking 2 ACEs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 ACE inhibitors. Please evaluate.#% </p><p><!--Message$athena_hypertension_510460$*--><b>-   Taking 2 CCBs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 calcium channel blockers . Please evaluate.#% </p><p><!--Message$athena_hypertension_510461$*--><b>-   Taking 2 alphablockers</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 alpha blockers. Please evaluate.#% </p><p><!--Message$athena_hypertension_510462$*--><b>-   Taking 2 thiazides</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 thiazide diuretics. Please evaluate.#% </p><p><!--Message$athena_hypertension_510607$*--><b>-   bronchospasm , add BB</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Monitor patient's response carefully if starting a beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_510608$*--><b>-   bronchospasm, increase dose BB</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_525534$*--><b>-   absolute contraindication to a current drug</b>  <i>Primary_Recommendation</i> : %#There appears to be a STRONG CONTRAINDICATION to a currently prescribed drug, evaluate clinical significance.#% </p><p><!--Message$athena_hypertension_525537$*--><b>-   HF ON BB and absolute contraindication BB</b>  <i>Primary_Recommendation</i> : %#There appears to be a STRONG CONTRAINDICATION to a currently prescribed drug (see "Precautions" tab), evaluate clinical significance.#% </p><p><!--Message$athena_hypertension_53781$*--><b>-   alpha blocker monotherapy rec ADD</b>  <i>Recommendation</i> : %#A clinical trial found unexpectedly that using an alpha1 receptor blocker as monotherapy for hypertension may not be adequate in reducing risk of some cardiovascular events.#% </p><p><!--Message$athena_hypertension_74989$*--><b>-   ADR for thiazide</b>  <i>Recommendation</i> : %#There is an allergy or adverse drug event reported for thiazide diuretics. Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_84362$*--><b>-   Hypokalemia diuretic caution collateral action</b>  <i>Recommendation</i> : %#This patient recently had a low potassium level. Use care if initiating diuretic therapy.#% </p><p><!--Message$athena_runtime_84895$*--><b>-   low sodium message HCTZ collateral action</b>  <i>Recommendation</i> : %#Patient's sodium is between 125 and 130 mg/dL. Hydrochlorothiazide may worsen hyponatremia. If you prescribe it, Na should be rechecked within 5 to 7 days.#% </p><p><!--Message$athena_runtime_84899$*--><b>-   BP not controlled but DBP < 70</b>  <i>Recommendation</i> : %#We are recommending treatment to lower systolic blood pressure. Use clinical judgment to evaluate the degree of diastolic blood pressure lowering that is acceptable.#% </p><p><!--Message$Lipid_dashboard_Class100001$*--><b>-   Dose level moderate intensity rosuvastation</b>  <i>Recommendation</i> : %#Moderate dose rosuvastatin is 5<=dose<20 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100004$*--><b>-   Dose level moderate intensity fluvastatin</b>  <i>Recommendation</i> : %#Moderate dose fluvastatin is 180 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100021$*--><b>-   Dose level moderate intensity atorvastatin</b>  <i>Recommendation</i> : %#Moderate dose atorvastatin is 10<=dose<40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100023$*--><b>-   Dose level moderate intensity lovastatin</b>  <i>Recommendation</i> : %#Moderate dose lovastatin is 40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100025$*--><b>-   Dose level moderate dose pravastatin</b>  <i>Recommendation</i> : %#Moderate dose pravastatin is 40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100028$*--><b>-   Dose level moderate simvastatin</b>  <i>Recommendation</i> : %#Dose level of moderate intensity simvastatin is 20-40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class160013$*--><b>-   Presence of fibric acid msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking a fibric acid (fenofibrate, gemfibrozil or clofibrate) which increases risk of myopathy.  Consider switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class160023$*--><b>-   Presence of niacin >1gm/day msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class220013$*--><b>-   Pres hem stroke risk/benefit of increase dose message</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke.  Increasing the dose of the statin can increase the risk of adverse events, including myopathy.  Consider the risk/benefit of increase dose.#% </p><p><!--Message$Lipid_dashboard_Class220014$*--><b>-   Asian consider risk/benefit of increase dose message</b>  <i>Recommendation</i> : %#Warning:  Patient may be Asian.  When prescribing rosuvastatin to Asians, there is a 2-fold elevation in the median exposure (AUC and Cmax) to the durg when compared to Caucasians.  Consider risk/benefit of increasing dose of statins.#% </p><p><!--Message$Lipid_dashboard_Class230022$*--><b>-   ASCVD Prim message moderate intensity statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease with history of hemorrhagic stroke oris over age.75. Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class250022$*--><b>-   Cannot tolerate formulary statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate formulary statin, consider non-formulary statin#% </p><p><!--Message$Lipid_dashboard_Class280020$*--><b>-   Pres niacin > 1gm/day and Pres statin</b>  <i>Primary_Recommendation</i> : %#Patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class280021$*--><b>-   Pres fibrate and Pres statin</b>  <i>Recommendation</i> : %#Patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class300000$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age related changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$Lipid_dashboard_Class30026$*--><b>-   ASCVD Prim Msg to start high dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease.  High intensity statins are recommended.  Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p><p><!--Message$Lipid_dashboard_Class30052$*--><b>-   DM Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has diabetes without atherosclerotic cardiovascular disease and 40<=age<=75.  Moderate intensity statins are recommended. Formulary moderate intensity statin are atorvastatin 10 mg simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg.  Non formulary moderate intensity statins are rosuvastatin 5 mg, fluvastatin 40 mg.#% </p><p><!--Message$Lipid_dashboard_Class320001$*--><b>-   temp all statins contraindicated</b>  <i>Recommendation</i> : %#temp all statins contraindicated#% </p><p><!--Message$Lipid_dashboard_Class360002$*--><b>-   Blocked add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class360003$*--><b>-   Blocked add statin missing eGFR past 3 mo</b>  <i>Recommendation</i> : %#We would normaly recommend adding a statin, but we are missing eGFR in the past 3 months..#% </p><p><!--Message$Lipid_dashboard_Class360006$*--><b>-   Blocked incr dose missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend increasing dose of a statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class370000$*--><b>-   Pres fibrate and Pres statin blocked incr dose</b>  <i>Recommendation</i> : %#We would normally recommend increasng the intensity of the statin, but the patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class370001$*--><b>-   Pres niacin > 1gm/day and Pres statin incr dose</b>  <i>Recommendation</i> : %#We would normally recommend increasing the intensity of the statin, but the patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class410000$*--><b>-   Presence of niacin >1gm/day msg blocked incr</b>  <i>Primary_Recommendation</i> : %#We would have normally recommended increasing dose of a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class450001$*--><b>-   Blocked incr dose really add missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend substituting a high intensity statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class460121$*--><b>-   Blocked incr dose really add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class70026$*--><b>-   ASCVD Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease and history of hemorrhagic stroke..  Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class90016$*--><b>-   Rosuvastatin-asian warning</b>  <i>Primary_Recommendation</i> : %#Warning when prescribing rosuvastatin to Asians:  there is a 2-fold elevation in median exposure (AUC and Cmax) to rosuvastatin in Asian subjects when compared with a Caucasian control group.#% </p><p><!--Message$athena_hypertension_272142$*--><b>-   recently refilled; expired warning</b>  <i>Primary_Recommendation</i> : %#Prescriptions for <drug_name> has(have) EXPIRED, although the patient has recently filled the medication(s).#% </p><p><!--Message$athena_hypertension_272143$*--><b>-   active and not refilled warning</b>  <i>Primary_Recommendation</i> : %#Prescription(s) for <drug_name> has(have) NOT BEEN FILLED RECENTLY.#% </p><p><!--Message$athena_hypertension_429434$*--><b>-   Primary: use ARB and ACE for non diabetic renal disease</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of non diabetic kidney disease, use of combined therapy with ARB and ACE may offer more renal protection than either alone.#% </p><p><!--Message$athena_hypertension_59854$*--><b>-   adr to ACE</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67708$*--><b>-   ADR to non DHP CCB</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67710$*--><b>-   ADR to alpha beta blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67712$*--><b>-   ADR to alpha blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67714$*--><b>-   ADR to Angiotensin II Receptor Blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67716$*--><b>-   ADR to Cardioselective Beta Blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68067$*--><b>-   ADR to DHP Calcium channel blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68069$*--><b>-   ADR to non-cardioselective beta blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68071$*--><b>-   ADR to thiazides</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_runtime_INSTANCE_00123$*--><b>-   presence of medication with adverse reaction</b>  <i>Recommendation</i> : %# #% </p><p><!--Message$ATHENA_CKD_Class190355$*--><b>-   4+ BP meds refer msg</b>  <i>Recommendation</i> : %#Patient is on 4 or more BP medications and his/her blood pressure is greater than 140/90.   Please refer to nephrologist#% </p><p><!--Message$ATHENA_CKD_Class30008$*--><b>-   Out of scope, refer to nephrologist msg</b>  <i>Primary_Recommendation</i> : %#Patient has eGFR<30 or eGFR<45 and ACR>=30 or eGFR<60 and ACR>300 or on 4 or more BP meds or has Stage 4 or 5 CKD.  These conditions are out of scope.  Please refer to a nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40028$*--><b>-   Msg to immunize for flu, pneumonia, hep B</b>  <i>Recommendation</i> : %#Consider immunizing patients againts the flu, pneumonia and hepatitis B.#% </p><p><!--Message$ATHENA_CKD_Class40029$*--><b>-   Msg for low salt diet</b>  <i>Recommendation</i> : %#Patients with CKD need to be on a low salt diet; <2 gm Na per day or <5gm NaCl per day.#% </p><p><!--Message$ATHENA_CKD_Class50017$*--><b>-   Low protein diet DM</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults with diabetes (2C).#% </p><p><!--Message$ATHENA_CKD_Class50018$*--><b>-   Low protein dient nonDM and eGFR<30</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults without diabetes and GFR <30 (2B)#% </p><p><!--Message$ATHENA_CKD_Class50021$*--><b>-   Prim msg: ACR>=30 have target BP 130/80</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR>=30 have their blood pressure <130/80#% </p><p><!--Message$ATHENA_CKD_Class50024$*--><b>-   Prim msg: ACR<30 have target BP 140/90</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR<30 have their blood pressure <140/90.#% </p><p><!--Message$ATHENA_CKD_Class50034$*--><b>-   Prim msg:  missing BP in past year</b>  <i>Primary_Recommendation</i> : %#Patient is missing BP measurement in past year.   For CKD patients with ACR>=30, BP target is 130/80.  For CKD patients with ACR<30, BP target is 140/90.#% </p><p><!--Message$ATHENA_CKD_Instance_20001$*--><b>-   Order microalbumin/creatinine ratio 3 months from last one</b>  <i>Recommendation</i> : %#The patient has abnormal microalbumin/creatinine ratio; Please order another test at least 3 months from the last one.#% </p><p><!--Message$ATHENA_CKD_Instance_30013$*--><b>-   Order creatinine</b>  <i>Primary_Recommendation</i> : %#No record of serum creatinine within a year, Please order the test.#% </p><p><!--Message$ATHENA_CKD_Instance_50015$*--><b>-   Order microalbumin/creatinine ratio</b>  <i>Recommendation</i> : %#Absence of microalbumin/creatinine ratio within a year; please order it now.#% </p><p><!--Message$ATHENA_CKD_Instance_50016$*--><b>-   Order Cr and microalbumin/creatinine ratio</b>  <i>Recommendation</i> : %#Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.#% </p><p><!--Message$ATHENA_CKD_Instance_50021$*--><b>-   Order serum creatinine 3 months from last one</b>  <i>Recommendation</i> : %#The patient has abnormal creatinine test  result; Please order another test at least 3 months from the last one.#% </p><p><!--Message$ATHENA_CKD_Instance_50034$*--><b>-   Achieve and maintain Hb A1C goal</b>  <i>Recommendation</i> : %#Important to achieve and maintain Hb A1C goal#% </p><p><!--Message$ATHENA_CKD_Instance_50035$*--><b>-   Important to use ACE or ARB</b>  <i>Recommendation</i> : %#Important to use ACE or ARB#% </p><p><!--Message$ATHENA_CKD_Instance_50039$*--><b>-   achieve/maintain blood pressure goal</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal#% </p><p><!--Message$ATHENA_CKD_Instance_60003$*--><b>-   Add CKD to record</b>  <i>Recommendation</i> : %#Please add chronic kidney disease to the patient's problem list.#% </p><p><!--Message$ATHENA_CKD_Instance_60040$*--><b>-   ?label</b>  <i>Recommendation</i> : %#This is branch 60#% </p><p><!--Message$ATHENA_CKD_Instance_60041$*--><b>-   -56</b>  <i>Recommendation</i> : %#This is branch -56#% </p><p><!--Message$ATHENA_CKD_Instance_70057$*--><b>-   Order confirmatory mALB/Cr</b>  <i>Primary_Recommendation</i> : %#There is a normal mALB/Cr more than 3 months after an abnormal mALB/Cr, order another mALB/Cr to confirm#% </p><p><!--Message$ATHENA_GlycemicControl_Class150023$*--><b>-   Absence of ACEI/ARB message</b>  <i>Recommendation</i> : %#Many DM practitioners add ACE inhibitorsor ARBs  to patient’s regimen regardless of kidney function.#% </p><p><!--Message$ATHENA_GlycemicControl_Class150028$*--><b>-   Set target HbA1c old</b>  <i>Recommendation</i> : %#Some patients need tighter control of their HbA1c.  Consider setting an alternate target HbA1c; initial target ranges can be found in VA DM Guidelines#% </p><p><!--Message$ATHENA_GlycemicControl_Class210017$*--><b>-   HbA1c <= 9</b>  <i>Primary_Recommendation</i> : %#Latest HbA1c <=9, meets dashboard goal. CDS does not give recommendations for HbA1c values between 6 and 9 because target HbA1c goal not available.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210018$*--><b>-   Severe hyperglycemia message</b>  <i>Primary_Recommendation</i> : %#If patient has severe hyperglycemia or excessive symptoms, consider starting insulin and a referral to Diabetic Management Team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210036$*--><b>-   Follow up in 3 months</b>  <i>Follow_Up</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class210046$*--><b>-   dDM Type I out of scope message</b>  <i>Primary_Recommendation</i> : %#Recommendations for DM Type I is out of scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class240013$*--><b>-   dAlert lor HbA1c or Glycohem</b>  <i>Primary_Recommendation</i> : %#ALERT:  patient has low HbA1c or low GlycoHemoglobin, at high risk for cardiovascular event and hypoglycemia.#% </p><p><!--Message$ATHENA_GlycemicControl_Class240044$*--><b>-   Insulin only management out of scope</b>  <i>Primary_Recommendation</i> : %#Management of insulin is beyond scope of this system.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260026$*--><b>-   message that ACE-I and ARB contraindicated</b>  <i>Recommendation</i> : %#ACE-I and ARB are both contraindicated.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260039$*--><b>-   ALERT:  high creatinine or low eGFR</b>  <i>Primary_Recommendation</i> : %#ALERT:  high creatinine (>2.5 male or >2.4 female) or low eGFR (<30)#% </p><p><!--Message$ATHENA_GlycemicControl_Class260042$*--><b>-   Management of insulin is outside the scope of this CDS</b>  <i>Primary_Recommendation</i> : %#Management of insulin is outside the scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class260043$*--><b>-   CDS does not issue rec when 6<=HbA1c<=9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class260051$*--><b>-   ALERT: there exists active and not refilled medication</b>  <i>Primary_Recommendation</i> : %#Placeholder:  ALERT: there exists active and not refilled medication.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260059$*--><b>-   ALERT:  SGOT or SGPT > 2.5*normal</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT > 2.5*normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330001$*--><b>-   Recommendation for pregnant women out of scope</b>  <i>Primary_Recommendation</i> : %#Warning:  These recommendations do not apply to women who are pregnant.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330022$*--><b>-   Liver Enzyme ALERT</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT greater than 3*Upper Limit of Normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class350011$*--><b>-   Low bicarb alert</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate levels are less than or equal to 21.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class410006$*--><b>-   eGFR  missing</b>  <i>Recommendation</i> : %#Cannot evaluate recommendation for adding ACE-I or ARB without eGFR lab within last month..#% </p><p><!--Message$ATHENA_GlycemicControl_Class420001$*--><b>-   K missing</b>  <i>Recommendation</i> : %#Cannot evaluate recommendation for adding ACE-I or ARB without K lab within last month..#% </p><p><!--Message$ATHENA_GlycemicControl_Class460111$*--><b>-   no SBP measurement during the last month</b>  <i>Recommendation</i> : %#Most recent blood pressure is older than 1 month.  Please measure BP, to evaluate usage of  ACE Inhibitor or ARB.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470007$*--><b>-   on 3+ agents</b>  <i>Recommendation</i> : %#Patient HbA1c is >9 and is on 3 oral agents.  Please refer to endocrinologist and specialized DM care team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470014$*--><b>-   DM-1 aand DM-2 message</b>  <i>Recommendation</i> : %#Diagnoses of both DM-1 and DM-2 detected.  Debug not clear.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480000$*--><b>-   Set target HbA1c</b>  <i>Recommendation</i> : %#Although the VA performance measure is to attain an HbA1c<9%, this is usually not the true target for an individual patient. The  <a href="http://@AUTOPMWEBSERVER@/DM/VA_GL_DiabetesMellitus_2010.pdf#page=49"> Table G1 from VA DM Guidelines </a> can be used as a reference to decide an individual patient’s target.#% </p><p><!--Message$ATHENA_GlycemicControl_Class490005$*--><b>-   Add ARB despite kidney function</b>  <i>Recommendation</i> : %#Patients with diabetes should be considered for use of ACE inhibitor or ARB in order to provide renal protection#% </p><p><!--Message$ATHENA_GlycemicControl_Class510002$*--><b>-   Presence of DM-1 and DM-2 message</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of both DM-1 and DM-2.  We have made recommendations ASSUMING that the patient has only DM-2.  If this is not the case, these recommendations are not appropriate#% </p><p><!--Message$ATHENA_GlycemicControl_Class590001$*--><b>-   Blocked MF message</b>  <i>Primary_Recommendation</i> : %#We would normally recommend Biguanide but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600175$*--><b>-   Start Aspirin message old</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy, if not contraindicated,  to reduce the risk of cardiovascular fatal events.#% </p><p><!--Message$ATHENA_GlycemicControl_Class620004$*--><b>-   Presence of drugs that affect blood glucse levels.</b>  <i>Primary_Recommendation</i> : %#Warning:  patient is taking either bromocriptine or colesevelam that has hypoglycemic properties#% </p><p><!--Message$ATHENA_GlycemicControl_Class660000$*--><b>-   Start Aspirin message</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy.  Additional information available <a href="http://@AUTOPMWEBSERVER@/DM/AdditionalAspirinTherapyInfo.pdf"> here </a>.#% </p><p><!--Message$ATHENA_GlycemicControl_Class660593$*--><b>-   ACEi and ARB both contraindicated no rule in</b>  <i>Recommendation</i> : %#ACE Inhibitors and ARBs are both contraindicated and cannot be used for renal protection#% </p><p><!--Message$ATHENA_GlycemicControl_Class730013$*--><b>-   Age > 65 and missing creatinine msg</b>  <i>Recommendation</i> : %#We would normally recommend glyburide, but patient's age is >= 65 and is missing creatinine lab in past month#% </p><p><!--Message$ATHENA_GlycemicControl_Class741056$*--><b>-   Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#We would normally be recommending adding metformin, but we are missing creatinine and eGFR in the past month#% </p><p><!--Message$ATHENA_GlycemicControl_Class750000$*--><b>-   Request confirmation of target goal</b>  <i>Recommendation</i> : %#Request confirmation of target goal#% </p><p><!--Message$ATHENA_GlycemicControl_Class80007$*--><b>-   Start Aspirin</b>  <i>Recommendation</i> : %#Consider aspirin therapy to reduce the risk of cardiovascular fatal events.#% </p><p><!--Message$ATHENA_GlycemicControl_Class80019$*--><b>-   Add ACE despite kidney function</b>  <i>Recommendation</i> : %#Patients with diabetes should be considered for use of ACE inhibitor or ARB in order to provide renal protection.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820003$*--><b>-   UGT inducers and canaglifozin warning</b>  <i>Primary_Recommendation</i> : %#If patient is on UGT induces (e.g. rifampin, pheytoin, phenobarbitol, ritonovir) and 45<eGFR<60, do not prescribe canafligozin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class830001$*--><b>-   Gen msg all patients re ACE/ARB</b>  <i>Primary_Recommendation</i> : %#Consider ACE or ARB for renal protection if eGFR and K are within acceptable levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class850569$*--><b>-   Bad drug partner message</b>  <i>Primary_Recommendation</i> : %#Patient is taking two DM medications that would normally not be taken together.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120110$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140145$*--><b>-   dose - rec add chlorpropamide</b>  <i>Recommendation</i> : %#100mg/day-125mg/day for elderly patients; 250mg/day in the mild-to-moderately severe, middle aged, stable patient#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140146$*--><b>-   dose - rec add piolgitazone</b>  <i>Recommendation</i> : %#15 - 45mg administered once daily.

May be given without regard to meals
Dosage adjustment is not required for renal insufficiency; however, there is insufficient data to recommend use in endstage renal disease.
Slow onset of action.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140147$*--><b>-   dose - rec add Repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140148$*--><b>-   dose - rec add Tolazamide</b>  <i>Recommendation</i> : %#1000 mg given once daily or divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140149$*--><b>-   dose - rec add micronized gliburide</b>  <i>Recommendation</i> : %#0.75 - 12mg given once daily or divided into 2 doses; doses >6mg when divided, may provide a better response

If the response to a single daily dose does not achieve treatment goals, dividing the dose may be effective.
In general, the hypoglycemic effects of glyburide and glipizide tend to plateau at 10mg and 20mg, respectively.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140150$*--><b>-   dose - rec add Tolbutamide</b>  <i>Recommendation</i> : %#250-2000mg divided into 2-3 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140154$*--><b>-   dose - rec add acarbose</b>  <i>Recommendation</i> : %#For acarbose or miglitol begin with 25 mg TID or initiate gradually:
25 mg QD x 1-2 weeks followed by 
25 mg BID for 1-2 weeks followed by
25 mg TID. Once a 25mg TID dosing regimen is reached, further increases may be made at a 4-8 week interval.

The usual maintenance dose is 50 mg TID. Maximum dose for acarbose is 100mg TID (50 mg TID if weight <60 kg) and 100mg tid for miglitol.

Dose is to be taken with the first bite of each main meal.

If the patient misses or adds a meal, they should omit or add the dose.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140155$*--><b>-   dose - rec add rosiglitazone</b>  <i>Recommendation</i> : %#4 - 8mg/day, given once daily or divided into 2 doses.

May be given without regard to meals
Dosage adjustment is not required for renal insufficiency; however, there is insufficient data to recommend use in endstage renal disease.
Slow onset of action.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140156$*--><b>-   dose - rec add miglitol</b>  <i>Recommendation</i> : %#For acarbose or miglitol begin with 25 mg TID or initiate gradually:
25 mg QD x 1-2 weeks followed by 
25 mg BID for 1-2 weeks followed by
25 mg TID. Once a 25mg TID dosing regimen is reached, further increases may be made at a 4-8 week interval.

The usual maintenance dose is 50 mg TID. Maximum dose for acarbose is 100mg TID (50 mg TID if weight <60 kg) and 100mg tid for miglitol.

Dose is to be taken with the first bite of each main meal.

If the patient misses or adds a meal, they should omit or add the dose.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140157$*--><b>-   dose - rec add nateglinide</b>  <i>Recommendation</i> : %#120mg before each meal.

Take 1 - 30 minutes before a meal.
If the patient misses or adds a meal, they should omit or add the dose#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140159$*--><b>-   dose - rec add repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140160$*--><b>-   dose - rec add Repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_90005$*--><b>-   Continue therapy- HbA1c under control</b>  <i>Recommendation</i> : %#Latest HbA1c under control.  Continue therapy and periodically reevaluate appropriateness of target.#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p><p><!--Message$KB_390055_Class1$*--><b>-   dose - rec add metformin ER</b>  <i>Recommendation</i> : %#Begin with 500mg daily with the evening meal. Dose may be increased by 500mg per week to a maximum of 2000mg once daily. If glycemic control is not achieved, consider dividing into 2 doses.#% </p><p><!--Message$KB_707783_Class7$*--><b>-   Elderly on meds hypoglycemia risk</b>  <i>Recommendation</i> : %#Elderly patients are at a higher risk for drug-associated hypoglycemia, due to altered metabolism and excretion rates, impaired symptom recognition, and potentially attenuated counter-regulatory responses. Instruct patient and family  to recognize signs and symptoms of hypoglycemia and its management.#% </p><p><!--Message$ATHENA_HF_Class110355$*--><b>-   meet target dose, not max dose lisinopril</b>  <i>Recommendation</i> : %#The target dose for lisinopril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.#% </p><p><!--Message$ATHENA_HF_Class110357$*--><b>-   target dose enalapril</b>  <i>Recommendation</i> : %#The target dose for enalapril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.#% </p><p><!--Message$ATHENA_HF_Class110379$*--><b>-   rec add ace: dose adjustent based on kidney functio</b>  <i>Recommendation</i> : %#Refer to specific ACE Inhibitor dose adjustments based on kidney function.#% </p><p><!--Message$ATHENA_HF_Class110380$*--><b>-   monitoring renal function and K for ACEI</b>  <i>Recommendation</i> : %#Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with preexisting hypotension, hyponatremia, diabetes
mellitus, or azotemia or in those taking potassium
supplements.#% </p><p><!--Message$ATHENA_HF_Class110383$*--><b>-   rec add hydralazine and nitrates- dose suggsetions</b>  <i>Recommendation</i> : %#Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.#% </p><p><!--Message$ATHENA_HF_Class110392$*--><b>-   BNP monitoring</b>  <i>Recommendation</i> : %#There is somewhat more evidence, and home self bnp monitoring is in development.   While I don’t do it, I think that it wouldn’t be bad to get a baseline BNP on a newly diagnosed patient.  Very high ones mean something and woulde make me more aggressive.  I prefer history and PE, but there may be value for PCP who may have less time for history and less skill with PE.#% </p><p><!--Message$ATHENA_HF_Class110414$*--><b>-   not use nutritional supplements</b>  <i>Class III</i> : %#Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class132286$*--><b>-   Digoxin StageC Class IIA 4</b>  <i>Recommendation</i> : %#Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig#% </p><p><!--Message$ATHENA_HF_Class160000$*--><b>-   NYHA classification</b>  <i>Recommendation</i> : %#Functional Capacity .....................................................Objective Assessment
Class I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class170329$*--><b>-   rec add hyralazine_nitrates IF symptoms</b>  <i>Class I</i> : %#Class I Recommendation for hydralazine and nitrates for patients who are African American, have an active prescription of an ACE inhibitor and beta blocker and diuretics and an ASSUMMPTION that patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation#% </p><p><!--Message$ATHENA_HF_Class170330$*--><b>-   rec add aldosterone antagonist IF symptoms</b>  <i>Class I</i> : %#Class I recommendation for aldosterone antagonist for patietst with HF, LVEF<=35, (creatinine <=2.5 and male) or (creatine <=2 and femalel) and an ASSUMPTiON that  patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation.#% </p><p><!--Message$ATHENA_HF_Class190000$*--><b>-   elevated BNP</b>  <i>Recommendation</i> : %#Although lower values of BNP or NT-proBNP exclude the presence of HF and higher values have
reasonably high positive predictive value to diagnose HF, elevated plasma levels
for both natriuretic peptides have been associated with a wide variety of cardiac (ACS, heart muscle disease, valvular heart disease, pericardial disease, atrial fibrilation, myocarditis, cardiac surgery, cardioverion) and noncardiac causes (advancing age, anemia, renal failure, obstuctive sleep apnea, severe pnemonia, pumonary hypertension, critical illness, bacterial sepsis, severe burns, toxic-metablic insults, including cancer chemotherapy and envenomation)..#% </p><p><!--Message$ATHENA_HF_Class200016$*--><b>-   Order BNP or NTproBNP lab</b>  <i>Recommendation</i> : %#BNP and NTproBNP lab values absent.  Either of these measurements is useful in clinical decision making in HF.  Please order BNP or NTproBNP. [Level of Evidence A]#% </p><p><!--Message$ATHENA_HF_Class240000$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p><p><!--Message$ATHENA_HF_Class240016$*--><b>-   rec add hyralazine_nitrates Astronaut II</b>  <i>Class I</i> : %#The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III or IIV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class340251$*--><b>-   Absence of ACE-I, add ACE-I</b>  <i>Primary_Recommendation</i> : %#Patient is not taking ACE-I; add ACE-I.#% </p><p><!--Message$ATHENA_HF_Class370002$*--><b>-   ICD primary prev rec Stage C Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class370004$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class370006$*--><b>-   CRT Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class400002$*--><b>-   Missing creatinine/eGFR might rec ACEi/ARB</b>  <i>Primary_Recommendation</i> : %#ATHENA Heart Failure CDS may have recommended ACE inhibitor/ARB but lab values for creatinine/eGFR are missing. Please order creatinine.#% </p><p><!--Message$ATHENA_HF_Class50061$*--><b>-   nutritional supplements</b>  <i>Class III</i> : %#Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.#% </p><p><!--Message$ATHENA_HF_Class50078$*--><b>-   Fluid management</b>  <i>Recommendation</i> : %#?messagebody#% </p><p><!--Message$ATHENA_HF_Class50081$*--><b>-   Assess activities of daily living</b>  <i>Recommendation</i> : %#Assess ability of patient to perform routine and desired activities of daily living. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50082$*--><b>-   Assess volume status</b>  <i>Recommendation</i> : %#Assess volume status and weight. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50083$*--><b>-   Assess use cardiotoxic drugs and behaviors</b>  <i>Recommendation</i> : %#Assess current use of alcohol, tobacco, illicit drugs, “alternative therapies,” and chemotherapy drugs, as well as diet and sodium intake. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50086$*--><b>-   Repeat Echocardiogram</b>  <i>Recommendation</i> : %#Repeat echocardiogram can provide useful information in patients with HF who have had a change in clinical status or who have experienced or recovered from a clinical event or received treatment that might have had a significant effect on cardiac function. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50091$*--><b>-   Fluid management</b>  <i>Class I</i> : %#Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50096$*--><b>-   Exercise</b>  <i>Class I</i> : %#Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70020$*--><b>-   Hypertension control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporaryguidelines. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70021$*--><b>-   Lipid disorder control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70022$*--><b>-   Blood sugar control message</b>  <i>Class I</i> : %#For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70023$*--><b>-   behavior  control message</b>  <i>Class I</i> : %#Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70024$*--><b>-   Ventricular rate/sinus rhythm  control message</b>  <i>Class I</i> : %#Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70025$*--><b>-   Thyroid disorder  control message</b>  <i>Class I</i> : %#Thyroid disorders should be treated in accordance with contemporary
guidelines in patients at high risk for developing HF. (Level
of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70026$*--><b>-   Periodic evaluation message</b>  <i>Class I</i> : %#Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70027$*--><b>-   atherosclerotic vascular disease control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF who have known
atherosclerotic vascular disease, healthcare providers should
follow current guidelines for secondary prevention. (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70028$*--><b>-   LV function evaluation message</b>  <i>Class I</i> : %#Healthcare providers should perform a noninvasive evaluation of
LV function (i.e., LVEF) in patients with a strong family history of
cardiomyopathy or in those receiving cardiotoxic interventions.
(Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70167$*--><b>-   Aldosterone antagonist warning</b>  <i>Recommendation</i> : %#Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.#% </p><p><!--Message$ATHENA_HF_Class70173$*--><b>-   Maximal exercise testing</b>  <i>Class II a</i> : %#Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)#% </p><p><!--Message$KB_048666_Class5$*--><b>-   Prim msg hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_104117_Class1$*--><b>-   Presence of ACE good message</b>  <i>Recommendation</i> : %#Patient is on ACE Inhibitor. Good!#% </p><p><!--Message$KB_234689_Class0$*--><b>-   diuretcs out of scope</b>  <i>Primary_Recommendation</i> : %#HF with reduced EF with fluid retention is an indication for diuretic therapy, but is beyond the scope of this project recommendations.#% </p><p><!--Message$KB_243202_Class1$*--><b>-   Out of scope message</b>  <i>Primary_Recommendation</i> : %#HF patients with preserved EJ function, LVEF>40) or without an LVEF value are out of scope of this CDS.#% </p><p><!--Message$KB_261275_Class13$*--><b>-   BB substitution</b>  <i>Recommendation</i> : %#Patient is taking a beta blocker that is not one of the recommeded beta blockers for heart failure patients. Evaluate susbtitution with carvedilol, bisoprolol or sustained release metoprolol succinate.#% </p><p><!--Message$KB_313397_Class1$*--><b>-   ?label</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs#% </p><p><!--Message$KB_899077_Class2$*--><b>-   rec add ACE-I dose based on 2013 ACCF/AHA Guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific ACE-I starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.#% </p><p><!--Message$KB_899077_Class4$*--><b>-   rec add ARB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below)  for specific ARB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
candesartan starting dose 4-8 mg/once; max dose 32 mg once
losartan starting dose 25-50 once; max dose 50-150 mg once
valsartan 20-40 mg twice; max dose 160 mg twice#% </p><p><!--Message$KB_899077_Class5$*--><b>-   rec add AA based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific AA starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
spironolactone starting dose 12.5 0 25.0 once; max dose 25 mg once or twice
eplerenone starting dose 25 mg once; max dose 50 mg once#% </p><p><!--Message$KB_899077_Class6$*--><b>-   rec add BB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
bisoprolol starting dose 1.25 mg once; max dose 10 mg once
carvedilol starting dose 3.125 mg twice; max dose 50 mg twice
carvedilol CR starting dose 10 mg once; max dose 80 mg once
metoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once#% </p><p><!--Message$KB_899077_Class7$*--><b>-   rec add hydralazine and nitrates based on 2013 ACCF/AHA guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific hydraline and nitrates starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
fixed dose combination starting dose 37.5 mg hydralazine + 20 mg isosorbide dintrate/ 3x; max dose 75 mg hydralazine + 40 mg isosorbide dinitrate 3x dialy
hydralazine and isosorbide dinitrate sstarting dose hydralazine 25-50 mg 3 or 4 x daily and isosorbide dintrate 20 to 30 mg 3 or 4 x dialy; max dose hydralazine 300 mg daily in divided doses and isosorbide dintrate 120 mg daily in divided doses#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10048$*--><b>-   Above Dashboard Target below JNC8 Target</b>  <i>Primary_Recommendation</i> : %#NEED TO DECIDE WHAT MESSAGE TO GIVE....

NEED TO DECIDE IF WILL DO SUBSTITUTIONS#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60000$*--><b>-   preferred drug:max dose or contraindication Refer</b>  <i>Recommendation</i> : %#Refer to hypertension specialist or explore drug options other than ACE inhibitor, ARB, calcium channel blocker or thiazides.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80010$*--><b>-   >4 active anti-hypertensive meds (broad) AND BP<220/110 AND absence IIHD AND DBP>=60</b>  <i>Recommendation</i> : %#Patient on more than 4 antihypertensive drugs. Refer to hypertension specialist.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80017$*--><b>-   BP below Dashboard and JNC target</b>  <i>Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_00099$*--><b>-   beta blocker and diltiazem</b>  <i>Recommendation</i> : %#Use caution if combining a beta blocker with diltiazem.#% </p><p><!--Message$athena_hypertension_00101$*--><b>-   Beta blocker and diabetes</b>  <i>Recommendation</i> : %#Beta blockers may mask symptoms of hypoglycemia and should be used with caution.#% </p><p><!--Message$athena_hypertension_00115$*--><b>-   Beta blocker and PVD</b>  <i>Recommendation</i> : %#Beta blockers may exacerbate symptoms of peripheral vascular disease.  It is important to ask about this potential side effect in your treated patient. #% </p><p><!--Message$athena_hypertension_00129$*--><b>-   beta blocker and verapamil</b>  <i>Recommendation</i> : %#Ordinarily we would have recommended a beta blocker as a first line agent in patients with hypertension.  However, the patient is taking verapamil, which is a contraindication to beta blocker therapy.  contraindication.#% </p><p><!--Message$athena_hypertension_00206$*--><b>-   On furosemide no CHF or RF</b>  <i>Recommendation</i> : %#Patient is taking furosemide or a loop diuretic and appears to have neither CHF nor renal insufficiency. Hydrochlorothiazide is generally a more efficacious diuretic in the management of hypertension.#% </p><p><!--Message$athena_hypertension_00223$*--><b>-   assumption Female between 50 and 60</b>  <i>Assumption</i> : %#We assume women older than 50 years are postmenopausal. If this is not the case for your patient, be alert for the possibility of pregnancy. These recommendations DO NOT apply to women who are pregnant.  Please make sure this patient is not pregnant before acting on recommendations.#% </p><p><!--Message$athena_hypertension_00244$*--><b>-   Low K. Consider hyperaldosteronism</b>  <i>Recommendation</i> : %#This patient's most recent potassium is below normal limits. Use care if initiating or continuing diuretic therapy. Hyperaldosteronism may be a consideration in this patient's hypokalemia.#% </p><p><!--Message$athena_hypertension_00451$*--><b>-   on beta blocker plus verapamil</b>  <i>Recommendation</i> : %#This patient has prescriptions for both verapamil and beta blocker.  Please re-evaluate this combination, which can increase risk of heart block.#% </p><p><!--Message$athena_hypertension_00518$*--><b>-   ISH Message</b>  <i>Recommendation</i> : %#Both thiazide diuretics and dihydropyridine calcium channel blockers are effective in lowering the risk of stroke in ISH,  but there have been no head to head comparisons. Thiazides are far less expensive.#% </p><p><!--Message$athena_hypertension_00569$*--><b>-   Central Alphas and Depression</b>  <i>Recommendation</i> : %#Central alpha-agonists (e.g., clonidine or methlydopa) may cause or exacerbate the symptoms of depression and should be used with caution.#% </p><p><!--Message$athena_hypertension_00570$*--><b>-   Reserpine and depression</b>  <i>Recommendation</i> : %#Reserpine may cause or exacerbate the symptoms of depression and should be used with caution.#% </p><p><!--Message$athena_hypertension_00641$*--><b>-   Labetalol and Liver Disease</b>  <i>Recommendation</i> : %#Labetalol has extensive first pass clearance and the rate of metabolism is sensitive to hepatic blood flow. Liver disease is a relative contraindication.#% </p><p><!--Message$athena_hypertension_00654$*--><b>-   Liver Disease and methyldopa</b>  <i>Recommendation</i> : %#Methyldopa can induce hepatitis; it is advisable to avoid its use in patients with liver disease.#% </p><p><!--Message$athena_hypertension_01936$*--><b>-   On clonidine</b>  <i>Recommendation</i> : %#National and VA Guidelines DO NOT recommend CLONIDINE as a preferred drug, either for uncomplicated hypertension or for specific comorbidities.#% </p><p><!--Message$athena_hypertension_04834$*--><b>-   assumption No ADE current drug</b>  <i>Assumption</i> : %#Current antihypertensive drugs have no adverse reactions listed.  If the patient has had an adverse reaction/allergy please enter it in "Orders" tab in CPRS under  "Allergies/Adverse Reactions".#% </p><p><!--Message$athena_hypertension_04852$*--><b>-   NO ADE recommended drug</b>  <i>Recommendation</i> : %#No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".#% </p><p><!--Message$athena_hypertension_04863$*--><b>-   assumption No BPH </b>  <i>Assumption</i> : %#We assume that patients do not have benign prostatic hyperplasia unless it is listed as a diagnosis. If this patient does have benign prostatic hyperplasia, please enter that diagnosis on the problem list. This can be done using the "problem list" tab in CPRS or mark "add" for the diagnosis in the encounter form. #% </p><p><!--Message$athena_hypertension_04884$*--><b>-   alpha blocker orthostasis</b>  <i>Recommendation</i> : %#This patient has an active prescription for an alpha adrenergic antagonist. We assume that you have checked the patient's standing blood pressure and that the patient does not have orthostasis (for example, SBP drop >20 mmHg).#% </p><p><!--Message$athena_hypertension_05575$*--><b>-   on clonidine, warning side effects</b>  <i>Recommendation</i> : %#Inquire about  the presence of side effects of clonidine such as dry mouth, postural hypotension and alterations in mental state. Evaluate clinical benefits versus harm.#% </p><p><!--Message$athena_hypertension_05580$*--><b>-   on clonidine, has compelling indication for BB</b>  <i>Recommendation</i> : %#This patient has a compelling indication for a beta adrenoreceptor antagonist. When blood pressure is controlled consider tapering off clonidine and initiating a beta adrenergic receptor blocker.#% </p><p><!--Message$athena_hypertension_09865$*--><b>-   ADE to Recommened Drug</b>  <i>Recommendation</i> : %#There is an allergy or adverse drug reaction reported for a drug that is recommended below. Consult the Patient History for a listing of the reported event and use clinical judgment to determine whether to disgard the recommendation.#% </p><p><!--Message$athena_hypertension_100871$*--><b>-   Clonidine withdrawal</b>  <i>Recommendation</i> : %#Use caution when discontinuing clonidine. Gradual dosage reduction may be necessary to avoid serious rebound hypertension.  This risk is increased when clonidine dose is greater than 0.6mg/day or diastolic is greater then 105mmHg.#% </p><p><!--Message$athena_hypertension_104229$*--><b>-   Susbtituting away fom alpha blocker, no BPH?</b>  <i>Recommendation</i> : %#We could not find a diagnosis of BPH. If there is a diagnosis of BPH please update the problem list and ignore this recommendation to substitute away from the alpha blocker.#% </p><p><!--Message$athena_hypertension_110155$*--><b>-   Heart failure and NOT on beta blocker</b>  <i>Recommendation</i> : %#While beta blockers are indicated in certain patients with CHF, managing patients with CHF on beta blockers is complex and beyond the scope of the Hypertension Guidelines.#% </p><p><!--Message$athena_hypertension_14109$*--><b>-   No BP in database, assumption target achieved</b>  <i>Primary_Recommendation</i> : %#NO blood pressure in database, please UPDATE BP in "Today's Decision BP": ASSUMPTION TARGET BP ACHIEVED.#% </p><p><!--Message$athena_hypertension_14130$*--><b>-   Lack of drug recommendation</b>  <i>Primary_Recommendation</i> : %#We are recommending INTENSIFY therapy but have not generated a drug recommendation. Consider consultation.#% </p><p><!--Message$athena_hypertension_144351$*--><b>-   ALPHA BLOCKER MONOTHERAPY NO  BPH</b>  <i>Primary_Recommendation</i> : %#ALPHA BLOCKER MONOTHERAPY for hypertension is currently NOT recommended, consider adding a drug independent of blood pressure control. If patient has BPH, please add diagnosis to CPRS.#% </p><p><!--Message$athena_hypertension_148449$*--><b>-   Alpha blocker and dose titration</b>  <i>Recommendation</i> : %#To decrease the likelihood of syncope or excessive hypotension treatment should usually be initiated with a dose of 1 or 2 mgs at bedtime. The dose should be increased in a stepwise fashion. Blood pressures should be measured to check for postural drop.#% </p><p><!--Message$athena_hypertension_149465$*--><b>-   SBP<100</b>  <i>Primary_Recommendation</i> : %#Most recent SBP<100mmHg, use clinical judgement to evaluate therapeutic strategy.#% </p><p><!--Message$athena_hypertension_15045$*--><b>-   no default drug to substitute with, absolute contraindication</b>  <i>Recommendation</i> : %#We are recommending SUBSTITUTING AWAY from a drug due to a strong contraindication but have not generated a drug recommendation. Consider consultation.#% </p><p><!--Message$athena_hypertension_15048$*--><b>-   No BP in database, assumption target not achieved</b>  <i>Primary_Recommendation</i> : %#NO blood pressure in database, please UPDATE BP in "Today's Decision BP": ASSUMPTION TARGET BP NOT ACHIEVED.#% </p><p><!--Message$athena_hypertension_154824$*--><b>-   alpha blocker monotherapy</b>  <i>Recommendation</i> : %#Treating the hypertensive man with BPH with alpha blocker MONOTHERAPY is currently not recommended.#% </p><p><!--Message$athena_hypertension_160438$*--><b>-   on clonidine</b>  <i>Recommendation</i> : %#Very little is known about the efficacy of clonidine in reducing morbidity associated with hypertension.#% </p><p><!--Message$athena_hypertension_166907$*--><b>-   ARB II-check K and Cr</b>  <i>Recommendation</i> : %#Check the patient's plasma creatinine and potassium concentrations when prescribing or increasing dose of  angiotensin II receptor blockers.#% </p><p><!--Message$athena_hypertension_168639$*--><b>-   assumption Women aged 60+ and menopause</b>  <i>Assumption</i> : %#We assume women older than 60 years are postmenopausal. #% </p><p><!--Message$athena_hypertension_174120$*--><b>-   SBP<100</b>  <i>Primary_Recommendation</i> : %#Most recent SBP<100mmHg, use clinical judgement to evaluate therapeutic strategy.#% </p><p><!--Message$athena_hypertension_178163$*--><b>-   DBP<60 and SBP<goal</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$athena_hypertension_179265$*--><b>-   PM BP not controlled, DBP<70</b>  <i>Primary_Recommendation</i> : %#We are recommending treatment to lower SBP. Use clinical judgment to evaluate the degree of DBP lowering that is acceptable.#% </p><p><!--Message$athena_hypertension_181132$*--><b>-   PM: MI on clonidine, no beta blocker</b>  <i>Primary_Recommendation</i> : %#Beta blockers are recommended for patients post MI but these drugs are not
generally advisable in conjunction with clonidine.#% </p><p><!--Message$athena_hypertension_185078$*--><b>-   assumption Dx on encounter form or problem list</b>  <i>Recommendation</i> : %#Diagnosis from encounter forms and problem list are used in the reasoning for this advisory. If patient has a relevant diagnosis not listed please update CPRS.#% </p><p><!--Message$athena_hypertension_185439$*--><b>-   Primary: Active prescription for BB and verapamil</b>  <i>Primary_Recommendation</i> : %#There is a risk of HEART BLOCK from combining verapamil and beta blocker.#% </p><p><!--Message$athena_hypertension_185968$*--><b>-   Assumption: Home BP Target Goal</b>  <i>Assumption</i> : %#When using home blood pressures to assess adequacy of blood pressure
control, remember that the targets are different.  There is no universally 
agreed-on upper limit of normal home blood pressure, but readings 
of  135/85 mmHg or greater should be considered elevated if the patient's 
clinic blood pressure target is 140/90 mmHg.  If the patient's clinic target BP 
is lower, for example 140/80 mmHg because of diabetes, the home blood pressure 
targets should be correspondingly lower.#% </p><p><!--Message$athena_hypertension_185971$*--><b>-   assumption: Absence Lab values</b>  <i>Assumption</i> : %#If there are no data for laboratory results (sodium, creatinine,
potasium, uric acid, etc.) Athena Hypertension Advisory assumes these values
are within the normal limits.  This may not be a correct 
assumption.  Please keep this in mind when you evaluate the recommendations 
made here.#% </p><p><!--Message$athena_hypertension_188555$*--><b>-   Active prescription for Clonidine and BB</b>  <i>Recommendation</i> : %#It is generally not desirable to combine clonidine and beta blocker because of their overlapping capacity to slow heart rate.#% </p><p><!--Message$athena_hypertension_192997$*--><b>-   Primary Msg: Add ACE I and dx renal disease</b>  <i>Primary_Recommendation</i> : %#Benefit of ADDING ACEI versus risk of HYPERKALEMIA requires clinical judgement in presence of renal disease.
#% </p><p><!--Message$athena_hypertension_206788$*--><b>-   assumption drug dose </b>  <i>Assumption</i> : %#Daily dosage calculation is based on the following formula:  [(strength of dosage form) x (number of dosage forms)]/days supply. If extra dosage forms (tablets) are dispensed there may be an overestimation of actual daily dose.  The calculated daily dose is displayed in the patient summary.#% </p><p><!--Message$athena_hypertension_222400$*--><b>-   substitution explanation metoprolol+felodipine</b>  <i>Recommendation</i> : %#This patient will benefit from metoprolol (secondary prevention of MI).  Because blood pressure elevation is significant we recommend substituting with felodipine and adding metoprolol. Recheck BP in 4-6 weeks.#% </p><p><!--Message$athena_hypertension_223693$*--><b>-   Assumption about secondary prevention MI</b>  <i>Assumption</i> : %#The evidence for benefits of secondary prevention of myocardial infarct is when beta adrenergic receptor antagonists are started within 2-4 weeks of the event. This program is limited in identifying this interval and therefore we recommend beta adrenergic receptor antagonists to patients with a history of MI.#% </p><p><!--Message$athena_hypertension_23973$*--><b>-   On ACE inhibitor and K sparing diuretic, hyperkalemia warning</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_253466$*--><b>-   HF and MI, using diltiazem</b>  <i>Recommendation</i> : %#Felodipine is the preferred calcium channel blocker because it has less myocardial depressant effects than diltiazem.#% </p><p><!--Message$athena_hypertension_254903$*--><b>-   compelling if symptomatic BPH</b>  <i>Recommendation</i> : %#Compellingly indicated if the patient has symptomatic BPH.#% </p><p><!--Message$athena_hypertension_259472$*--><b>-   BPH and use of alpha blocker</b>  <i>Recommendation</i> : %#Patient may benefit from using an alpha blocker. Evaluate adding an alpha blocker to this patient's therapy and adjusting other drug doses accordingly.#% </p><p><!--Message$athena_hypertension_260886$*--><b>-   Primary: On clonidine ADD Alpha blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotension before adding alpha blocker to clonidine.#% </p><p><!--Message$athena_hypertension_260890$*--><b>-   Primary: On clonidine INCREASE DOSE Alpha blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotension before increasing dose of alpha blocker in patient on clonidine.#% </p><p><!--Message$athena_hypertension_260895$*--><b>-   Primary: Not on clonidine Increase dose Alpha Blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotenstion before increasing dose of alpha blocker.#% </p><p><!--Message$athena_hypertension_262501$*--><b>-   ADR ACE (DM or HF), not rec ARB risk cross reactivity</b>  <i>Recommendation</i> : %#This patient had an adverse drug reaction to ACE inhibitor. ARB's are not recommended due to the risk of cross reactivity.#% </p><p><!--Message$athena_hypertension_264390$*--><b>-   high K (>5.5)</b>  <i>Recommendation</i> : %#Greatly elevated K, requires immediate intervention.#% </p><p><!--Message$athena_hypertension_268571$*--><b>-   No BB and CAD</b>  <i>Recommendation</i> : %#VA Hypertension guidelines recommend beta blockers for patients with coronary artery disease. Current evidence strongly supports beta blockers for secondary prevention of myocardial infarction however for primary prevention it remains unclear if they are superior to thiazide diuretics.#% </p><p><!--Message$athena_hypertension_269219$*--><b>-   Na<=125 and on thiazide</b>  <i>Recommendation</i> : %#A recent sodium was below 125 mEq/l. Consider reducing dose or discontinuing diuretic therapy based on current value.#% </p><p><!--Message$athena_hypertension_269228$*--><b>-   sinoatrial node dysfunction, no pacemaker, on BB</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction, no pacemaker and a prescription for beta blocker and is therefore at increased risk for heart block. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269231$*--><b>-   on BB, depression caution</b>  <i>Recommendation</i> : %#Use caution as beta blockers may cause or exacerbate symptoms of depression; however, many patients tolerate them without difficulty.#% </p><p><!--Message$athena_hypertension_269233$*--><b>-   on amiodarone and BB</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and beta adrenergic receptor antagonist may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_269237$*--><b>-   sinoatrial node dysfunction, no pacemaker, on diltiazem or verapamil</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction, no pacemaker and a prescription for diltiazem or verapamil and is therefore at increased risk for heart block. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269239$*--><b>-   on amiodarone and diltiazem (or verapamil)</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and diltiazem or verapamil may result in excessive lowering of heart rate. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269243$*--><b>-   gout and thiazides</b>  <i>Recommendation</i> : %#Thiazides may increase uric acid levels and induce an acute gout attack. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269249$*--><b>-   low K and on thiazide primary msg</b>  <i>Primary_Recommendation</i> : %#Hypokalemia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_269253$*--><b>-   high uric acid, on thiazides</b>  <i>Recommendation</i> : %#This patient has a prescription for a thiazide diuretic, and the most recent uric acid is above normal limits.  We recommend that you check uric acid.#% </p><p><!--Message$athena_hypertension_269261$*--><b>-   assumption no dx hypertension</b>  <i>Assumption</i> : %#If this patient does not have hypertension, or if this patient already has a diagnosis of secondary hypertension on the problem list, please take a moment to tell us that, using the "comment" box at the bottom of the recommendations screen.  You can also send us an email, if you like, in DHCP (VA Palo Alto): Susana Martins (Susana.Martins@med.va). You can open DHCP to send email without closing your CPRS-GUI window.#% </p><p><!--Message$athena_hypertension_269263$*--><b>-   assumption exclusion </b>  <i>Assumption</i> : %#This program does NOT provide recommendations for patients with SECONDARY HYPERTENSION, NARCOLEPSY, ASCITES, SPINAL-CORD INJURY , or IDIOPATHIC HYPERTHROPHIC SUBAORTIC STENOSIS. If this patient has one or more of these diagnoses, please ADD it to the patient's PROBLEM LIST.#% </p><p><!--Message$athena_hypertension_269598$*--><b>-   ACE and high K (>5.5), on thiazides</b>  <i>Recommendation</i> : %#Patient's MOST RECENT K>5.5mEq/L. Recheck and follow K+ closely, consider decreasing dose of ACE inhibitor.#% </p><p><!--Message$athena_hypertension_272593$*--><b>-   Carvedilol+MI+BPH, no HF</b>  <i>Recommendation</i> : %#Patient has a diagnosis of myocardial infarction and benign prostatic hyperplasia and NO heart failure. Use of metoprolol (secondary prevention of myocardial infarction) and terazosin may provide more benefits than carvedilol. If patient has heart failure please update the problem list.#% </p><p><!--Message$athena_hypertension_272595$*--><b>-   Combination therapy</b>  <i>Recommendation</i> : %#There is not much information on combination therapy for hypertension. If BP is not controlled after 3 months at maximum tolerated dose we suggest substituting one or more drugs.#% </p><p><!--Message$athena_hypertension_295517$*--><b>-   DBP<60 on NO meds, REC add med</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed 
with repeat BPs, evaluate benefit:risk of adding recommended drugs.#% </p><p><!--Message$athena_hypertension_29761$*--><b>-   disclaimer about procedure reports delete</b>  <i>Recommendation</i> : %#Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.#% </p><p><!--Message$athena_hypertension_29764$*--><b>-   disclaimer for EKG reports</b>  <i>Recommendation</i> : %#Diagnosis from EKG reports are not extracted. If patient has an arrythmia that is not included in the problem list please update it.#% </p><p><!--Message$athena_hypertension_29771$*--><b>-   assumption disclaimer about procedure reports</b>  <i>Assumption</i> : %#Diagnoses from procedure reports (EKG, X-ray, etc.) are not recognizable to ATHENA DSS.  ATHENA pulls diagnoses from the problem list and the list of diagnoses for each visit on the encounter forms.  The Patient Summary in ATHENA shows the diagnoses for this patient that are known to the program. If patient has a diagnosis that is not included in the Patient Summary, please update the problem list, or include the diagnosis on today's encounter form.#% </p><p><!--Message$athena_hypertension_308494$*--><b>-   labetolol substitution- primary message</b>  <i>Primary_Recommendation</i> : %#Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred#% </p><p><!--Message$athena_hypertension_31097$*--><b>-   Cr>2.0 and HCTZ dosing message</b>  <i>Recommendation</i> : %#While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.#% </p><p><!--Message$athena_hypertension_31112$*--><b>-   unspecified heart block, on BB</b>  <i>Recommendation</i> : %#This patient has a diagnosis of unspecified heart block. Second or third degree heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug. Update problem list.#% </p><p><!--Message$athena_hypertension_32502$*--><b>-   pregnancy and on ACE primary msg</b>  <i>Primary_Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for ACE inhibitors. Discontinue ACE inhibitor.#% </p><p><!--Message$athena_hypertension_32514$*--><b>-   PRECAUTION, ON HCTZ AND Na<=125 primary msg</b>  <i>Primary_Recommendation</i> : %#Hyponatremia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_325595$*--><b>-   On high dose hctz</b>  <i>Primary_Recommendation</i> : %#HCTZ DOSE ABOVE 25 mg DOES NOT ADD TO BP CONTROL for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_hypertension_331482$*--><b>-   3 drugs, increasing dose, no HCTZ</b>  <i>Recommendation</i> : %#In general, multidrug regimens should include a thiazide diuretic unless contraindicated. However, since that would add a 4th antihypertensive drug to this patient's regimen, we recommend consultation.#% </p><p><!--Message$athena_hypertension_33446$*--><b>-   ADR ACE inhibitor and ON ACE</b>  <i>Primary_Recommendation</i> : %#An ADVERSE DRUG EVENT has been listed for ACE inhibitor.  EVALUATE THE CLINICAL SIGNIFICANCE.#% </p><p><!--Message$athena_hypertension_37144$*--><b>-   ADE to ACE precaution msg</b>  <i>Recommendation</i> : %#An adverse drug event has been listed for ACE inhibitor.  Analyzing the significance of the adverse event is beyond the scope of this program.  Evaluate the clinical significance of the reported adverse event.#% </p><p><!--Message$athena_hypertension_37146$*--><b>-   unspecified heart block primary msg</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of unspecified heart block. Second or third degree heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers.#% </p><p><!--Message$athena_hypertension_37150$*--><b>-   pregnancy and on ACE precaution msg</b>  <i>Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for ACE inhibitors. Discontinue ACE inhibitor.#% </p><p><!--Message$athena_hypertension_37152$*--><b>-   PRECAUTION, ON HCTZ AND Na<=125 precaution msg</b>  <i>Recommendation</i> : %#Hyponatremia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_37154$*--><b>-   on BB presence of bronchospasm precaution msg</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist. Please monitor patient carefully if maintaining beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_37155$*--><b>-   presence gout complicated and on thiazides precaution msg</b>  <i>Recommendation</i> : %#Presence of tophaceous gout is a STRONG CONTRAINDICATION for use of thiazides. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_37156$*--><b>-   heart block without pacemaker, on beta blocker precaution msg</b>  <i>Recommendation</i> : %#Presence of heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_37157$*--><b>-   low K and on thiazide precaution msg</b>  <i>Recommendation</i> : %#Hypokalemia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_372688$*--><b>-   Ischemic Heart disease and DBP<60 and BP not at target</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_375576$*--><b>-   add BB & dislipidemia</b>  <i>Recommendation</i> : %#Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.#% </p><p><!--Message$athena_hypertension_382799$*--><b>-   Home BP  for Target</b>  <i>Primary_Recommendation</i> : %#A HOME BP is used to determine if patient met BP TARGET (see assumptions for detailed description).#% </p><p><!--Message$athena_hypertension_394087$*--><b>-   Hyponatremia in the past, Rec add Thiazide</b>  <i>Primary_Recommendation</i> : %#Patient had SEVERE HYPONATREMIA in the past, monitor introduction of thiazide therapy closely.#% </p><p><!--Message$athena_hypertension_397722$*--><b>-   PM: Sinoatrial node dysfunction , no pacemaker on a BB</b>  <i>Primary_Recommendation</i> : %#Presence of Sinoatrial node dysfunction without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_406825$*--><b>-   Risk Group C and DM</b>  <i>Recommendation</i> : %#This patient has hypertension and diabetes (Risk Group C per JNC6) and should be considered for prompt and intensive pharmacologic therapy.  Aggressive lowering of blood pressure in people with diabetes and hypertension reduces cardiovascular morbidity and mortality, therefore recommended BP goal is less than 130/85.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_hypertension_407232$*--><b>-   assumption Disclaimer</b>  <i>Assumption</i> : %#Recommendations of the ATHENA DSS must be considered in the context of full information about the patient and the clinician-patient interaction.  The final responsibility for medical management rests with the prescribing/treating clinician (physician or nurse practitioner).  While we have made every effort to ensure that the recommendations generated by ATHENA DSS reflect the current evidence for management of hypertension, we cannot guarantee that the program will generate a recommendation for the best treatment in all cases.  Please use your clinical judgment in evaluating recommendations from ATHENA DSS.  If you see recommendations that you believe represent errors in the program, please call them to our attention.#% </p><p><!--Message$athena_hypertension_407235$*--><b>-   assumption Update BP</b>  <i>Assumption</i> : %#A BP entered into the ATHENA system today will not be entered into the patient's electronic medical record.  The program will use the BP to update the recommendations on the screen, but it will not write the BP to VistA, so the BP will not show up in   CPRS-GUI.  You can enter additional BP's into the patient's permanent medical record by clicking 'BP' in the Vitals box on the CPRS-GUI main screen.  Click 'Enter Vitals' in the top left of the screen, select the appropriate appointment location, and then enter the new blood pressure at the prompt.  Any BP you add to the patient's medical record today will be available to this program at the patient's next visit. The ATHENA system will have a write-back feature implemented in the near future that will allow you to write BP's you enter in ATHENA to CPRS.#% </p><p><!--Message$athena_hypertension_409238$*--><b>-   Ischemic heart disease and nitrates</b>  <i>Assumption</i> : %#Recommending nitrates for management of hypertension in patients with ischemic heart disease is beyond the scope of this program.#% </p><p><!--Message$athena_hypertension_40932$*--><b>-   primary msg Warning pregnancy female<50yrs</b>  <i>Primary_Recommendation</i> : %#RECOMMENDATIONS DO NOT APPLY TO PREGNANT WOMEN (or women likely to become pregnant or nursing mother).#% </p><p><!--Message$athena_hypertension_410347$*--><b>-   assumption about targets for home BP</b>  <i>Assumption</i> : %#Consensus of Expert Team (Mary Goldstein, Brian Hoffman, Gene Oddone, Paul, ... Cushman, David Simel,...) defined the following targets for home BP's: Absence of Diabetes or CKD: 135/85mmHg; Presence of Diabetes or CKD: 135/80mmHg and presence of proteinuria >1g/day: 125/75mmHg. If patient has multiple conditions ATHENA uses the lowest target.#% </p><p><!--Message$athena_hypertension_412235$*--><b>-   Assumption about eGFR</b>  <i>Assumption</i> : %#The eGFR is calculated based on the most recent serum creatinine.#% </p><p><!--Message$athena_hypertension_43300$*--><b>-   SBP>=220 or DBP>=115, etiology message</b>  <i>Primary_Recommendation</i> : %#Marked elevations of BP have many possible explanations, for example: non-adherence to therapy, inadequate diuretic treatment or renal dysfunction.#% </p><p><!--Message$athena_hypertension_43301$*--><b>-   SBP>=220 or DBP>=115, urgent attention</b>  <i>Primary_Recommendation</i> : %#SBP>220 or DBP>115 so treatment recommendations are beyond the scope of this program. If MARKED BP ELEVATION is confirmed, then the patient needs further TREATMENT and EARLY FOLLOW-UP to MONITOR THERAPEUTIC EFFICACY. #% </p><p><!--Message$athena_hypertension_44146$*--><b>-   Risk group C, no meds and high normal BP</b>  <i>Primary_Recommendation</i> : %#Some patients with HIGH NORMAL BP (per JNC6) and a diagnosis of renal insufficiency, heart failure or diabetes should be considered for PROMPT pharmacologic therapy.#% </p><p><!--Message$athena_hypertension_464777$*--><b>-   low Na and on thiazides precaution msg</b>  <i>Recommendation</i> : %#This patient has a prescription for a diuretic, and the most recent sodium is below normal limits.  We recommend that you recheck the sodium.#% </p><p><!--Message$athena_hypertension_467644$*--><b>-   minimum dose ACE and secondary prevention DM</b>  <i>Recommendation</i> : %#Clinical trials showing the efficacy of ACE-Inhibitors in patients with diabetes mellitus for secondary prevention have used minimum daily dosage equivalent to approximately 5-10 mg of lisinopril, so it is not known if lower doses are effective.  However, it is often prudent to start at a lower dosage and titrate upward slowly.#% </p><p><!--Message$athena_hypertension_468867$*--><b>-   assumption about prescriptions</b>  <i>Assumption</i> : %#If a prescription expires, it will not appear on the active medication list though the patient may still be taking the medication.  This will be reflected correctly in the prescription graph (see BP-Prescription Graphs tab).  #% </p><p><!--Message$athena_hypertension_484968$*--><b>-   primary: Cough as ADR to ACE, no angioedema, rec add ARB</b>  <i>Primary_Recommendation</i> : %#Patient has cough as an ADR to ACE and there is no record of angioedema, please exclude possibility of other serious adverse reactions before prescribing ARB.#% </p><p><!--Message$athena_hypertension_492203$*--><b>-   heart block without pacemaker, on beta blocker primary msg</b>  <i>Primary_Recommendation</i> : %#Presence of heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_492207$*--><b>-   presence gout complicated and on thiazides</b>  <i>Primary_Recommendation</i> : %#Presence of tophaceous gout is a STRONG CONTRAINDICATION for use of thiazides. Use caution if maintaining prescription of this drug.
#% </p><p><!--Message$athena_hypertension_493229$*--><b>-   assumption: Medication calculations</b>  <i>Assumption</i> : %#Medication information used by ATHENA is based on the "fill date"  (or reflll or partial fill) from the VA pharmacy database.  the "fill date" indicates that the prescription was filled by the pharmacy, but it does not necessarily mean that the patient picked up the medication. We also use information from the pharmacy database about how many pills/tablets the patient picked up.  We use this information, together with the "days supplied" (to take account of tablet-splitting), in estimating how many days of coverage for the medication the patient has.#% </p><p><!--Message$athena_hypertension_504686$*--><b>-   Presence of phosphodiasterase-5 enzyme inhibitors  and alpha blocker</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an alpha blocker and a phosphodiasterase-5 enzyme inhibitors.  Increased risk of hypotension when taking both drugs.#% </p><p><!--Message$athena_hypertension_508280$*--><b>-   ATHENA HTN Disclaimer</b>  <i>Recommendation</i> : %#The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.#% </p><p><!--Message$athena_hypertension_508281$*--><b>-   Pointer to ATHENA HTN Disclaimer</b>  <i>Primary_Recommendation</i> : %#Please see the Precautions tab for the disclaimer on the ATHENA HTN demo system.#% </p><p><!--Message$athena_hypertension_510168$*--><b>-   Using 2 ACE's</b>  <i>Primary_Recommendation</i> : %#USING 2 ACE#% </p><p><!--Message$athena_hypertension_510604$*--><b>-   bronchospasm, rec increase BB</b>  <i>Recommendation</i> : %#Bronchospasm is a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_522476$*--><b>-   LDL disclaimer</b>  <i>Assumption</i> : %#LDL laboratory values are coded differently at different medical centers. In some cases complete information may not be available to the ATHENA System. Clinican decision regarding LDL should be based on CPRS information.
#% </p><p><!--Message$athena_hypertension_524500$*--><b>-   creatinine>uln females</b>  <i>Recommendation</i> : %#Warning: creatinine value is greater than 1.3 mg/dL, upper limit of normal for females.#% </p><p><!--Message$athena_hypertension_69873$*--><b>-   primary ARB and pregnancy</b>  <i>Primary_Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for Angiotensin II Receptor Blocker (ARB). Discontinue ARB.#% </p><p><!--Message$athena_hypertension_69874$*--><b>-   precaution ARB and pregnancy</b>  <i>Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for Angiotensin II Receptor Blocker (ARB). Discontinue ARB.#% </p><p><!--Message$athena_hypertension_81529$*--><b>-   primary message: on HCTZ; 3.0<K<3.5</b>  <i>Primary_Recommendation</i> : %#Most recent serum Potassium relatively low. Thiazides can contribute to hypokalemia.#% </p><p><!--Message$athena_hypertension_81530$*--><b>-   precautions: on HCTZ; 3.0<K<3.5</b>  <i>Recommendation</i> : %#Most recent serum Potassium relatively low. Thiazides can contribute to hypokalemia.#% </p><p><!--Message$athena_hypertension_81532$*--><b>-   USING HCTZ, K<3.5</b>  <i>Recommendation</i> : %#Low dose diuretics may unmask hyperaldosteronism, manifesting as hypokalemia.#% </p><p><!--Message$athena_hypertension_82821$*--><b>-   ALPHA BLOCKER MONOTHERAPY w BPH</b>  <i>Primary_Recommendation</i> : %#ALPHA BLOCKER MONOTHERAPY for hypertension is currently NOT recommended, consider adding a drug independent of blood pressure control.#% </p><p><!--Message$athena_hypertension_84361$*--><b>-   CCB and Angina collateral action message</b>  <i>Recommendation</i> : %#If indicated, the patient should be warned about the possibility of chest pain after discontinuing a calcium channel blocker. Some patients experience angina that is 'unmasked' when a calcium channel blocker is discontinued.#% </p><p><!--Message$athena_hypertension_INSTANCE_00056$*--><b>-   creatinine > uln warning males</b>  <i>Recommendation</i> : %#Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.#% </p><p><!--Message$athena_hypertension_INSTANCE_00062$*--><b>-   assumption no creatinine message</b>  <i>Assumption</i> : %#We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.#% </p><p><!--Message$athena_hypertension_INSTANCE_00063$*--><b>-   assumption no systolic or diastolic BP message</b>  <i>Assumption</i> : %#We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.#% </p><p><!--Message$athena_hypertension_INSTANCE_00130$*--><b>-   heart failure beta blocker message</b>  <i>Recommendation</i> : %#Beta blockers have a strong mortality benefit for persons with heart failure from LV dysfunction. Because the initiation and titration of beta blockers requires careful monitoring, consider referring patient to a special program for heart failure patients.#% </p><p><!--Message$athena_hypertension_INSTANCE_00537$*--><b>-   continue life style change w/o drug message</b>  <i>Primary_Recommendation</i> : %#Blood pressure appears to be adequately controlled based on the most recent available BP. Continue to follow patient and encourage healthy lifestyle.#% </p><p><!--Message$athena_hypertension_INSTANCE_00552$*--><b>-   check compliance</b>  <i>Recommendation</i> : %#Patient's blood pressure is not adequately controlled.  Check that the patient is taking the drugs that have been prescribed.#% </p><p><!--Message$athena_hypertension_INSTANCE_00600$*--><b>-   HCTZ dosing message</b>  <i>Recommendation</i> : %#HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_runtime_14973$*--><b>-   Beta blocker secondary prevention</b>  <i>Recommendation</i> : %#Beta blockers may reduce the risk for subsequent MI and sudden cardiac death and should be considered for this patient.#% </p><p><!--Message$athena_runtime_15058$*--><b>-   CAD and CHF No beta blocker</b>  <i>Recommendation</i> : %#Beta blockers have not been recommended because their use in patients with CHF is outside the scope of this guideline.#% </p><p><!--Message$athena_runtime_15104$*--><b>-   Multiple dose increase</b>  <i>Recommendation</i> : %#When modifying the dosage of multiple drugs, doses should be carefully titrated one medication at a time to minimize the potential of dose related adverse events.#% </p><p><!--Message$athena_runtime_77285$*--><b>-   stepping down message</b>  <i>Primary_Recommendation</i> : %#Consider stopping antihypertensive medication.#% </p><p><!--Message$athena_runtime_77286$*--><b>-   substitution message</b>  <i>Primary_Recommendation</i> : %#Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.#% </p><p><!--Message$athena_runtime_INSTANCE_00019$*--><b>-   encourage smoking cessation</b>  <i>Recommendation</i> : %#If patient is still smoking, please encourage smoking cessation#% </p><p><!--Message$athena_runtime_INSTANCE_00051$*--><b>-   interim SBP goal</b>  <i>Recommendation</i> : %#For elderly patients with marked systolic hypertension (SBP>160), an interim goal of SBP below 160 mmHg may be necessary.#% </p><p><!--Message$athena_runtime_INSTANCE_00054$*--><b>-   risk group B message</b>  <i>Recommendation</i> : %#This patient has one or more risk factors for clinical cardiovascular disease (Risk Group B per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt and intensive pharmacologic therapy.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_runtime_INSTANCE_00074$*--><b>-   risk group C message, no DM</b>  <i>Recommendation</i> : %#This patient has clinically manifest cardiovascular disease or target organ damage (Risk Group C per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt pharmacologic therapy, even if the BP is in the high-normal range.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_runtime_INSTANCE_00303$*--><b>-   betablocker dyslipidemia warning message</b>  <i>Recommendation</i> : %#Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.#% </p><p><!--Message$Lipid_dashboard_Class100010$*--><b>-   Pres hem stroke msg, risk/benefit of increasing dose</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke but is not at goal..  Consider risk/benefit of increasing statin dose or intensity.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100011$*--><b>-   Increase dose to moderate intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has DM.  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class100012$*--><b>-   Increase dose to high intensity msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider increasing dose to high intensity dose.#% </p><p><!--Message$Lipid_dashboard_Class100013$*--><b>-   Substitute high intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider substituting high intensity atorvastatin or rosuvastatin in place of existing statin#% </p><p><!--Message$Lipid_dashboard_Class100014$*--><b>-   Intolerance to increase statin dose msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of statns, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>#% </p><p><!--Message$Lipid_dashboard_Class100015$*--><b>-   Refusal or intolerance to statin</b>  <i>Recommendation</i> : %#If patient refuses statins or cannot tolerate statins, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100019$*--><b>-   Monitor liver function as appropriate</b>  <i>Recommendation</i> : %#Monitor liver function as appropriate.#% </p><p><!--Message$Lipid_dashboard_Class100031$*--><b>-   ADR to statin msg</b>  <i>Primary_Recommendation</i> : %#If patient has an ADR to a statin or cannot tolerate current dose, consider decreasing dose, substituting a different statin or stopping statin.  If stopping statin or if patient refuses to continue statins, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class110003$*--><b>-   Women ages 18-50:  pregnant women</b>  <i>Primary_Recommendation</i> : %#Pregnant women and nursing mothers are out of scope for this CDS.#% </p><p><!--Message$Lipid_dashboard_Class110008$*--><b>-   Treat hi TG mgs</b>  <i>Primary_Recommendation</i> : %#Triglycerides are >=500 mg/dL.  Evaluate and treat.#% </p><p><!--Message$Lipid_dashboard_Class110011$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Consider therapeutic life style changes <link to TLC>#% </p><p><!--Message$Lipid_dashboard_Class120001$*--><b>-   Order baseline CK?</b>  <i>Recommendation</i> : %#Baseline measurement of creatinine kinase (CK) is reasonable for those individuals believed to be at increased risk for adverse muscle events based upon personal or family history of statin intolerance or muscle disease or concomitant drug therapy that might increase the risk for myopathy.#% </p><p><!--Message$Lipid_dashboard_Class180005$*--><b>-   Goals achieved</b>  <i>Primary_Recommendation</i> : %#Patient is on moderate or high dose statin or LDL<100.  Goal achieved#% </p><p><!--Message$Lipid_dashboard_Class210027$*--><b>-   Contraindicated statin AND statin interacting drug</b>  <i>Recommendation</i> : %#Patient is on a statin that is contraindicated and is taking a <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>. that increases the rist of myopathy.   Please make a decision of which statin and what dose to prescribe or consult your local pharmacist <link to statin interacting drugs>#% </p><p><!--Message$Lipid_dashboard_Class210037$*--><b>-   No contraindication AND statin interacting drug</b>  <i>Recommendation</i> : %#Patient is on  a statin AND a<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>. that increases the rist of myopathy.   Please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class220010$*--><b>-   Statin at maximum dosage level</b>  <i>Recommendation</i> : %#Statin at maximum dosage level.  should not be here.#% </p><p><!--Message$Lipid_dashboard_Class220027$*--><b>-   ASCVD msg high intensity statins contraindicated</b>  <i>Recommendation</i> : %#High intensity statins contraindicated.  Recommended moderate intensity formulatry statins.#% </p><p><!--Message$Lipid_dashboard_Class230001$*--><b>-   No statin rec for add statin</b>  <i>Primary_Recommendation</i> : %#No statin can be recommended..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class240017$*--><b>-   Absence of DM and ASDVD out of scope msg</b>  <i>Primary_Recommendation</i> : %#Patient does not have DM or ASCVD and is out of scope of this CDS.#% </p><p><!--Message$Lipid_dashboard_Class240022$*--><b>-   > 1 statin cannot generate recommendations msg</b>  <i>Primary_Recommendation</i> : %#We are unable to generate recommendations because patient is taking more than 1 statin, which is generally not recommended.#% </p><p><!--Message$Lipid_dashboard_Class250010$*--><b>-   Follow up in 4-12 weeks</b>  <i>Recommendation</i> : %#Follow up in 4-12 weeks#% </p><p><!--Message$Lipid_dashboard_Class250011$*--><b>-   Cannot tolerate high dose formulary statin msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity formulary statin, consider non-formulary statin or moderate dose statin#% </p><p><!--Message$Lipid_dashboard_Class250023$*--><b>-   Rsik/benefit msg for frail, abnormal liver/renal, Asian</b>  <i>Primary_Recommendation</i> : %#Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p><p><!--Message$Lipid_dashboard_Class260010$*--><b>-   Stop contraindicated statin</b>  <i>Primary_Recommendation</i> : %#Presence of contraindication to statin.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class260011$*--><b>-   Prim msg:  statin DDI do not increase dose</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class270009$*--><b>-   Intolerance to increase high intensity statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of atrovastatin or rosuvastatin statns, consider  <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class280004$*--><b>-   Dose level high intensity statins</b>  <i>Recommendation</i> : %#High intensity statins are recommended for patients with ASCVD.  Thie means atorvastatin (formulary) 40-80/day mg or rosuvastatin (non-formulatry) 20 mg/day.#% </p><p><!--Message$Lipid_dashboard_Class280007$*--><b>-   Dose level moderate intensity statins</b>  <i>Recommendation</i> : %#Formulary moderate intensity statins are atorvastatin 10 mg/day; simvastatin 20-40 mg/day; pravastatin 40 mg/day; lovastatin 40 mg/day.  Non-formulary moderate intensity statins are  rosuvastatin 5 mg/day; fluvastatin 80 mg/day.#% </p><p><!--Message$Lipid_dashboard_Class300117$*--><b>-   Prim msg:  statin DDI pres of statin</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about continuing use of statin or increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class30038$*--><b>-   Dose level high intensity atorvastatin</b>  <i>Recommendation</i> : %#High dose for atorvastatin is  40 mg/day or greater#% </p><p><!--Message$Lipid_dashboard_Class30040$*--><b>-   Dose level high intensity rosuvastatin</b>  <i>Recommendation</i> : %#High dose rosuvastastin is 20 mg/day or greater#% </p><p><!--Message$Lipid_dashboard_Class30059$*--><b>-   Dose level moderate intensity atorvastatin</b>  <i>Recommendation</i> : %#Moderate dose for atorvastatin is >=20 mg/day but <40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class330001$*--><b>-   Increase dose to moderate intensity ASCVD</b>  <i>Primary_Recommendation</i> : %#Patient has ASCVD and is over age 75..  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.  If patient cannot tolerate increaseing dose, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>..#% </p><p><!--Message$Lipid_dashboard_Class380000$*--><b>-   No incr dose statin msg</b>  <i>Recommendation</i> : %#We cannot recommend increasing intensity of statin.   Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class410212$*--><b>-   ASCVD Prim Msg to start high dose statin (not conditional)</b>  <i>Primary_Recommendation</i> : %#High intensity statins are recommended for patients with atherosclerotic cardiovascular disease.   Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p><p><!--Message$Lipid_dashboard_Class420000$*--><b>-   Statin rec DM patients if not 40<=age<=75</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75  (inclusinve) derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range.
Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian.#% </p><p><!--Message$Lipid_dashboard_Class430000$*--><b>-   Substitute high intensity statin for low dose statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity statns (atorvastatin>=40mg, rosuvastatin>=20mg), consider increasing dose to moderate intensity (atorvastatin >=10mg, rosuvastatin >=5 mg, simvastatin >=20 mg, lovastatin >=40 mg, fluvastatin >=80 mg.)  or<a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class70046$*--><b>-   Patient on drug that interacts w statin</b>  <i>Primary_Recommendation</i> : %#Patient is on a 
<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>  that increases the risk of myopathy; please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class70047$*--><b>-   Patient refuses statin</b>  <i>Recommendation</i> : %#If patient refuses statin or cannot tolerate statin, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class80030$*--><b>-   Statin rec DM patients if not 18<=Age<40</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75 derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range..#% </p><p><!--Message$Lipid_dashboard_Class80044$*--><b>-   No statin recommended for Substitution msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking statin that is contraindicated AND we cannot find another statin that is not contraindicated..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class90071$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p></li><li>[Parameterized Messages] </li></ul>
</ul>
<li><b>CKD</b><br>
<ul>
<li><b>CKD Dashboard Consultation Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] </li><li>[Parameterized Messages] </li></ul>
<li><b>CKD Dashboard Algorithm Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_CKD_Class100006$*--><b>-   PTH elevated, not normal Ca or phosphate or vitamin D labs</b>  <i>Primary_Recommendation</i> : %#PTH is elevated and Ca or phosphate or vitamin D labs are not within normal range.  Please assess.#% </p><p><!--Message$ATHENA_CKD_Class110001$*--><b>-   Msg to order vitamin D lab when PTH elevated</b>  <i>Recommendation</i> : %#PTH is elevated and vitamin D levels need to be assessed but lab is missing.  Please order vitamin D lab.#% </p><p><!--Message$ATHENA_CKD_Class170261$*--><b>-   ACR>300 refer</b>  <i>Primary_Recommendation</i> : %#ACR>300.  Please refer to nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40030$*--><b>-   Pres of ASCVD msg to consider antiplatelet</b>  <i>Recommendation</i> : %#Consider antiplatelet therapy for patients with CKD and atherosclerotic vascular disease.#% </p><p><!--Message$ATHENA_CKD_Class40032$*--><b>-   Pres JNC8 BP meds msg</b>  <i>Recommendation</i> : %#Patients with CKD and on BP medications need to be aware of the possiblity of postural hypotension/#% </p><p><!--Message$ATHENA_CKD_Class40034$*--><b>-   Age>75 warning msg</b>  <i>Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_CKD_Class60014$*--><b>-   ALERT:  Calcium outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Calcium level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60016$*--><b>-   ALERT:  Phosphate outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Phosphate level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60018$*--><b>-   ALERT: Alk Phos outside normal range</b>  <i>Recommendation</i> : %#ALERT: Alkaline Phosphatase level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class70011$*--><b>-   Msg to order HGB annually</b>  <i>Recommendation</i> : %#Patients with CKD and 30<=eGFR<60 are recommended to have their HGB checked annually.#% </p><p><!--Message$ATHENA_CKD_Class70012$*--><b>-   Msg to order HGB lab as clinically appropriate</b>  <i>Recommendation</i> : %#Missing HGB lab.  Order as clinically appropriate for CKD patients with eGFR>=60.#% </p><p><!--Message$ATHENA_CKD_Class70016$*--><b>-   Dx of anemia</b>  <i>Primary_Recommendation</i> : %#ALERT:  Patient has anemia:   HGB<13 (male) or HGB<12 (femiale).#% </p><p><!--Message$ATHENA_CKD_Class90000$*--><b>-   ALERT:  bicarb outside normal range</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate values (CO2) are outside the normal range#% </p><p><!--Message$ATHENA_CKD_Class90006$*--><b>-   ALERT:  PTH values outside normal range</b>  <i>Recommendation</i> : %#ALERT:  PTH  level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class190355$*--><b>-   4+ BP meds refer msg</b>  <i>Recommendation</i> : %#Patient is on 4 or more BP medications and his/her blood pressure is greater than 140/90.   Please refer to nephrologist#% </p><p><!--Message$ATHENA_CKD_Class40028$*--><b>-   Msg to immunize for flu, pneumonia, hep B</b>  <i>Recommendation</i> : %#Consider immunizing patients againts the flu, pneumonia and hepatitis B.#% </p><p><!--Message$ATHENA_CKD_Class40029$*--><b>-   Msg for low salt diet</b>  <i>Recommendation</i> : %#Patients with CKD need to be on a low salt diet; <2 gm Na per day or <5gm NaCl per day.#% </p><p><!--Message$ATHENA_CKD_Class50017$*--><b>-   Low protein diet DM</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults with diabetes (2C).#% </p><p><!--Message$ATHENA_CKD_Class50018$*--><b>-   Low protein dient nonDM and eGFR<30</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults without diabetes and GFR <30 (2B)#% </p><p><!--Message$ATHENA_CKD_Class50021$*--><b>-   Prim msg: ACR>=30 have target BP 130/80</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR>=30 have their blood pressure <130/80#% </p><p><!--Message$ATHENA_CKD_Class50024$*--><b>-   Prim msg: ACR<30 have target BP 140/90</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR<30 have their blood pressure <140/90.#% </p><p><!--Message$ATHENA_CKD_Class50034$*--><b>-   Prim msg:  missing BP in past year</b>  <i>Primary_Recommendation</i> : %#Patient is missing BP measurement in past year.   For CKD patients with ACR>=30, BP target is 130/80.  For CKD patients with ACR<30, BP target is 140/90.#% </p></li><li>[Parameterized Messages]  <p><!--Parameterized_Message$ATHENA_CKD_Class180009$*--><b>-   out of scope conditions</b>%#Patient has ?out_of_scope.  This condition is out of scope.  Please refer to a nephrologist.#%</p>    <p><!--Parameterized_Message$ATHENA_CKD_Class60036$*--><b>-   Missing CKD labs</b>%#CKD patients with eGFR<45 would normally have ?missingLab but this/these lab value(s) are missing.#%</p>   </li></ul>
<li><b>CKD Dashboard collateral messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] </li><li>[Parameterized Messages] </li></ul>
</ul>
<li><b>Glycemic Control</b><br>
<ul>
<li><b>Glycemic Control Algorithm Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_GlycemicControl_Class310002$*--><b>-   Msg to order HbA1c</b>  <i>Recommendation</i> : %#HbA1c is either missing or older than 1 year; CDS cannot give recommendations.  Please order HbA1c.#% </p><p><!--Message$ATHENA_GlycemicControl_Class540025$*--><b>-   Follow up in 3 months if rec add drug</b>  <i>Recommendation</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class850006$*--><b>-   Presence of gemfibrozil and thiazolidinedione bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking gemfibrozil and thiazolidinedione, which are contraindciated.  Please evaluate#% </p><p><!--Message$ATHENA_GlycemicControl_Class850007$*--><b>-   Presence of SGLT2 inhibitor and UGT2 inducer bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking an SGLT2 inhibitor (canaglifozin or empaflifozin) and a UDG2 inducer which are contraindciated.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210017$*--><b>-   HbA1c <= 9</b>  <i>Primary_Recommendation</i> : %#Latest HbA1c <=9, meets dashboard goal. CDS does not give recommendations for HbA1c values between 6 and 9 because target HbA1c goal not available.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210018$*--><b>-   Severe hyperglycemia message</b>  <i>Primary_Recommendation</i> : %#If patient has severe hyperglycemia or excessive symptoms, consider starting insulin and a referral to Diabetic Management Team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210046$*--><b>-   dDM Type I out of scope message</b>  <i>Primary_Recommendation</i> : %#Recommendations for DM Type I is out of scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class240013$*--><b>-   dAlert lor HbA1c or Glycohem</b>  <i>Primary_Recommendation</i> : %#ALERT:  patient has low HbA1c or low GlycoHemoglobin, at high risk for cardiovascular event and hypoglycemia.#% </p><p><!--Message$ATHENA_GlycemicControl_Class240044$*--><b>-   Insulin only management out of scope</b>  <i>Primary_Recommendation</i> : %#Management of insulin is beyond scope of this system.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470007$*--><b>-   on 3+ agents</b>  <i>Recommendation</i> : %#Patient HbA1c is >9 and is on 3 oral agents.  Please refer to endocrinologist and specialized DM care team.#% </p></li><li>[Parameterized Messages]  <p><!--Parameterized_Message$library_Class160004$*--><b>-   Give warning when There exists medication whose daily dose is greater than the upper limit of maximum recommended dose range</b>%#The daily dose of medications ?meds is above the maximum recommended dose. Please review.#%</p>    <p><!--Parameterized_Message$ATHENA_GlycemicControl_Class850168$*--><b>-   Param msg for bad drug partners</b>%#Patient is on ?bad_drug_partners that are usually not prescribed together.#%</p>   </li></ul>
<li><b>Glycemic Control Consultation Messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_GlycemicControl_Class150033$*--><b>-   On metformin check serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class290002$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_GlycemicControl_Class300002$*--><b>-   Glyburide serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Glyburide have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class360002$*--><b>-   Disclaimer HbA1c btwn 6 and 9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class50002$*--><b>-   On Metformin check serum B12 level</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum B12 checked at least every 2 years.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260039$*--><b>-   ALERT:  high creatinine or low eGFR</b>  <i>Primary_Recommendation</i> : %#ALERT:  high creatinine (>2.5 male or >2.4 female) or low eGFR (<30)#% </p><p><!--Message$ATHENA_GlycemicControl_Class260051$*--><b>-   ALERT: there exists active and not refilled medication</b>  <i>Primary_Recommendation</i> : %#Placeholder:  ALERT: there exists active and not refilled medication.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330001$*--><b>-   Recommendation for pregnant women out of scope</b>  <i>Primary_Recommendation</i> : %#Warning:  These recommendations do not apply to women who are pregnant.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330022$*--><b>-   Liver Enzyme ALERT</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT greater than 3*Upper Limit of Normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class350011$*--><b>-   Low bicarb alert</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate levels are less than or equal to 21.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480000$*--><b>-   Set target HbA1c</b>  <i>Recommendation</i> : %#Although the VA performance measure is to attain an HbA1c<9%, this is usually not the true target for an individual patient. The  <a href="http://@AUTOPMWEBSERVER@/DM/VA_GL_DiabetesMellitus_2010.pdf#page=49"> Table G1 from VA DM Guidelines </a> can be used as a reference to decide an individual patient’s target.#% </p><p><!--Message$ATHENA_GlycemicControl_Class510002$*--><b>-   Presence of DM-1 and DM-2 message</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of both DM-1 and DM-2.  We have made recommendations ASSUMING that the patient has only DM-2.  If this is not the case, these recommendations are not appropriate#% </p><p><!--Message$ATHENA_GlycemicControl_Class620004$*--><b>-   Presence of drugs that affect blood glucse levels.</b>  <i>Primary_Recommendation</i> : %#Warning:  patient is taking either bromocriptine or colesevelam that has hypoglycemic properties#% </p><p><!--Message$ATHENA_GlycemicControl_Class660000$*--><b>-   Start Aspirin message</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy.  Additional information available <a href="http://@AUTOPMWEBSERVER@/DM/AdditionalAspirinTherapyInfo.pdf"> here </a>.#% </p><p><!--Message$ATHENA_GlycemicControl_Class830001$*--><b>-   Gen msg all patients re ACE/ARB</b>  <i>Primary_Recommendation</i> : %#Consider ACE or ARB for renal protection if eGFR and K are within acceptable levels.#% </p></li><li>[Parameterized Messages]  <p><!--Parameterized_Message$ATHENA_GlycemicControl_Class380017$*--><b>-   drug mpr<0.9 message</b>%#Patient appears not to be adhering to ?drugName (MPR= ?mpr %). Confirm and evaluate clinical strategy.#%</p>   </li></ul>
<li><b>Glycemic Control collateral messages <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</b> )])
<ul>
<li>[Fixed Messsages] <p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p></li><li>[Parameterized Messages] </li></ul>
</ul>
</ul>
<h2>Session time: 2015-02-17</h2>
<h2>GuidelineID: Print Messages Guideline</h2>
<h4>Recommended Actions</h4>
<pre>
 <b>Message: ATHENA HF Astronaut algorithm on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_HF_Class110353$*--><b>-   PM rec add AA and using ACE</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE inhibitor. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$ATHENA_HF_Class110388$*--><b>-   age > 70, dose adjustments may be necessary</b>  <i>Recommendation</i> : %#For patients older than 70 years be alert of the possible need for dose adjustment based on eGFR.#% </p><p><!--Message$ATHENA_HF_Class110823$*--><b>-   Combined use ACEI, ARB and aldosterone antagonist not rec</b>  <i>Primary_Recommendation</i> : %#Routine combined use of an ACEI, ARB, and aldosterone antagonist is NOT RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class170004$*--><b>-   Use of drugs adversely affect HF status Astronaut</b>  <i>Primary_Recommendation</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs (not aspirin), most antiarrhythmic drugs,  most
calcium channel blocking drugs (except amlodipine) and thiazolidinediones). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class230001$*--><b>-   ICD primary prev rec Stage C Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class230003$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class230005$*--><b>-   CRT when LVEF<=35% and QRS>=0.15s and LBBB Astronaut II</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class371546$*--><b>-   PM ARB (add or on) and pregnancy warning</b>  <i>Primary_Recommendation</i> : %#Angiotensin receptor blocker is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$ATHENA_HF_Class380470$*--><b>-   PM Rec BB stage C HF and on other BB</b>  <i>Recommendation</i> : %#Patient already has active prescription for a different beta blocker. Consider appropriateness of change to the recommended beta blocker.#% </p><p><!--Message$ATHENA_HF_Class390000$*--><b>-   PM Active prescription for ACEi and 80<=SBP<110</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP is between 80 and 110, evaluate continuing prescription for ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390004$*--><b>-   .PM active prescription ACE inhibitor and SBP<80</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP<80, consider STOPPING ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390605$*--><b>-   Add hydralazine SBP<110</b>  <i>Primary_Recommendation</i> : %#Would recommend add hydralazine but SBP is less than 110mmHg. Evaluate clinical significance#% </p><p><!--Message$ATHENA_HF_Class401993$*--><b>-   PM CKD stage 4 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 4. Evaluate clinical significance.#% </p><p><!--Message$KB_150996_Class0$*--><b>-   Rec add AA suppressed no NYHA or DM</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because 
patient is missing values for NYHA Class symptoms or presence of DM.#% </p><p><!--Message$KB_155357_Class35$*--><b>-   PM rec add AA and using ARB</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for angiotensin receptor blocker. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$KB_155357_Class59$*--><b>-   deleting nitrates because prescription for phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Should stop nitrates but continue hydralazine. Need to stop either nitrates or the phosphodiesterase inhibitors#% </p><p><!--Message$KB_155357_Class69$*--><b>-   PM on other BB rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Patient already has active prescription for a different beta blocker.  Consider appropriateness of change to the recommended beta blocker#% </p><p><!--Message$KB_155357_Class72$*--><b>-   PM on sotalol rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Note that patient has prescription for sotalol. Consider discussion with cardiology before changing beta blockers#% </p><p><!--Message$KB_222371_Class1$*--><b>-   Rec add AA suppressed K</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because patient is missing values for potassium#% </p><p><!--Message$KB_222371_Class3$*--><b>-   rec add hydralazine or nitrates suppressed no symptoms</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralaine and/or nitrates was not evaluated because patient is missing data for NYHA Class symptoms.#% </p><p><!--Message$KB_222371_Class4$*--><b>-   rec add AA suppressed no BNP</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist when patient has NYHA Class II symptoms was not evaluated because patient is missing values for BNP#% </p><p><!--Message$KB_222371_Class6$*--><b>-   rec add hydralazine and nitrates suppressed no Race</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralazine and/or isosobide dinitrates  to African Americans was not evaluated because patient is missing values for race#% </p><p><!--Message$KB_313397_Class14$*--><b>-   PM rec add ACEi CKD stage5 or eGFR>15</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class16$*--><b>-   PM Rec add ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor. Use caution if prescribing.#% </p><p><!--Message$KB_313397_Class18$*--><b>-   PM add ACEi and 20 percent increase creatinine after starting ACEi</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class22$*--><b>-   PM Rec add ACEi and active prescription for Aliskerin</b>  <i>Recommendation</i> : %#Patient has a prescription for aliskerin; evaluate clinical significance and impact of prescription for ACE inhibitor#% </p><p><!--Message$KB_313397_Class23$*--><b>-   PM Rec add ACE and presence K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_335875_Class22$*--><b>-   PM CKD stage 5 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 5. Evaluate clinical significance.#% </p><p><!--Message$KB_335875_Class8$*--><b>-   PM SBP<110 and (rec add BB or rec add AA)</b>  <i>Primary_Recommendation</i> : %#Most recent SBP less than 110mmHg. Evaluate clinical significance and therapeutic implications.#% </p><p><!--Message$KB_486502_Class0$*--><b>-   PM 20% increase of creatinine after starting ACE inhibitor</b>  <i>Recommendation</i> : %#Patient had an increase of more than 20% of creatinine (comparing pre ACE inhibitor value with peak value within 3m after starting ACE inhibitor) after starting ACE inhibitor.#% </p><p><!--Message$KB_486502_Class2$*--><b>-   PM Rec ADD ARB and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59; evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class3$*--><b>-   PM  hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_486502_Class6$*--><b>-   PM Rec ADD ACEi and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ACE inhibitor and frequency of monitoring labs.#% </p><p><!--Message$KB_502940_Class6$*--><b>-   PM Pregancy warning (add ACEi or on ACEi)</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status#% </p><p><!--Message$KB_243202_Class1$*--><b>-   Out of scope message</b>  <i>Primary_Recommendation</i> : %#HF patients with preserved EJ function, LVEF>40) or without an LVEF value are out of scope of this CDS.#% </p><p><!--Message$KB_261275_Class13$*--><b>-   BB substitution</b>  <i>Recommendation</i> : %#Patient is taking a beta blocker that is not one of the recommeded beta blockers for heart failure patients. Evaluate susbtitution with carvedilol, bisoprolol or sustained release metoprolol succinate.#% </p>
 <b>Message: HF Parameterized Algorithm Messages</b>
 Message Type: Parameterized Messages
 Message:  <p><!--Parameterized_Message$ATHENA_HF_Class390610$*--><b>-   most recent SBP<110 and on hydralazine</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of hydralazine.#%</p>    <p><!--Parameterized_Message$ATHENA_HF_Class440007$*--><b>-   SBP<80 and on ARB</b>%#Patient's most recent SBP (date ?date) was less than 80mmHg. Consider evaluating dose of angiotensin receptor blocker.#%</p>    <p><!--Parameterized_Message$KB_155357_Class13$*--><b>-   most recent K >5 and on ARB</b>%#Patient's most recent potassium (date ?date) was greater than 5; consider discontinuing angiotensin receptor blocker or other drugs contributing to hyperkalemia. Evaluate clinical significance.#%</p>    <p><!--Parameterized_Message$KB_155357_Class16$*--><b>-   SBP<110 and on ARB</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of angiotensin receptor blocker.#%</p>    <p><!--Parameterized_Message$KB_155357_Class21$*--><b>-   Female, most recent creatinine >=2.3, on ACE</b>%#Patient has active prescription for ACE inhibitorand most recent creatinine (date ?date) is greater than 2.2.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class28$*--><b>-   Male, most recent creatinine >=2.5, on ACE</b>%#Patient has active prescription for ACE inhibitor and most recent creatinine (date ?date) is greater than 2.4.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class31$*--><b>-   Female, most recent creatinine >=2.3, on ARB</b>%#Patient has active prescription for angiotensin receptor blocker and most recent creatinine (date ?date) is greater than 2.2.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class34$*--><b>-   Male, most recent creatinine >=2.5, on ARB</b>%#Patient has active prescription for an angiotensin receptor blocker and most recent creatinine (date ?date) is greater than 2.4.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_155357_Class7$*--><b>-   most recent K>5 and on ACE inhibitor</b>%#Patient's most recent potassium (date ?date) was greater than 5; consider discontinuing ACE inhibitor or other drugs contributing to hyperkalemia. Evaluate clinical significance.#%</p>    <p><!--Parameterized_Message$KB_212231_Class2$*--><b>-   SBP<110 and on ACE inhibitor</b>%#Patient's most recent SBP (date ?date) was less than 110mmHg. Consider evaluating dose of ACE inhibitor.#%</p>    <p><!--Parameterized_Message$KB_335875_Class14$*--><b>-   Most recent eGFR<30 and on ACE</b>%#Patient has active prescription for ACE inhibitor and most recent eGFR (date ?date) is less than 30.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_335875_Class21$*--><b>-   Most recent eGFR<30 and on ARB</b>%#Patient has active prescription for an angiotensin receptor blocker and most recent eGFR (date ?date) is less than 30.  Evaluate clinically.#%</p>    <p><!--Parameterized_Message$KB_783525_Class3$*--><b>-   ?label</b>%#Patient is taking ?harmful_HF_drug that may be harmful to those with HF.#%</p>   
 <b>Message: ATHENA HF Astronaut on-screen consultation messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_HF_Class380817$*--><b>-   PM on nitrates and  hydralazine and phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Patient has active prescriptions for hydralazine, a nitrate and a phosphodiesterase inhibitor. Must discontinue either nitrate or phsophodiesterase inhibitor.#% </p><p><!--Message$ATHENA_HF_Class440002$*--><b>-   PM: most recent K >5</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE Inhibitor and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class440004$*--><b>-   PM: On ARB and K>5</b>  <i>Recommendation</i> : %#Patient has active prescription for and ARB and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$KB_313397_Class11$*--><b>-   PM On ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor.#% </p><p><!--Message$KB_313397_Class19$*--><b>-   PM on ACEi and 20 percent increase in creatinine after starting ACEi or ARB</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class20$*--><b>-   PM on ACE and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class24$*--><b>-   PM On ACEi and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class7$*--><b>-   PM on ACEi and CKD stage 3 or 4 or 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class9$*--><b>-   PM on ace and ckd stage 5 or eGFR<15</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_486502_Class10$*--><b>-   PM On ARB and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class12$*--><b>-   PM on ARB and 20 percent increase in creatinine after starting ARB or ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for aldosterone antagonist blocker.#% </p><p><!--Message$KB_486502_Class15$*--><b>-   PM on ARB and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class17$*--><b>-   PM On ARB and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class5$*--><b>-   PM On ARB and CKD stage 3/4 OR 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class8$*--><b>-   PM on ARB and (CKD stage 5 OR most recent  eGFR<15)</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_234689_Class0$*--><b>-   diuretcs out of scope</b>  <i>Primary_Recommendation</i> : %#HF with reduced EF with fluid retention is an indication for diuretic therapy, but is beyond the scope of this project recommendations.#% </p>
 <b>Message: HF Parameterized Consultation Messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: HF collateral on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_HF_Class170020$*--><b>-   Presence of NSAID HF collateral message Astronaut</b>  <i>Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class401702$*--><b>-   add nitrates age>=70</b>  <i>Recommendation</i> : %#Isosorbide dinitrate  may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401845$*--><b>-   add hydralazine age>=70</b>  <i>Recommendation</i> : %#Hidralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class110380$*--><b>-   monitoring renal function and K for ACEI</b>  <i>Recommendation</i> : %#Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with preexisting hypotension, hyponatremia, diabetes
mellitus, or azotemia or in those taking potassium
supplements.#% </p><p><!--Message$ATHENA_HF_Class240016$*--><b>-   rec add hyralazine_nitrates Astronaut II</b>  <i>Class I</i> : %#The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III or IIV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70167$*--><b>-   Aldosterone antagonist warning</b>  <i>Recommendation</i> : %#Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.#% </p><p><!--Message$KB_899077_Class2$*--><b>-   rec add ACE-I dose based on 2013 ACCF/AHA Guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific ACE-I starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.#% </p><p><!--Message$KB_899077_Class4$*--><b>-   rec add ARB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below)  for specific ARB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
candesartan starting dose 4-8 mg/once; max dose 32 mg once
losartan starting dose 25-50 once; max dose 50-150 mg once
valsartan 20-40 mg twice; max dose 160 mg twice#% </p><p><!--Message$KB_899077_Class5$*--><b>-   rec add AA based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific AA starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
spironolactone starting dose 12.5 0 25.0 once; max dose 25 mg once or twice
eplerenone starting dose 25 mg once; max dose 50 mg once#% </p><p><!--Message$KB_899077_Class6$*--><b>-   rec add BB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
bisoprolol starting dose 1.25 mg once; max dose 10 mg once
carvedilol starting dose 3.125 mg twice; max dose 50 mg twice
carvedilol CR starting dose 10 mg once; max dose 80 mg once
metoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once#% </p><p><!--Message$KB_899077_Class7$*--><b>-   rec add hydralazine and nitrates based on 2013 ACCF/AHA guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific hydraline and nitrates starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
fixed dose combination starting dose 37.5 mg hydralazine + 20 mg isosorbide dintrate/ 3x; max dose 75 mg hydralazine + 40 mg isosorbide dinitrate 3x dialy
hydralazine and isosorbide dinitrate sstarting dose hydralazine 25-50 mg 3 or 4 x daily and isosorbide dintrate 20 to 30 mg 3 or 4 x dialy; max dose hydralazine 300 mg daily in divided doses and isosorbide dintrate 120 mg daily in divided doses#% </p>
 <b>Message: HF Parameterized collateral messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: Lipid consultation on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$Lipid_dashboard_Class300000$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age related changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$Lipid_dashboard_Class110003$*--><b>-   Women ages 18-50:  pregnant women</b>  <i>Primary_Recommendation</i> : %#Pregnant women and nursing mothers are out of scope for this CDS.#% </p><p><!--Message$Lipid_dashboard_Class110008$*--><b>-   Treat hi TG mgs</b>  <i>Primary_Recommendation</i> : %#Triglycerides are >=500 mg/dL.  Evaluate and treat.#% </p><p><!--Message$Lipid_dashboard_Class110011$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Consider therapeutic life style changes <link to TLC>#% </p><p><!--Message$Lipid_dashboard_Class120001$*--><b>-   Order baseline CK?</b>  <i>Recommendation</i> : %#Baseline measurement of creatinine kinase (CK) is reasonable for those individuals believed to be at increased risk for adverse muscle events based upon personal or family history of statin intolerance or muscle disease or concomitant drug therapy that might increase the risk for myopathy.#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p>
 <b>Message: Lipid Parameterized Consultation Messages</b>
 Message Type: Parameterized Messages
 Message:  <p><!--Parameterized_Message$library_Class160004$*--><b>-   Give warning when There exists medication whose daily dose is greater than the upper limit of maximum recommended dose range</b>%#The daily dose of medications ?meds is above the maximum recommended dose. Please review.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class120004$*--><b>-   ?label</b>%#Patient is on ?LDL_elevating_drug that may elevate LDL-C. Evaluate and treat.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class130005$*--><b>-   ?label</b>%#Patient has a diagnosis of ?LDL_elevating_dx that may elevate LDL-C. Evaluate and treat.#%</p>    <p><!--Parameterized_Message$Lipid_dashboard_Class340005$*--><b>-   Duplicate drug message</b>%#The patient has more than one prescription for ?dup_drug..  Foreach of the drugs mentioned, dosages were summed for the purposes of these recommendations#%</p>   
 <b>Message: Lipid algorithm on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$Lipid_dashboard_Class250022$*--><b>-   Cannot tolerate formulary statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate formulary statin, consider non-formulary statin#% </p><p><!--Message$Lipid_dashboard_Class280020$*--><b>-   Pres niacin > 1gm/day and Pres statin</b>  <i>Primary_Recommendation</i> : %#Patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class280021$*--><b>-   Pres fibrate and Pres statin</b>  <i>Recommendation</i> : %#Patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class100010$*--><b>-   Pres hem stroke msg, risk/benefit of increasing dose</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke but is not at goal..  Consider risk/benefit of increasing statin dose or intensity.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100011$*--><b>-   Increase dose to moderate intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has DM.  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class100012$*--><b>-   Increase dose to high intensity msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider increasing dose to high intensity dose.#% </p><p><!--Message$Lipid_dashboard_Class100013$*--><b>-   Substitute high intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider substituting high intensity atorvastatin or rosuvastatin in place of existing statin#% </p><p><!--Message$Lipid_dashboard_Class100014$*--><b>-   Intolerance to increase statin dose msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of statns, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>#% </p><p><!--Message$Lipid_dashboard_Class180005$*--><b>-   Goals achieved</b>  <i>Primary_Recommendation</i> : %#Patient is on moderate or high dose statin or LDL<100.  Goal achieved#% </p><p><!--Message$Lipid_dashboard_Class230001$*--><b>-   No statin rec for add statin</b>  <i>Primary_Recommendation</i> : %#No statin can be recommended..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class240017$*--><b>-   Absence of DM and ASDVD out of scope msg</b>  <i>Primary_Recommendation</i> : %#Patient does not have DM or ASCVD and is out of scope of this CDS.#% </p><p><!--Message$Lipid_dashboard_Class240022$*--><b>-   > 1 statin cannot generate recommendations msg</b>  <i>Primary_Recommendation</i> : %#We are unable to generate recommendations because patient is taking more than 1 statin, which is generally not recommended.#% </p><p><!--Message$Lipid_dashboard_Class250010$*--><b>-   Follow up in 4-12 weeks</b>  <i>Recommendation</i> : %#Follow up in 4-12 weeks#% </p><p><!--Message$Lipid_dashboard_Class250023$*--><b>-   Rsik/benefit msg for frail, abnormal liver/renal, Asian</b>  <i>Primary_Recommendation</i> : %#Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p><p><!--Message$Lipid_dashboard_Class260010$*--><b>-   Stop contraindicated statin</b>  <i>Primary_Recommendation</i> : %#Presence of contraindication to statin.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class270009$*--><b>-   Intolerance to increase high intensity statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of atrovastatin or rosuvastatin statns, consider  <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class300117$*--><b>-   Prim msg:  statin DDI pres of statin</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about continuing use of statin or increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class330001$*--><b>-   Increase dose to moderate intensity ASCVD</b>  <i>Primary_Recommendation</i> : %#Patient has ASCVD and is over age 75..  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.  If patient cannot tolerate increaseing dose, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>..#% </p><p><!--Message$Lipid_dashboard_Class420000$*--><b>-   Statin rec DM patients if not 40<=age<=75</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75  (inclusinve) derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range.
Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian.#% </p><p><!--Message$Lipid_dashboard_Class430000$*--><b>-   Substitute high intensity statin for low dose statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity statns (atorvastatin>=40mg, rosuvastatin>=20mg), consider increasing dose to moderate intensity (atorvastatin >=10mg, rosuvastatin >=5 mg, simvastatin >=20 mg, lovastatin >=40 mg, fluvastatin >=80 mg.)  or<a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class70046$*--><b>-   Patient on drug that interacts w statin</b>  <i>Primary_Recommendation</i> : %#Patient is on a 
<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>  that increases the risk of myopathy; please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class70047$*--><b>-   Patient refuses statin</b>  <i>Recommendation</i> : %#If patient refuses statin or cannot tolerate statin, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p>
 <b>Message: Lipid Parameterized Algorithm Messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: Lipid collateral on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$Lipid_dashboard_Class160013$*--><b>-   Presence of fibric acid msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking a fibric acid (fenofibrate, gemfibrozil or clofibrate) which increases risk of myopathy.  Consider switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class160023$*--><b>-   Presence of niacin >1gm/day msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class230022$*--><b>-   ASCVD Prim message moderate intensity statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease with history of hemorrhagic stroke oris over age.75. Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class30052$*--><b>-   DM Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has diabetes without atherosclerotic cardiovascular disease and 40<=age<=75.  Moderate intensity statins are recommended. Formulary moderate intensity statin are atorvastatin 10 mg simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg.  Non formulary moderate intensity statins are rosuvastatin 5 mg, fluvastatin 40 mg.#% </p><p><!--Message$Lipid_dashboard_Class360002$*--><b>-   Blocked add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class360003$*--><b>-   Blocked add statin missing eGFR past 3 mo</b>  <i>Recommendation</i> : %#We would normaly recommend adding a statin, but we are missing eGFR in the past 3 months..#% </p><p><!--Message$Lipid_dashboard_Class360006$*--><b>-   Blocked incr dose missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend increasing dose of a statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class410212$*--><b>-   ASCVD Prim Msg to start high dose statin (not conditional)</b>  <i>Primary_Recommendation</i> : %#High intensity statins are recommended for patients with atherosclerotic cardiovascular disease.   Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p>
 <b>Message: Lipid Parameterized collateral messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: HTN management diagram on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p>
 <b>Message: HTN Parameterized Algorithm Messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: HTN consultation guideline on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_HTN_Dashboard_Class10035$*--><b>-   Ischemic Heart disease and DBP<60 and BP at target</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90004$*--><b>-   PM: K>5 and active prescription for ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an ACE Inhibitor and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90006$*--><b>-   PM: K>5 and active prescription for ARB</b>  <i>Recommendation</i> : %#Patient has an active prescription for an ARB and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10048$*--><b>-   Above Dashboard Target below JNC8 Target</b>  <i>Primary_Recommendation</i> : %#NEED TO DECIDE WHAT MESSAGE TO GIVE....

NEED TO DECIDE IF WILL DO SUBSTITUTIONS#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80010$*--><b>-   >4 active anti-hypertensive meds (broad) AND BP<220/110 AND absence IIHD AND DBP>=60</b>  <i>Recommendation</i> : %#Patient on more than 4 antihypertensive drugs. Refer to hypertension specialist.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80017$*--><b>-   BP below Dashboard and JNC target</b>  <i>Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_372688$*--><b>-   Ischemic Heart disease and DBP<60 and BP not at target</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_43301$*--><b>-   SBP>=220 or DBP>=115, urgent attention</b>  <i>Primary_Recommendation</i> : %#SBP>220 or DBP>115 so treatment recommendations are beyond the scope of this program. If MARKED BP ELEVATION is confirmed, then the patient needs further TREATMENT and EARLY FOLLOW-UP to MONITOR THERAPEUTIC EFFICACY. #% </p>
 <b>Message: HTN Parameterized Consultation Messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: HTN collateral on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_CKD_Class100006$*--><b>-   PTH elevated, not normal Ca or phosphate or vitamin D labs</b>  <i>Primary_Recommendation</i> : %#PTH is elevated and Ca or phosphate or vitamin D labs are not within normal range.  Please assess.#% </p><p><!--Message$ATHENA_CKD_Class10016$*--><b>-   ACR<30 and BP>140/90</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal of <=140/90 when ACR<30.#% </p><p><!--Message$ATHENA_CKD_Class10018$*--><b>-   ACR>=30 and BP>130/80</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal of <=130/80 when ACR>=30.#% </p><p><!--Message$ATHENA_CKD_Class110001$*--><b>-   Msg to order vitamin D lab when PTH elevated</b>  <i>Recommendation</i> : %#PTH is elevated and vitamin D levels need to be assessed but lab is missing.  Please order vitamin D lab.#% </p><p><!--Message$ATHENA_CKD_Class140002$*--><b>-   blocked msg to add K</b>  <i>Recommendation</i> : %#We would normally be ordering ACE/ARB, but cannot do so because we are missing K in the past month.#% </p><p><!--Message$ATHENA_CKD_Class140005$*--><b>-   blocked message to measure BP</b>  <i>Recommendation</i> : %#We would normally be recommending ACE/ARB, but cannot do so because we are missing BP measurements in the past month#% </p><p><!--Message$ATHENA_CKD_Class170261$*--><b>-   ACR>300 refer</b>  <i>Primary_Recommendation</i> : %#ACR>300.  Please refer to nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40030$*--><b>-   Pres of ASCVD msg to consider antiplatelet</b>  <i>Recommendation</i> : %#Consider antiplatelet therapy for patients with CKD and atherosclerotic vascular disease.#% </p><p><!--Message$ATHENA_CKD_Class40032$*--><b>-   Pres JNC8 BP meds msg</b>  <i>Recommendation</i> : %#Patients with CKD and on BP medications need to be aware of the possiblity of postural hypotension/#% </p><p><!--Message$ATHENA_CKD_Class40034$*--><b>-   Age>75 warning msg</b>  <i>Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_CKD_Class60014$*--><b>-   ALERT:  Calcium outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Calcium level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60016$*--><b>-   ALERT:  Phosphate outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Phosphate level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60018$*--><b>-   ALERT: Alk Phos outside normal range</b>  <i>Recommendation</i> : %#ALERT: Alkaline Phosphatase level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class70011$*--><b>-   Msg to order HGB annually</b>  <i>Recommendation</i> : %#Patients with CKD and 30<=eGFR<60 are recommended to have their HGB checked annually.#% </p><p><!--Message$ATHENA_CKD_Class70012$*--><b>-   Msg to order HGB lab as clinically appropriate</b>  <i>Recommendation</i> : %#Missing HGB lab.  Order as clinically appropriate for CKD patients with eGFR>=60.#% </p><p><!--Message$ATHENA_CKD_Class70016$*--><b>-   Dx of anemia</b>  <i>Primary_Recommendation</i> : %#ALERT:  Patient has anemia:   HGB<13 (male) or HGB<12 (femiale).#% </p><p><!--Message$ATHENA_CKD_Class90000$*--><b>-   ALERT:  bicarb outside normal range</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate values (CO2) are outside the normal range#% </p><p><!--Message$ATHENA_CKD_Class90006$*--><b>-   ALERT:  PTH values outside normal range</b>  <i>Recommendation</i> : %#ALERT:  PTH  level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Instance_50037$*--><b>-   Please complete mALB/creatinine ratio screening</b>  <i>Recommendation</i> : %#Please complete urine screening for CKD#% </p><p><!--Message$ATHENA_CKD_Instance_50038$*--><b>-   Please complete creatinine screening</b>  <i>Recommendation</i> : %#Please complete creatinine screening#% </p><p><!--Message$ATHENA_GlycemicControl_Class150033$*--><b>-   On metformin check serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class160003$*--><b>-   On metformin check CBC</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have CBC measured  at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class210400$*--><b>-   Check serum creatiine if on metformin</b>  <i>Recommendation</i> : %#Check serum creatinine yearly if on metformin#% </p><p><!--Message$ATHENA_GlycemicControl_Class230026$*--><b>-   Start insulin msg in presence of SU</b>  <i>Recommendation</i> : %#If adding Insulin in the presence of SU, titrate SU down while titrating insulin up.#% </p><p><!--Message$ATHENA_GlycemicControl_Class290002$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_GlycemicControl_Class300002$*--><b>-   Glyburide serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Glyburide have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class310002$*--><b>-   Msg to order HbA1c</b>  <i>Recommendation</i> : %#HbA1c is either missing or older than 1 year; CDS cannot give recommendations.  Please order HbA1c.#% </p><p><!--Message$ATHENA_GlycemicControl_Class350001$*--><b>-   Disclaimer Insulin</b>  <i>Primary_Recommendation</i> : %#Patient is on Insulin; management of insulin is outside the scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class360002$*--><b>-   Disclaimer HbA1c btwn 6 and 9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class430001$*--><b>-   ALERT:  30<eGFR<60 or creatinine 1.5- 2.5 male etc</b>  <i>Primary_Recommendation</i> : %#Patient's renal function is impaired, it is extremely important to monitor renal function and potassium#% </p><p><!--Message$ATHENA_GlycemicControl_Class440011$*--><b>-   collateral msg 30<eGFR<60 or 1.5<creatinine<2.5 male or 1.3<creatinine<2.3 female</b>  <i>Recommendation</i> : %#We are recommending use of ACE/ARB, but be reminded to obtain new labs within 1-2 weeks#% </p><p><!--Message$ATHENA_GlycemicControl_Class440018$*--><b>-   collateral msage eGFR>=60, low creatinine</b>  <i>Recommendation</i> : %#We are recommending use of ACE/ARB, but be reminded to obtain new labs within 1-2 weeks#% </p><p><!--Message$ATHENA_GlycemicControl_Class480007$*--><b>-   Absence in past month eGFR and creat and K and SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR, K and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480008$*--><b>-   Absence in past month eGFR and creat and K and Presence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR and K within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480009$*--><b>-   Absence in past month eGFR and creat and SBP and Presence K</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:  eGFR and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480010$*--><b>-   Absence in past month  K and SBP and Presence of eGFR</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:   K and BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480011$*--><b>-   Absence in past month eGFR and creat and Presence K and SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:   eGFR within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480012$*--><b>-   Presence in past month eGFR or creat and K and Absence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals: BP within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480013$*--><b>-   Presence in past month eGFR or creat and Absence K and Presence SBP</b>  <i>Primary_Recommendation</i> : %#Cannot recommend adding ACE-I/ARB without the following labs and/or vitals:. K within the last month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class500000$*--><b>-   Absence of eGFR cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR and creatinine labs within past month are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class50002$*--><b>-   On Metformin check serum B12 level</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum B12 checked at least every 2 years.#% </p><p><!--Message$ATHENA_GlycemicControl_Class540025$*--><b>-   Follow up in 3 months if rec add drug</b>  <i>Recommendation</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class550037$*--><b>-   Absence of bicarb cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because bicarb within past year is missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550038$*--><b>-   Absence of SGOT and SGOT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because SGOT and SGPT  labs within past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550039$*--><b>-   Absence of eGFR and bicarb cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and bicarb labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550041$*--><b>-   Absence of eGFR and SGOT/SGPT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550043$*--><b>-   Absence of bicarb and SGOT/SGPT cannot add MF</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because bicarb and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class550045$*--><b>-   Absence of eGFR, bicarb, SGOT/SGPT</b>  <i>Recommendation</i> : %#We would normally recommend metformin, but cannot do so because eGFR/creatinine within the past month and bicarb and SGOT/SGPT labwithin past year are missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60001$*--><b>-   add chlorpropamide elderly</b>  <i>Recommendation</i> : %#100mg/day-125mg/day for elderly patients.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60002$*--><b>-   add chlorpropamide middle aged</b>  <i>Recommendation</i> : %#250mg/day in the mild-to-moderately severe, middle aged, stable patient#% </p><p><!--Message$ATHENA_GlycemicControl_Class60005$*--><b>-   add tolazamide age>=65</b>  <i>Recommendation</i> : %#100mg/day for elderly patients#% </p><p><!--Message$ATHENA_GlycemicControl_Class60006$*--><b>-   add tolazamide age<65</b>  <i>Recommendation</i> : %#100mg/day-250mg/day in the mild-to-moderately severe patient#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class730029$*--><b>-   Missing creatinine past year and age>65</b>  <i>Recommendation</i> : %#We would normally increase the dose of gliburide, but patient's agie is >=65 and creatinine lab within the past year is missing.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class850006$*--><b>-   Presence of gemfibrozil and thiazolidinedione bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking gemfibrozil and thiazolidinedione, which are contraindciated.  Please evaluate#% </p><p><!--Message$ATHENA_GlycemicControl_Class850007$*--><b>-   Presence of SGLT2 inhibitor and UGT2 inducer bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking an SGLT2 inhibitor (canaglifozin or empaflifozin) and a UDG2 inducer which are contraindciated.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_HF_Class100014$*--><b>-   Fluid management if using diuretics</b>  <i>Class I</i> : %#Continue to manage diuretics and salt restriction for optimal volume control.  (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class100015$*--><b>-   fluid management NOT on diuretics</b>  <i>Class I</i> : %#Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class100847$*--><b>-   rec cardiac resynchronization therapy</b>  <i>Class I</i> : %#Patients with LVEF of less than or equal to 35%, sinus rhythm, and NYHA functional class III ambulatory class IV symptoms
despite recommended optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than or equal to 0.12 seconds, should receive cardiac resynchronization therapy, with or without an ICD, unless contraindicated (203–218). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class110348$*--><b>-   LVEF<30</b>  <i>Recommendation</i> : %#Most recent LVEF <30, patient should have a cardiac evaluation.#% </p><p><!--Message$ATHENA_HF_Class110350$*--><b>-   30<=LVEF<40</b>  <i>Recommendation</i> : %#Patient has a low LVEF, consider cardiac evaluation or repeat left ventricular ejection fraction in about 3 months.#% </p><p><!--Message$ATHENA_HF_Class110353$*--><b>-   PM rec add AA and using ACE</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE inhibitor. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$ATHENA_HF_Class110361$*--><b>-   add bb before inc dose ace</b>  <i>Recommendation</i> : %#In clinical trial, adding a beta blocker showed greater improvement in heart failure symptoms and outcomes versus increasing dose of ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class110363$*--><b>-   ICD info to discuss with patient</b>  <i>Recommendation</i> : %#Discussion should clarify in simple words exactly what an ICD does and doesn’t do.
Of every 100 patients like yourself, during the next 5 years 7-8 will live longer because of device but:    
- 28-30 will die anyway
- Most (>50%) will never use their device but we have no sure way to know who they are
- 8-10 will have an inappropriate shock which may increase the risk of dying 
- 4-10 will have other complications, some of which will be fatal
- Your heart failure is more likely to worsen
- Someday you may wish to have the defibrillation feature inactivated#% </p><p><!--Message$ATHENA_HF_Class110366$*--><b>-   expectation of survival</b>  <i>Recommendation</i> : %#When evaluating expectation of survival with a good functional status, it is important that this estimation be based on non-cardiac survival.#% </p><p><!--Message$ATHENA_HF_Class110368$*--><b>-   order ecg</b>  <i>Recommendation</i> : %#Order ECG to determine QRS duration and candidacy for a CRT.#% </p><p><!--Message$ATHENA_HF_Class110371$*--><b>-   inital dose recommendation digoxin when age>70, egfr<30 or lean body mass.</b>  <i>Recommendation</i> : %#Initial recommended dose of digoxin is 0.125mcg daily (or every other day).#% </p><p><!--Message$ATHENA_HF_Class110388$*--><b>-   age > 70, dose adjustments may be necessary</b>  <i>Recommendation</i> : %#For patients older than 70 years be alert of the possible need for dose adjustment based on eGFR.#% </p><p><!--Message$ATHENA_HF_Class110823$*--><b>-   Combined use ACEI, ARB and aldosterone antagonist not rec</b>  <i>Primary_Recommendation</i> : %#Routine combined use of an ACEI, ARB, and aldosterone antagonist is NOT RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class120883$*--><b>-   Acute MI, use contemporary guidelines</b>  <i>Class I</i> : %#Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).#% </p><p><!--Message$ATHENA_HF_Class124168$*--><b>-   Use of drugs adversely affect HF status</b>  <i>Class I</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most
calcium channel blocking drugs). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class160001$*--><b>-   CRT NYHA classification Astronaut</b>  <i>Recommendation</i> : %#Functional Capacity .....................................................Objective Assessment
Class I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class160002$*--><b>-   NYHA classification</b>  <i>Recommendation</i> : %#NYHA Class I...............................Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	/A. No objective evidence of cardiovascular disease.

NYHA Class II............................. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	/	B. Objective evidence of minimal cardiovascular disease.

NYHA Class III. .............................Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	/C. Objective evidence of moderately severe cardiovascular disease.

NYHA Class IV. ...........................Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.		/D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class160433$*--><b>-   ICD primary prev rec Stage C Astronaut</b>  <i>Class I</i> : %#Class I:  Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and ASSUMING NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.#% </p><p><!--Message$ATHENA_HF_Class170004$*--><b>-   Use of drugs adversely affect HF status Astronaut</b>  <i>Primary_Recommendation</i> : %#Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., nonsteroidal anti-inflammatory drugs (not aspirin), most antiarrhythmic drugs,  most
calcium channel blocking drugs (except amlodipine) and thiazolidinediones). (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class170011$*--><b>-   Use of ACE inhibitor and NSAID Astronaut</b>  <i>Primary_Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170016$*--><b>-   Add ACE inhibitor while on NSAID not aspirin primary message</b>  <i>Primary_Recommendation</i> : %#Presence of NSAID detected.  Warning:  Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170020$*--><b>-   Presence of NSAID HF collateral message Astronaut</b>  <i>Recommendation</i> : %#Nonsteroidal anti-inflammatory drugs(except aspirin) can cause sodium retention and peripheral vasoconstriction and can attenuate the efficacy and enhance the toxicity of diuretics and ACEIs#% </p><p><!--Message$ATHENA_HF_Class170336$*--><b>-   CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation Astronaut</b>  <i>Class II a</i> : %#Class IIa:  For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of those patients with NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B).  PRESENCE OF HF SYMPTOMS DATA IS NOT AVAILABLE AND IS ASSUMED TO BE PRESENT.#% </p><p><!--Message$ATHENA_HF_Class230001$*--><b>-   ICD primary prev rec Stage C Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class230003$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class230005$*--><b>-   CRT when LVEF<=35% and QRS>=0.15s and LBBB Astronaut II</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class371546$*--><b>-   PM ARB (add or on) and pregnancy warning</b>  <i>Primary_Recommendation</i> : %#Angiotensin receptor blocker is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$ATHENA_HF_Class380470$*--><b>-   PM Rec BB stage C HF and on other BB</b>  <i>Recommendation</i> : %#Patient already has active prescription for a different beta blocker. Consider appropriateness of change to the recommended beta blocker.#% </p><p><!--Message$ATHENA_HF_Class380817$*--><b>-   PM on nitrates and  hydralazine and phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Patient has active prescriptions for hydralazine, a nitrate and a phosphodiesterase inhibitor. Must discontinue either nitrate or phsophodiesterase inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390000$*--><b>-   PM Active prescription for ACEi and 80<=SBP<110</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP is between 80 and 110, evaluate continuing prescription for ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390004$*--><b>-   .PM active prescription ACE inhibitor and SBP<80</b>  <i>Primary_Recommendation</i> : %#Patient's most recent SBP<80, consider STOPPING ACE inhibitor.#% </p><p><!--Message$ATHENA_HF_Class390015$*--><b>-   Absence labs will not rec ACEi</b>  <i>Recommendation</i> : %#Patient does not have creatinine, eGFR and/or potassium in past year. ACE could have been recommended if labs existed. Please order labs.#% </p><p><!--Message$ATHENA_HF_Class390605$*--><b>-   Add hydralazine SBP<110</b>  <i>Primary_Recommendation</i> : %#Would recommend add hydralazine but SBP is less than 110mmHg. Evaluate clinical significance#% </p><p><!--Message$ATHENA_HF_Class401702$*--><b>-   add nitrates age>=70</b>  <i>Recommendation</i> : %#Isosorbide dinitrate  may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401845$*--><b>-   add hydralazine age>=70</b>  <i>Recommendation</i> : %#Hidralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$ATHENA_HF_Class401993$*--><b>-   PM CKD stage 4 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 4. Evaluate clinical significance.#% </p><p><!--Message$ATHENA_HF_Class440002$*--><b>-   PM: most recent K >5</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for ACE Inhibitor and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class440004$*--><b>-   PM: On ARB and K>5</b>  <i>Recommendation</i> : %#Patient has active prescription for and ARB and most recent K greater than 5. Monitor closely.#% </p><p><!--Message$ATHENA_HF_Class50052$*--><b>-   Refer cardiology for ICD (ischemic cardiomyopathy)</b>  <i>Class II a</i> : %#Placement of an ICD is reasonable in patients with ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of 30% or less, are NYHA functional class I on chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. 
If this is the case, refer to cardiology.#% </p><p><!--Message$ATHENA_HF_Class50058$*--><b>-   Refer cardiology for ICD (non-ischemic cardiomyopathy)</b>  <i>Class II b</i> : %#Placement of an ICD might be considered in patients without HF who have nonischemic cardiomyopathy and an LVEF less than or equal to 30% who are in NYHA functional class I with chronic optimal medical therapy and have a reasonable expectation of survival with good functional status for more than 1 year.
If this is the case refer to cardiology.#% </p><p><!--Message$ATHENA_HF_Class50062$*--><b>-   valvular disease</b>  <i>Class I</i> : %#Valve replacement or repair should be recommended for patients with hemodynamically significant valvular stenosis or regurgitation and no symptoms of HF in accordance with contemporary guidelines.#% </p><p><!--Message$ATHENA_HF_Class50065$*--><b>-   coronary revascularization</b>  <i>Class I</i> : %#Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).#% </p><p><!--Message$ATHENA_HF_Class50099$*--><b>-   ICD secondary prevention</b>  <i>Recommendation</i> : %#Patient has an indication for an implantable cardioverter-defibrillator, refer to cardiology.
 (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70139$*--><b>-   ICD secondary prev rec Stage C</b>  <i>Class I</i> : %#An implantable cardioverter-defibrillator is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of HF and reduced LVEF who have a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70140$*--><b>-   ICD primary prev rec Stage C</b>  <i>Class I</i> : %#Implantable cardioverter-defibrillator therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in patients with non-ischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI, a LVEF less than or equal to 35%, and NYHA functional class II or III symptoms while receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70170$*--><b>-   atrial fibrillation and HF</b>  <i>Class II a</i> : %#It is reasonable to treat patients with atrial fibrillation and HF with a strategy to maintain sinus rhythm or with a strategy to control ventricular rate alone. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70188$*--><b>-   CRT when LVEF<=35% and QRS>=0.12s and atrial fibrillation</b>  <i>Class II a</i> : %#For patients who have LVEF less than or equal to 35%, a QRS duration of greater than or equal to 0.12 seconds, and atrial fibrillation (AF), CRT with or without an ICD is reasonable for the treatment of NYHA functional class III or ambulatory class IV heart failure symptoms on optimal recommended medical therapy. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70193$*--><b>-   CRT  frequent dependence ventricular pacing</b>  <i>Class II a</i> : %#For patients with LVEF of less than or equal to 35% with NYHA functional class III or ambulatory class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable (2). (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70197$*--><b>-   nutritional supplements and stage C</b>  <i>Class III</i> : %#Use of NUTRITIONAL SUPPLEMENTS as treatment for HF is NOT INDICATED in patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70199$*--><b>-   hormonal therapies and stage C</b>  <i>Class III</i> : %#HORMONAL THERAPIES other than to replete deficiencies are NOT RECOMMENDED and may be harmful to patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: C)#% </p><p><!--Message$KB_150996_Class0$*--><b>-   Rec add AA suppressed no NYHA or DM</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because 
patient is missing values for NYHA Class symptoms or presence of DM.#% </p><p><!--Message$KB_155357_Class35$*--><b>-   PM rec add AA and using ARB</b>  <i>Primary_Recommendation</i> : %#Patient has active prescription for angiotensin receptor blocker. Potassium and kidney function should be measured within 3 days of starting aldosterone antagonists, at 1 week, then every 4 weeks for the first 12 weeks, then every 3 months thereafter.#% </p><p><!--Message$KB_155357_Class52$*--><b>-   Age >=70, add hydralazine</b>  <i>Recommendation</i> : %#Hydralazine may be eliminated more slowly in elderly patients. Initiate therapy at the low end of the dosing range.#% </p><p><!--Message$KB_155357_Class59$*--><b>-   deleting nitrates because prescription for phosphodiesterase inhibitors</b>  <i>Primary_Recommendation</i> : %#Should stop nitrates but continue hydralazine. Need to stop either nitrates or the phosphodiesterase inhibitors#% </p><p><!--Message$KB_155357_Class69$*--><b>-   PM on other BB rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Patient already has active prescription for a different beta blocker.  Consider appropriateness of change to the recommended beta blocker#% </p><p><!--Message$KB_155357_Class72$*--><b>-   PM on sotalol rec add BB for stage C HF</b>  <i>Primary_Recommendation</i> : %#Note that patient has prescription for sotalol. Consider discussion with cardiology before changing beta blockers#% </p><p><!--Message$KB_222371_Class1$*--><b>-   Rec add AA suppressed K</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist has not been evaluated because patient is missing values for potassium#% </p><p><!--Message$KB_222371_Class3$*--><b>-   rec add hydralazine or nitrates suppressed no symptoms</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralaine and/or nitrates was not evaluated because patient is missing data for NYHA Class symptoms.#% </p><p><!--Message$KB_222371_Class4$*--><b>-   rec add AA suppressed no BNP</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding aldosterone antagonist when patient has NYHA Class II symptoms was not evaluated because patient is missing values for BNP#% </p><p><!--Message$KB_222371_Class6$*--><b>-   rec add hydralazine and nitrates suppressed no Race</b>  <i>Primary_Recommendation</i> : %#Recommendation for adding hydralazine and/or isosobide dinitrates  to African Americans was not evaluated because patient is missing values for race#% </p><p><!--Message$KB_313397_Class11$*--><b>-   PM On ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor.#% </p><p><!--Message$KB_313397_Class14$*--><b>-   PM rec add ACEi CKD stage5 or eGFR>15</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class16$*--><b>-   PM Rec add ACEi and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for ACE Inhibitor. Use caution if prescribing.#% </p><p><!--Message$KB_313397_Class18$*--><b>-   PM add ACEi and 20 percent increase creatinine after starting ACEi</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class19$*--><b>-   PM on ACEi and 20 percent increase in creatinine after starting ACEi or ARB</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class2$*--><b>-   PM rec add ACEi CKD stage3 or 4 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class20$*--><b>-   PM on ACE and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class22$*--><b>-   PM Rec add ACEi and active prescription for Aliskerin</b>  <i>Recommendation</i> : %#Patient has a prescription for aliskerin; evaluate clinical significance and impact of prescription for ACE inhibitor#% </p><p><!--Message$KB_313397_Class23$*--><b>-   PM Rec add ACE and presence K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class24$*--><b>-   PM On ACEi and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_313397_Class7$*--><b>-   PM on ACEi and CKD stage 3 or 4 or 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_313397_Class9$*--><b>-   PM on ace and ckd stage 5 or eGFR<15</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for ACE inhibitor.#% </p><p><!--Message$KB_335875_Class22$*--><b>-   PM CKD stage 5 ICD</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of CKD stage 5. Evaluate clinical significance.#% </p><p><!--Message$KB_335875_Class25$*--><b>-   Delete</b>  <i>Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs.#% </p><p><!--Message$KB_335875_Class8$*--><b>-   PM SBP<110 and (rec add BB or rec add AA)</b>  <i>Primary_Recommendation</i> : %#Most recent SBP less than 110mmHg. Evaluate clinical significance and therapeutic implications.#% </p><p><!--Message$KB_486502_Class0$*--><b>-   PM 20% increase of creatinine after starting ACE inhibitor</b>  <i>Recommendation</i> : %#Patient had an increase of more than 20% of creatinine (comparing pre ACE inhibitor value with peak value within 3m after starting ACE inhibitor) after starting ACE inhibitor.#% </p><p><!--Message$KB_486502_Class10$*--><b>-   PM On ARB and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of renal artery stenosis; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class12$*--><b>-   PM on ARB and 20 percent increase in creatinine after starting ARB or ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient had 20% increase in creatinine after initiation of ACE inhibitor or ARB; evaluate clinical significance and impact of prescription for aldosterone antagonist blocker.#% </p><p><!--Message$KB_486502_Class15$*--><b>-   PM on ARB and prescription for Aliskiren (current)</b>  <i>Primary_Recommendation</i> : %#Patient has a prescription for aliskiren; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class17$*--><b>-   PM On ARB and K sparing diuretic</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for potassium sparing diuretics; evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_486502_Class19$*--><b>-   DELETE  PM rec ADD ACE inhibitor and renal artery stenosis</b>  <i>Primary_Recommendation</i> : %#?messagebody#% </p><p><!--Message$KB_486502_Class2$*--><b>-   PM Rec ADD ARB and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59; evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class3$*--><b>-   PM  hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_486502_Class5$*--><b>-   PM On ARB and CKD stage 3/4 OR 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ARB and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class6$*--><b>-   PM Rec ADD ACEi and CKD stage 3/4 or most recent 15<=eGFR<60</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or most recent eGFR between 15 and 59); evaluate clinical significance and impact of prescription for ACE inhibitor and frequency of monitoring labs.#% </p><p><!--Message$KB_486502_Class8$*--><b>-   PM on ARB and (CKD stage 5 OR most recent  eGFR<15)</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 5 (or eGFR less than 15), evaluate clinical significance and impact of prescription for angiotensin receptor blocker.#% </p><p><!--Message$KB_502940_Class0$*--><b>-   PM Pregnancy message</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status.#% </p><p><!--Message$KB_502940_Class6$*--><b>-   PM Pregancy warning (add ACEi or on ACEi)</b>  <i>Primary_Recommendation</i> : %#ACE inhibitor is contraindicated in pregnant women; assess pregnancy status#% </p><p><!--Message$KB_810954_Class14$*--><b>-   PM Angioedema as a reaction to ACEi</b>  <i>Recommendation</i> : %#Patient has angioedema as a recorded allergy to ACE inhibitor. Evaluate clinical significance.#% </p><p><!--Message$KB_982939_Class0$*--><b>-   PM Angioedema as a reaction to ARB</b>  <i>Primary_Recommendation</i> : %#Patient has angioedema as a recorded allergy to angiotensin receptor blocker. Evaluate clinical significance.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10035$*--><b>-   Ischemic Heart disease and DBP<60 and BP at target</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60001$*--><b>-   DM rec based expert opinion</b>  <i>Recommendation</i> : %#This is not JNC8 recommendation but is based on expert opinion.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60002$*--><b>-   CKD rec add ACE age>75</b>  <i>Recommendation</i> : %#Per JNC8 there is lack of evidence to support use of ACE Inhibitor for patients with CKD and age>75 years. Evaluate clinical benefit.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60028$*--><b>-   CKD JNC8 and age>75</b>  <i>Recommendation</i> : %#Per JNC8 there is lack of evidence to support use of ARB for patients with CKD and age>75 years. Evaluate clinical benefit.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class70443$*--><b>-   BP above target JNC8</b>  <i>Recommendation</i> : %#BP above target. Evaluate clinical significance. Follow up in a month.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90004$*--><b>-   PM: K>5 and active prescription for ACE inhibitor</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an ACE Inhibitor and most recent K >5. Monitor closely.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class90006$*--><b>-   PM: K>5 and active prescription for ARB</b>  <i>Recommendation</i> : %#Patient has an active prescription for an ARB and most recent K >5. Monitor closely.#% </p><p><!--Message$athena_hypertension_03650$*--><b>-   DHP add and Angina</b>  <i>Recommendation</i> : %#Felodipine is not FDA-Approved for the indication of angina, but by VA guidelines it is the DHP calcium channel antagonist of choice.#% </p><p><!--Message$athena_hypertension_03659$*--><b>-   Add Beta Blocker and Diltiazem</b>  <i>Recommendation</i> : %#Use caution if combining a beta blocker with diltiazem because of the risk of heart block or myocardial depression. Use of a dihydropyridine calcium channel blocker (eg. felodipine) in conjunction with beta blocker may be more appropriate to avoid this interaction.#% </p><p><!--Message$athena_hypertension_03661$*--><b>-   Add Beta blocker and DM</b>  <i>Recommendation</i> : %#Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.#% </p><p><!--Message$athena_hypertension_03663$*--><b>-   Add Beta blocker and PVD</b>  <i>Recommendation</i> : %#Beta blockers may exacerbate symptoms of peripheral vascular disease (PVD). It is important to follow the effect on your individual patient.#% </p><p><!--Message$athena_hypertension_03665$*--><b>-   Add Beta blockers and Verapamil</b>  <i>Recommendation</i> : %#Patient has strong indication for beta blocker and beta blockers should not be used concurrently with verapamil. Consider titrating off verapamil to allow beta blocker.#% </p><p><!--Message$athena_hypertension_03667$*--><b>-   Add Beta blocker and Depression</b>  <i>Recommendation</i> : %#Use caution as beta blockers may cause or exacerbate symptoms of depression; however, many patients tolerate them without difficulty.#% </p><p><!--Message$athena_hypertension_03669$*--><b>-   Beta blocker secondary prevention</b>  <i>Recommendation</i> : %#Beta blockers reduce the risk for subsequent MI and sudden cardiac death and should be considered for this patient apart from their use as a antihypertensive.#% </p><p><!--Message$athena_hypertension_04779$*--><b>-   Furosemide without CHF or RF</b>  <i>Recommendation</i> : %#Patient is taking furosemide and appears to have neither CHF nor renal failure. Hydrochlorothiazide is generally the more efficacious diuretic in the management of hypertension.#% </p><p><!--Message$athena_hypertension_04821$*--><b>-   ISH MESSAGE</b>  <i>Recommendation</i> : %#Both thiazide diuretics and dihydropyridine calcium channel blockers are effective in lowering the risk of stroke in ISH,  but there have been no head to head comparisons. Thiazides are far less expensive.#% </p><p><!--Message$athena_hypertension_05571$*--><b>-   add beta blocker delete clonidine</b>  <i>Recommendation</i> : %#Use caution when discontinuing clonidine. Gradual dosage reduction may be necessary to avoid serious rebound hypertension.  Add beta adrenoreceptor antagonist only after discontinuing clonidine.#% </p><p><!--Message$athena_hypertension_07645$*--><b>-   delete CCB, no CAD </b>  <i>Recommendation</i> : %#If indicated, the patient should be warned about the possibility of chest pain after discontinuing a calcium channel blocker. Some patients experience angina that is 'unmasked' when a calcium channel blocker is discontinued.#% </p><p><!--Message$athena_hypertension_104230$*--><b>-   Add HCTZ/BB diabetes, ACE compellingly indicated if proteinuria</b>  <i>Recommendation</i> : %#If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.#% </p><p><!--Message$athena_hypertension_11566$*--><b>-   ON HCTZ and gout complicated</b>  <i>Recommendation</i> : %#Complicated gout is a strong contraindication for use of thiazides, although some patients tolerate and therefore benefit from this drug therapy. Consider the possibility of gout complications, particularly if you increase the dose of hydrochlorothiazide.#% </p><p><!--Message$athena_hypertension_11567$*--><b>-   Hypokalemia and on thiazide</b>  <i>Recommendation</i> : %#Hypokalemia is a strong contraindication for use of thiazide diuretics. Discontinue use of thiazide diuretics. #% </p><p><!--Message$athena_hypertension_11568$*--><b>-   Hyponatremia and ON HCTZ</b>  <i>Recommendation</i> : %#Hyponatremia is a strong contraindication for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_118523$*--><b>-   MI and SBP<100</b>  <i>Recommendation</i> : %#Most recent Systolic BP in database is less than 100. Use your clinical judgment about safety of  adding, substituting, or maintaining drug regimen.#% </p><p><!--Message$athena_hypertension_12824$*--><b>-   ON ARB, Hyperkalemia</b>  <i>Recommendation</i> : %#Hyperkalemia is a strong contraindication for Angiotensin II receptor blockers (ARB). May need to discontinue ARB.#% </p><p><!--Message$athena_hypertension_143079$*--><b>-   Gout, UA < 6.9</b>  <i>Recommendation</i> : %#When uric acid level is 'normal', thiazides may be used if gout is well controlled, that is, there have been no gouty attacks in the past year. However, additional hypouricemic treatment may be needed.#% </p><p><!--Message$athena_hypertension_143086$*--><b>-   gout and ua >6.8</b>  <i>Recommendation</i> : %#Thiazides should be avoided in patients with diagnosis of gout and elevated uric acid.#% </p><p><!--Message$athena_hypertension_150674$*--><b>-   Adding drug, DBP<100 and SBP<160, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_150676$*--><b>-   Adding drug, SBP>=160 or DBP>=100</b>  <i>Primary_Recommendation</i> : %#ADD antihypertensive medication: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_154823$*--><b>-   ISH, using non DHP and add DHP</b>  <i>Recommendation</i> : %#Evidence for benefit of calcium channel blockers in isolated systolic hypertension is for dihydropiridine calcium channel blockers.#% </p><p><!--Message$athena_hypertension_160432$*--><b>-   BB and diltiazen and MI</b>  <i>Recommendation</i> : %#Patient has an indication for beta blocker. Use caution if combining a beta blocker with diltiazem because of the risk of heart block or myocardial depression. Consider replacing diltiazen with a beta blocker if clinically warranted.#% </p><p><!--Message$athena_hypertension_174212$*--><b>-   Urinary incontinence and ADD HCTZ</b>  <i>Recommendation</i> : %#There is little information about the likelihood that introduction of low-dose thiazides will adversely affect bladder function.  Follow individual patient response to treatment.#% </p><p><!--Message$athena_hypertension_189162$*--><b>-   Primary: Secondary Prevention BP controlled add ACEI/BB</b>  <i>Primary_Recommendation</i> : %#Patient may benefit from the addition of a drug for secondary prevention.#% </p><p><!--Message$athena_hypertension_192999$*--><b>-   Add ACE inhibitor and dx of renal disease</b>  <i>Recommendation</i> : %#ACE inhibitors can cause hyperkalemia and the risk in this patient needs to be evaluated carefully as the pt has an ICD9 code for renal disease.
#% </p><p><!--Message$athena_hypertension_207030$*--><b>-   sinoatrial node dysfunction + pacemaker+ diltiazem/verapamil</b>  <i>Recommendation</i> : %#Diltiazem or verapamil may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.#% </p><p><!--Message$athena_hypertension_207035$*--><b>-   sinoatrial node dysfunction and pacemaker BB</b>  <i>Recommendation</i> : %#Beta adrenergic receptor antagonists may worsen bradycardia in patients with sinoatrial node dysfunction. This patient's pacemaker, if functioning properly, should protect against adverse events.#% </p><p><!--Message$athena_hypertension_210254$*--><b>-   alpha blocker monotherapy</b>  <i>Recommendation</i> : %#Blood pressure is adequately controlled based on the most recent BP, however alpha blocker MONOTHERAPY is currently not recommended.#% </p><p><!--Message$athena_hypertension_213176$*--><b>-   sinoatrial node dysfunction and no pacemaker</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction and no pacemaker, exercise caution if adding diltiazem or verapamil.#% </p><p><!--Message$athena_hypertension_213178$*--><b>-   BB, sinoatrial node dysfunction, no pacemaker</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction and no pacemaker, exercise caution if adding a beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_21662$*--><b>-   SBP<100</b>  <i>Recommendation</i> : %#Most recent Systolic BP in database is less than 100. Use your clinical judgment about safety of  adding, substituting, or maintaining drug regimen.#% </p><p><!--Message$athena_hypertension_223056$*--><b>-   Substituting verapamil with metoprolol</b>  <i>Recommendation</i> : %#This patient will benefit from metoprolol (secondary prevention of MI). Recheck BP in 4-6 weeks.#% </p><p><!--Message$athena_hypertension_224126$*--><b>-   felodipine less myocardial effects</b>  <i>Recommendation</i> : %#Felodipine is the preferred calcium channel blocker because it has less myocardial effects than diltiazem.#% </p><p><!--Message$athena_hypertension_224834$*--><b>-   pulse<65 add BB</b>  <i>Recommendation</i> : %#Patient has a relatively slow heart rate. Beta adrenergic receptor antagonists may lower heart rate further.#% </p><p><!--Message$athena_hypertension_228843$*--><b>-   ADR ACE I cross reactivity</b>  <i>Recommendation</i> : %#Angiotensin II receptor blockers (ARBs) are recommended if the patient develops cough during use of ACE inhibitor.  There is a risk of cross-reactivity between ACE Inhibitors and ARBs; for some ADEs other than cough, ARBs may also be contraindicated.#% </p><p><!--Message$athena_hypertension_229056$*--><b>-   Amiodarone add diltiazem</b>  <i>Recommendation</i> : %#'Concurrent use of amiodarone and diltiazem may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_238977$*--><b>-   BPH, add HCTZ</b>  <i>Recommendation</i> : %#Thiazide diuretics may worsen urinary symptoms of benign prostatic hyperplasia.#% </p><p><!--Message$athena_hypertension_23967$*--><b>-   Increase dose ACE, on K sparing diuretics</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_23970$*--><b>-   increase dose K sparing diuretic, on ACE inhibitor</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_244812$*--><b>-   amiodarone add beta blocker</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and beta adrenergic receptor antagonist may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_26264$*--><b>-   presence of angina, deleting NDHP CCB</b>  <i>Recommendation</i> : %#This patient has a diagnosis of ANGINA, and also has compelling indications for other antihypertensive agents. Use clinical judgement to evaluate benefit/harm of substituting away from diltiazem.#% </p><p><!--Message$athena_hypertension_26265$*--><b>-   2nd/3rd degree heart block, no pacemaker on BB</b>  <i>Recommendation</i> : %#Second or 3rd degree heart block without presence of a pacemaker is a strong contraindication for use of beta adrenergic receptor antagonists, but therapy must be individualized. Consider consultation.#% </p><p><!--Message$athena_hypertension_262653$*--><b>-   high K when rec increase dose ACE</b>  <i>Recommendation</i> : %#Serum K+ is high based on most recent value in database, please recheck. If HYPERKALEMIA is confirmed consider decreasing dose of ACE inhibitor or adding a diuretic.#% </p><p><!--Message$athena_hypertension_263505$*--><b>-   Uric acid >6.8</b>  <i>Recommendation</i> : %#The risk of gout with thiazides is increased when uric acid is above normal.#% </p><p><!--Message$athena_hypertension_269217$*--><b>-   hyperkalemia, delete ACE, absence of triamterene</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ACE-I should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_269267$*--><b>-   add metoprolol, adjust dose other drugs</b>  <i>Recommendation</i> : %#When adding metoprolol to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269270$*--><b>-   add ACE(2ary prevention HF), dose adjustment </b>  <i>Recommendation</i> : %#When adding ACE inhibitor to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269274$*--><b>-   Add ACE +Diabetes AND proteinuria/renal manifestations- dose adjustment</b>  <i>Recommendation</i> : %#When adding ACE inhibitor to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.#% </p><p><!--Message$athena_hypertension_269593$*--><b>-   ISH on thiazide</b>  <i>Recommendation</i> : %#Beta receptor antagonists may have added benefit in decreasing the risk of stroke in patients with ISH who are taking thiazides.  Alternatively, a dihydropyridine, nitrendipine, has been shown to be effective in ISH as compared to placebo.  However, dihydropiridines available in the U.S., such as felodipine, have not been studied as an addition to thiazide in this setting. Very little is known about the added benefits from particular drug combinations.#% </p><p><!--Message$athena_hypertension_270092$*--><b>-   heart failure and ndhp</b>  <i>Recommendation</i> : %#Patient has heart failure which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.#% </p><p><!--Message$athena_hypertension_270094$*--><b>-   heart block and add ndhp</b>  <i>Recommendation</i> : %#Patient has heart block which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.#% </p><p><!--Message$athena_hypertension_270098$*--><b>-   add beta blocker, obstructive pulmonary disease</b>  <i>Recommendation</i> : %#Cardiovascular benefits of beta blocker therapy may outweigh the increased risk of bronchospasm in this patient.#% </p><p><!--Message$athena_hypertension_273237$*--><b>-   HF + MI consider felodipine</b>  <i>Recommendation</i> : %#Felodipine is the preferred CCB because it has less myocardial effects than diltiazen.#% </p><p><!--Message$athena_hypertension_284058$*--><b>-   triamterene or amiloride, high K and ACE Inhibitor</b>  <i>Recommendation</i> : %#A potassium sparing diuretic (triamterene or amiloride) is not indicated in light of this patient's hyperkalemia.#% </p><p><!--Message$athena_hypertension_288910$*--><b>-   Rec substituting away from furosemide</b>  <i>Recommendation</i> : %#Consider replacing the loop diuretic with HCTZ. Patient is taking a loop diuretic and appears to have neither CHF nor renal insufficiency. HCTZ, while a low efficacy diuretic in comparison to furosemide, may have greater efficacy in controlling hypertension.#% </p><p><!--Message$athena_hypertension_288914$*--><b>-   Add HCTZ, delete Loop diuretic, Cr>2</b>  <i>Recommendation</i> : %#This patient has a creatinine greater than 2.0. Thiazide diuretics may be
effective antihypertensives with creatinine up to 2.5; if the BP does not
respond, furosemide is an alternative. If you use furosemide, note that
twice daily dosing is preferred over once daily.#% </p><p><!--Message$athena_hypertension_29650$*--><b>-   ISH treatment benefits</b>  <i>Recommendation</i> : %#In a meta-analysis, isolated systolic hypertension and wide pulse pressure in elderly persons increased the risk for all cause mortality, cardiovascular events and stroke. Treatment reduced the risk by 13% for all cause mortality, 30% for stroke and 26% for cardiovascular events in 3.8 years.#% </p><p><!--Message$athena_hypertension_301093$*--><b>-   PM 5<K<5.4 and rec increase dose  ACE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; caution and close monitoring are recommended if ACE inhibitor dose is increased.#% </p><p><!--Message$athena_hypertension_301094$*--><b>-   PM 5.0<K<5.4  and using ace, no rec dose increase</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; close monitoring recommended if ACE inhibitor continued.#% </p><p><!--Message$athena_hypertension_303336$*--><b>-   using sotalol & presence bronchospasm</b>  <i>Primary_Recommendation</i> : %#Patient has history of BRONCHOSPASM which may be contraindication to beta blocker sotalol; assess tolerance. Sotalol may be essential for arrhythmia.#% </p><p><!--Message$athena_hypertension_303337$*--><b>-   using sotalol & presence heart block/no pacemaker</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of heart block without a pacemaker which may be contraindication to beta blocker sotalol; however, sotalol may be essential for arrhythmia. Consider cardiology consultation.#% </p><p><!--Message$athena_hypertension_303338$*--><b>-   using sotalol & presence unpecified heart block/no pacemaker</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of unspecified heart block without a pacemaker which may be contraindication to beta blocker sotalol; however, sotalol may be essential for arrhythmia. Consider cardiology consultation.#% </p><p><!--Message$athena_hypertension_303341$*--><b>-   5<K<=5.4 and using ARB, rec INCREASE DOSE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; caution and close monitoring are recommended if ARB dose is increased.#% </p><p><!--Message$athena_hypertension_303343$*--><b>-   5<K<=5.4 and using ARB, NOT rec INCREASE DOSE</b>  <i>Primary_Recommendation</i> : %#Most recent POTASSIUM is in the HIGH NORMAL RANGE; close monitoring recommended if ARB continued.#% </p><p><!--Message$athena_hypertension_305971$*--><b>-   PM using triamterene and ACE I, not rec increase dose ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescriptions for both potassium sparing diuretic (triamterene) and ACEi: caution re risk of hyperkalemia#% </p><p><!--Message$athena_hypertension_305972$*--><b>-   PM: using triamterene and ARB, not rec increase dose ARB</b>  <i>Primary_Recommendation</i> : %#Patient has prescriptions for both potassium sparing diuretic (triamterene) and ARB: caution re risk of hyperkalemia#% </p><p><!--Message$athena_hypertension_305974$*--><b>-   PM using triamterene and ACE I, rec increase dose ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if increasing dose ACEi, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305976$*--><b>-   PM using triamterene , rec ADD ACE</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if adding ACEi, consider discontinuing triamterene to avoid hyperkalemia.
#% </p><p><!--Message$athena_hypertension_305977$*--><b>-   PM using triamterene and ARB, rec increase dose</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if increasing dose ARB, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305978$*--><b>-   PM using triamterene , rec ADD ARB</b>  <i>Primary_Recommendation</i> : %#Patient has prescription for potassium sparing diuretic (triamterene); if adding ARB, consider discontinuing triamterene to avoid hyperkalemia.#% </p><p><!--Message$athena_hypertension_305983$*--><b>-   Precaution: hyperkalemia, on ACE and absence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ACE inhibitor should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305984$*--><b>-   hyperkalemia, delete ACE primary msg, presence of triamterene</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305985$*--><b>-   Precaution: hyperkalemia, on ACEi and on triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305986$*--><b>-   PRIMARY: hyperkalemia, on ARB , absence of triamterence</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ARB should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305987$*--><b>-   precaution: hyperkalemia, on ARB, absence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, ARB should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305988$*--><b>-   PRIMARY: hyperkalemia, on ARB , presence of triamterence</b>  <i>Primary_Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_305989$*--><b>-   precaution: hyperkalemia, on ARB, presence of triamterene</b>  <i>Recommendation</i> : %#HYPERKALEMIA observed in most recent lab test, TRIAMTERENE should be temporarily DISCONTINUED or have the dose DECREASED until K is normal.#% </p><p><!--Message$athena_hypertension_306255$*--><b>-   hypokalemia, increase dose diuretics</b>  <i>Recommendation</i> : %#This patient has a prescription for a diuretic, and the most recent K+ is below normal limits.  Use caution and recheck potassium before increasing thiazide dosage.#% </p><p><!--Message$athena_hypertension_31098$*--><b>-   HCTZ dosing message and creatinine<=2.0</b>  <i>Recommendation</i> : %#HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_hypertension_31100$*--><b>-   HCTZ dosing message and CR>2.0</b>  <i>Recommendation</i> : %#While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.#% </p><p><!--Message$athena_hypertension_31109$*--><b>-   Unspecified heart block, absence 1st, 2nd or 3rd degree heart block</b>  <i>Recommendation</i> : %#This patient has a diagnosis of unspecified heart block. Second or third degree heart block without presence of a pacemaker is a strong contraindication for use of beta adrenergic receptor antagonists, but therapy must be individualized. Consider consultation and update problem list.#% </p><p><!--Message$athena_hypertension_312849$*--><b>-   Gout, no uric acid</b>  <i>Recommendation</i> : %#Thiazides may be used if gout is well controlled, however thiazides may worsen symptoms of gout if uric acid is elevated.#% </p><p><!--Message$athena_hypertension_314611$*--><b>-   Check K and creatinine when increasing dose, [Cr<=1.5(male) or Cr<=1.3(female)]</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_314614$*--><b>-   Check K and creatinine when increasing dose, Cr>1.5 (male)</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors. When considering frequency of follow up, please note that this patient's last creatinine was >1.5.#% </p><p><!--Message$athena_hypertension_314618$*--><b>-   adding ace inhibitor, check Cr and K, [Cr<=1.5(male) or Cr<=1.3(female)] and K<5.6</b>  <i>Recommendation</i> : %#Check the patient's creatinine and potassium concentrations when prescribing  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_314621$*--><b>-   adding ACE inhibitor, creatinine message if K>5.5</b>  <i>Recommendation</i> : %#Check the patient's creatinine when prescribing or increasing dose of  ACE Inhibitors.#% </p><p><!--Message$athena_hypertension_32504$*--><b>-   on BB presence of bronchospasm primary msg</b>  <i>Primary_Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Please evaluate carefully if maintaining patient on beta adrenergic receptor antagonist or increasing the dose.#% </p><p><!--Message$athena_hypertension_327119$*--><b>-   ISH definition</b>  <i>Recommendation</i> : %#Strictly speaking, ISH is defined as pre-treatment SBP >= 140 and DBP < 90.#% </p><p><!--Message$athena_hypertension_327120$*--><b>-   consult message on thiazides target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP ELEVATED despite high doses of 4 antihypertensives.#% </p><p><!--Message$athena_hypertension_328273$*--><b>-   verapamil and HF, increase dose</b>  <i>Recommendation</i> : %#Verapamil can have potent negative inotropic effect.  Apparently this patient with heart failure is already tolerating it; however, use caution if you decide to increase dose.#% </p><p><!--Message$athena_hypertension_330345$*--><b>-   ACE inhibitor and HF</b>  <i>Recommendation</i> : %#Use of ACE inhibitors in patients with heart failure and ejection fraction <0.35 significantly reduces overall mortality and hospital admissions.  For patients with ejection fraction >=0.35 ACE inhibitors may be beneficial but this is not established.#% </p><p><!--Message$athena_hypertension_33188$*--><b>-   pulse<65, increase dose BB</b>  <i>Recommendation</i> : %#Patient has a relatively slow heart rate. Increasing dose of beta adrenergic receptor antagonists may lower heart rate further.#% </p><p><!--Message$athena_hypertension_334164$*--><b>-   add ACE inhibitor, Diabetes AND proteinuria/renal manifestations</b>  <i>Recommendation</i> : %#Use of ACE inhibitors in patients with diabetes and proteinuria significantly reduces risk of myocardial infarction, stroke, overt nephropathy and cardiovascular death.#% </p><p><!--Message$athena_hypertension_350271$*--><b>-   increase dose ARB, High K</b>  <i>Recommendation</i> : %#Serum K+ is high based on most recent value in database, please recheck. If HYPERKALEMIA is confirmed consider decreasing dose of ARB or adding a diuretic.#% </p><p><!--Message$athena_hypertension_35597$*--><b>-   Zero daily dose in non-contraindicated drug warning</b>  <i>Primary_Recommendation</i> : %#DRUG DOSE information from pharmacy database is MISSING for an antihypertensive drug. Evaluate if dose increase is appropriate.#% </p><p><!--Message$athena_hypertension_360318$*--><b>-   add ace and "race black on thiazides"</b>  <i>Recommendation</i> : %#In the ALLHAT trial, ACEi was less effective in lowering BP in Afr-Amer than diuretics & CCB.  The differences were abolished when ACEi was combined with thiazides.#% </p><p><!--Message$athena_hypertension_361684$*--><b>-   marginally elevated BP, Target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_361691$*--><b>-   Adding drug, marginally elevated BP Target 140/90</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_362750$*--><b>-   ISH thiazides</b>  <i>Recommendation</i> : %#Thiazide diuretics reduce risk of stroke, cardiovascular events, and mortality in patients with isolated systolic hypertension.#% </p><p><!--Message$athena_hypertension_37158$*--><b>-   ADR ACE I beyond scope of program</b>  <i>Recommendation</i> : %#An adverse drug event (ADE) has been listed for ACE inhibitor.  Analyzing the nature or significance of the ADE is beyond the scope of this program. #% </p><p><!--Message$athena_hypertension_379470$*--><b>-   intensify message, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_39003$*--><b>-   ISH BP Target, SBP>=180</b>  <i>Recommendation</i> : %#For an elderly patient with marked systolic hypertension (SBP>=180), initial target is SBP below 160 mmHg.#% </p><p><!--Message$athena_hypertension_39007$*--><b>-   ISH target, 140<=SBP<180- age >60 years</b>  <i>Recommendation</i> : %#For an elderly patient with isolated systolic hypertension and SBP between 160 and 180mmHg, initial target is to lower SBP by 20 mmHg.#% </p><p><!--Message$athena_hypertension_391779$*--><b>-   MI (ACE) and JNC7 rec aldosterone antagonists</b>  <i>Recommendation</i> : %#ACE Inhibitor is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.#% </p><p><!--Message$athena_hypertension_391783$*--><b>-   MI (BB)  and JNC7 rec aldosterone antag</b>  <i>Recommendation</i> : %#Beta Adrenergic Receptor Antagonist is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.#% </p><p><!--Message$athena_hypertension_405292$*--><b>-   High Postural hypotension risk- age</b>  <i>Primary_Recommendation</i> : %#Older persons are at higher risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405293$*--><b>-   High Postural hypotension risk- DM</b>  <i>Primary_Recommendation</i> : %#Diabetic patients are at higher risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405294$*--><b>-   High Postural hypotension risk- diuretic</b>  <i>Primary_Recommendation</i> : %#Active prescription for a  diuretic increases risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_405296$*--><b>-   High Postural hypotension risk-  cerebral vascular disease</b>  <i>Primary_Recommendation</i> : %#Cerebral vascular disease increases risk of postural hypotension. Check orthostatic BP.#% </p><p><!--Message$athena_hypertension_407883$*--><b>-   add ACE and presence of cerebrovascular disease</b>  <i>Recommendation</i> : %#With respect to the prevention of recurrent stroke,PROGRESS demonstrated that addition of the diuretic, indapamide, to the ACEI, perindopril,caused a 43 percent reduction in stroke occurence.#% </p><p><!--Message$athena_hypertension_407884$*--><b>-   PM: Stroke and BP control</b>  <i>Primary_Recommendation</i> : %#BP control extremely important to prevent further cardiovascular events.#% </p><p><!--Message$athena_hypertension_408418$*--><b>-   DHP and migraine</b>  <i>Recommendation</i> : %#Calcium channel antagonists may have a favorable effect on migraine. There is very little evidence to guide the choice of drug for this indication.#% </p><p><!--Message$athena_hypertension_412565$*--><b>-   on 4 drugs, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION.#% </p><p><!--Message$athena_hypertension_413512$*--><b>-   on 4 drugs, absence thiazides, not marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_413763$*--><b>-   Adding drug, marginally elevated BP, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_414890$*--><b>-   marginally elevated BP, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_419564$*--><b>-   Adding drug, DBP<100 and SBP<160, target 130/85</b>  <i>Primary_Recommendation</i> : %#Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_427221$*--><b>-   intensify message, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP.#% </p><p><!--Message$athena_hypertension_428368$*--><b>-   intensify message, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_429435$*--><b>-   Primary: use ARB and ACE for non diabetic renal disease</b>  <i>Recommendation</i> : %#Patient has a diagnosis of non diabetic kidney disease, use of combined therapy with ARB and ACE may offer more renal protection than either alone.#% </p><p><!--Message$athena_hypertension_432951$*--><b>-   Add ACE/ARB & CKD; alert creatinine rise</b>  <i>Recommendation</i> : %#A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.#% </p><p><!--Message$athena_hypertension_434555$*--><b>-   On 1 drug, BP >= 160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_435003$*--><b>-   On 2 or 3 drugs, BP >=160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_436122$*--><b>-   Ischemic Heart disease and DBP<60 and BP not controlled</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_436124$*--><b>-   ischemic heart disease, dbp<60 and BP controlled</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$athena_hypertension_436463$*--><b>-   on 4 drugs, absence thiazides, BP > =160/100</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_436668$*--><b>-   on 4 drugs, presence thiazides, BP >= 160/100</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_437283$*--><b>-   on 4 drugs, not max dose, bp >=160/100</b>  <i>Primary_Recommendation</i> : %#Recommend INTENSIFYING antihypertensive therapy: BP MARKEDLY ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_437493$*--><b>-   on 4 drugs, not max dose, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_437494$*--><b>-   on 4 drugs, bp not marginally elevated, < 160/100, target 140/90</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_438122$*--><b>-   on 4 drugs, bp marginally elevated, target 130/85</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_438123$*--><b>-   on 4 drugs, bp not marginally elevated, bp < 160/100, target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.
#% </p><p><!--Message$athena_hypertension_439133$*--><b>-   On thiazides, sodium < 125 alert</b>  <i>Primary_Recommendation</i> : %#ALERT!  Patient has active prescription for thiazide diuretics and HYPONATREMIA.#% </p><p><!--Message$athena_hypertension_439556$*--><b>-   on thiazides, K<3.5 alert</b>  <i>Primary_Recommendation</i> : %#ALERT!  Patient has active prescription for thiazide diuretics and HYPOKALEMIA.#% </p><p><!--Message$athena_hypertension_441551$*--><b>-   on 4 drugs, bp marginally elevated, target 140/90</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_453682$*--><b>-   4 drugs, marginally elevated BP, target 130/85, presence of dm,chf,ri consult message</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION#% </p><p><!--Message$athena_hypertension_453683$*--><b>-   On 4 drugs, absence of thiazide, not marginally elevated, target 130/85</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_458684$*--><b>-   Adding drug, marginally elevated BP, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider antihypertensive medication; F/up 1month.#% </p><p><!--Message$athena_hypertension_458690$*--><b>-   Adding drug, DBP < 100 and SBP < 160, target 140/80</b>  <i>Primary_Recommendation</i> : %#Recommend ADDING antihypertensive medication: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458697$*--><b>-   marginally elevated BP, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_458700$*--><b>-   intensify message, target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458701$*--><b>-   on 4 drugs, bp not marginally elevated, bp < 160/100, target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider INTENSIFYING drug treatment: BP ELEVATED based on most recent available BP; F/up 1month.#% </p><p><!--Message$athena_hypertension_458702$*--><b>-   on 4 drugs, bp marginally elevated, target 140/80</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED:  If confirmed (at home or in clinic) consider INTENSIFYING antihypertensive therapy; F/up 1month.#% </p><p><!--Message$athena_hypertension_458703$*--><b>-   4 drugs, marginally elevated BP, target 140/80, presence of dm,consult message</b>  <i>Primary_Recommendation</i> : %#BP is SLIGHTLY ELEVATED despite high doses of 4 antihypertensive medications:  If confirmed (at home or in clinic) consider CONSULTATION#% </p><p><!--Message$athena_hypertension_458704$*--><b>-   On 4 drugs, absence of thiazide, not marginally elevated, target 140/80</b>  <i>Primary_Recommendation</i> : %#Multidrug regimens should generally include a thiazide diuretic. However, since that would add a 5th antihypertensive drug to this patient's regimen, we recommend CONSULTATION.#% </p><p><!--Message$athena_hypertension_458706$*--><b>-   consult message on hctz target 140/80</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_462726$*--><b>-   add ACE and Creatinine>1.5 (male)</b>  <i>Recommendation</i> : %#ACE inhibitor is recommended because most recent creatinine is above 1.5mg/dl, disregard if renal insufficiency is acute. Recheck creatinine and potassium concentration after starting ACE inhibitor therapy.#% </p><p><!--Message$athena_hypertension_465027$*--><b>-   Check K and creatinine when increasing dose, Cr>1.3 (female)</b>  <i>Recommendation</i> : %#Check patient's creatinine and potassium concentrations when increasing dose of  ACE Inhibitors. When considering frequency of follow up, please note that this patient's last creatinine was >1.3.#% </p><p><!--Message$athena_hypertension_465029$*--><b>-   add ACE and Creatinine>1.3 (female)</b>  <i>Recommendation</i> : %#ACE inhibitor is recommended because most recent creatinine is above 1.3mg/dl (upper normal limit for females), disregard if renal insufficiency is acute. Recheck creatinine and potassium concentration after starting ACE inhibitor therapy.#% </p><p><!--Message$athena_hypertension_469429$*--><b>-   consult message on hctz target 130/85</b>  <i>Primary_Recommendation</i> : %#Consider CONSULTATION: BP MARKEDLY ELEVATED despite high doses of 4 antihypertensive medications.#% </p><p><!--Message$athena_hypertension_469832$*--><b>-   BP controlled, HCTZ>25mg</b>  <i>Primary_Recommendation</i> : %#HCTZ dose above 25mg has no added antihypertensive effect for most patients, and increases risk of adverse effects. Consider adjusting the dose to 25mg.#% </p><p><!--Message$athena_hypertension_469833$*--><b>-   SBP>=100, BP controlled, HCTZ absent or <=25mg</b>  <i>Primary_Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_484963$*--><b>-   primary: rec add ARB and presence of cough as ADR ACE</b>  <i>Primary_Recommendation</i> : %#Patient has cough as an ADR to ACE and there is no record of angioedema, please exclude possibility of other serious adverse reactions before prescribing ARB.#% </p><p><!--Message$athena_hypertension_491109$*--><b>-   Atrial fibrillation and add NDHP orBB</b>  <i>Recommendation</i> : %#Management of  arrythmia is complex and may require consultation with specialist.#% </p><p><!--Message$athena_hypertension_501754$*--><b>-   bronchospasm</b>  <i>Recommendation</i> : %#Bronchospasm is a strong contraindication for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_506843$*--><b>-   Hyponatremia in the past</b>  <i>Recommendation</i> : %#Patient had severe hyponatremia in the past, monitor introduction of thiazide therapy closely.#% </p><p><!--Message$athena_hypertension_510458$*--><b>-   Taking 2 bbs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 beta adrenergic receptor antagonists. Please evaluate.#% </p><p><!--Message$athena_hypertension_510459$*--><b>-   Taking 2 ACEs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 ACE inhibitors. Please evaluate.#% </p><p><!--Message$athena_hypertension_510460$*--><b>-   Taking 2 CCBs</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 calcium channel blockers . Please evaluate.#% </p><p><!--Message$athena_hypertension_510461$*--><b>-   Taking 2 alphablockers</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 alpha blockers. Please evaluate.#% </p><p><!--Message$athena_hypertension_510462$*--><b>-   Taking 2 thiazides</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for 2 thiazide diuretics. Please evaluate.#% </p><p><!--Message$athena_hypertension_510607$*--><b>-   bronchospasm , add BB</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Monitor patient's response carefully if starting a beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_510608$*--><b>-   bronchospasm, increase dose BB</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_525534$*--><b>-   absolute contraindication to a current drug</b>  <i>Primary_Recommendation</i> : %#There appears to be a STRONG CONTRAINDICATION to a currently prescribed drug, evaluate clinical significance.#% </p><p><!--Message$athena_hypertension_525537$*--><b>-   HF ON BB and absolute contraindication BB</b>  <i>Primary_Recommendation</i> : %#There appears to be a STRONG CONTRAINDICATION to a currently prescribed drug (see "Precautions" tab), evaluate clinical significance.#% </p><p><!--Message$athena_hypertension_53781$*--><b>-   alpha blocker monotherapy rec ADD</b>  <i>Recommendation</i> : %#A clinical trial found unexpectedly that using an alpha1 receptor blocker as monotherapy for hypertension may not be adequate in reducing risk of some cardiovascular events.#% </p><p><!--Message$athena_hypertension_74989$*--><b>-   ADR for thiazide</b>  <i>Recommendation</i> : %#There is an allergy or adverse drug event reported for thiazide diuretics. Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_84362$*--><b>-   Hypokalemia diuretic caution collateral action</b>  <i>Recommendation</i> : %#This patient recently had a low potassium level. Use care if initiating diuretic therapy.#% </p><p><!--Message$athena_runtime_84895$*--><b>-   low sodium message HCTZ collateral action</b>  <i>Recommendation</i> : %#Patient's sodium is between 125 and 130 mg/dL. Hydrochlorothiazide may worsen hyponatremia. If you prescribe it, Na should be rechecked within 5 to 7 days.#% </p><p><!--Message$athena_runtime_84899$*--><b>-   BP not controlled but DBP < 70</b>  <i>Recommendation</i> : %#We are recommending treatment to lower systolic blood pressure. Use clinical judgment to evaluate the degree of diastolic blood pressure lowering that is acceptable.#% </p><p><!--Message$Lipid_dashboard_Class100001$*--><b>-   Dose level moderate intensity rosuvastation</b>  <i>Recommendation</i> : %#Moderate dose rosuvastatin is 5<=dose<20 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100004$*--><b>-   Dose level moderate intensity fluvastatin</b>  <i>Recommendation</i> : %#Moderate dose fluvastatin is 180 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100021$*--><b>-   Dose level moderate intensity atorvastatin</b>  <i>Recommendation</i> : %#Moderate dose atorvastatin is 10<=dose<40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100023$*--><b>-   Dose level moderate intensity lovastatin</b>  <i>Recommendation</i> : %#Moderate dose lovastatin is 40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100025$*--><b>-   Dose level moderate dose pravastatin</b>  <i>Recommendation</i> : %#Moderate dose pravastatin is 40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class100028$*--><b>-   Dose level moderate simvastatin</b>  <i>Recommendation</i> : %#Dose level of moderate intensity simvastatin is 20-40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class160013$*--><b>-   Presence of fibric acid msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking a fibric acid (fenofibrate, gemfibrozil or clofibrate) which increases risk of myopathy.  Consider switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class160023$*--><b>-   Presence of niacin >1gm/day msg</b>  <i>Recommendation</i> : %#We would have normally recommended a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class220013$*--><b>-   Pres hem stroke risk/benefit of increase dose message</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke.  Increasing the dose of the statin can increase the risk of adverse events, including myopathy.  Consider the risk/benefit of increase dose.#% </p><p><!--Message$Lipid_dashboard_Class220014$*--><b>-   Asian consider risk/benefit of increase dose message</b>  <i>Recommendation</i> : %#Warning:  Patient may be Asian.  When prescribing rosuvastatin to Asians, there is a 2-fold elevation in the median exposure (AUC and Cmax) to the durg when compared to Caucasians.  Consider risk/benefit of increasing dose of statins.#% </p><p><!--Message$Lipid_dashboard_Class230022$*--><b>-   ASCVD Prim message moderate intensity statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease with history of hemorrhagic stroke oris over age.75. Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class250022$*--><b>-   Cannot tolerate formulary statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate formulary statin, consider non-formulary statin#% </p><p><!--Message$Lipid_dashboard_Class280020$*--><b>-   Pres niacin > 1gm/day and Pres statin</b>  <i>Primary_Recommendation</i> : %#Patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class280021$*--><b>-   Pres fibrate and Pres statin</b>  <i>Recommendation</i> : %#Patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class300000$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age related changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$Lipid_dashboard_Class30026$*--><b>-   ASCVD Prim Msg to start high dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease.  High intensity statins are recommended.  Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p><p><!--Message$Lipid_dashboard_Class30052$*--><b>-   DM Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has diabetes without atherosclerotic cardiovascular disease and 40<=age<=75.  Moderate intensity statins are recommended. Formulary moderate intensity statin are atorvastatin 10 mg simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg.  Non formulary moderate intensity statins are rosuvastatin 5 mg, fluvastatin 40 mg.#% </p><p><!--Message$Lipid_dashboard_Class320001$*--><b>-   temp all statins contraindicated</b>  <i>Recommendation</i> : %#temp all statins contraindicated#% </p><p><!--Message$Lipid_dashboard_Class360002$*--><b>-   Blocked add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class360003$*--><b>-   Blocked add statin missing eGFR past 3 mo</b>  <i>Recommendation</i> : %#We would normaly recommend adding a statin, but we are missing eGFR in the past 3 months..#% </p><p><!--Message$Lipid_dashboard_Class360006$*--><b>-   Blocked incr dose missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend increasing dose of a statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class370000$*--><b>-   Pres fibrate and Pres statin blocked incr dose</b>  <i>Recommendation</i> : %#We would normally recommend increasng the intensity of the statin, but the patient is taking fibric acid (gemfibrozil, clofibrate, fenofibrate) that increases risk of myopahty.  Consider stopping fibric acid.#% </p><p><!--Message$Lipid_dashboard_Class370001$*--><b>-   Pres niacin > 1gm/day and Pres statin incr dose</b>  <i>Recommendation</i> : %#We would normally recommend increasing the intensity of the statin, but the patient is taking niacin > 1 gm/day which can increse risk of myopathy..  Consider stopping niacin or reducing dose of niacin.#% </p><p><!--Message$Lipid_dashboard_Class410000$*--><b>-   Presence of niacin >1gm/day msg blocked incr</b>  <i>Primary_Recommendation</i> : %#We would have normally recommended increasing dose of a statin, but patient is taking niacin>1gm/da which increase risk of myopathy.  Consider decreasing dose of niacin or switching to a statin instead.#% </p><p><!--Message$Lipid_dashboard_Class450001$*--><b>-   Blocked incr dose really add missing eGFR past year</b>  <i>Recommendation</i> : %#We would normally recommend substituting a high intensity statin, but we are missing eGFR in the past year.#% </p><p><!--Message$Lipid_dashboard_Class460121$*--><b>-   Blocked incr dose really add statin missing SGOT/SGPT past year</b>  <i>Recommendation</i> : %#We would normally recommend adding a statin, but we are missing SGOT and SGPT in the past year.#% </p><p><!--Message$Lipid_dashboard_Class70026$*--><b>-   ASCVD Prim Msg to start moderate dose statin</b>  <i>Primary_Recommendation</i> : %#Patient has atherosclerotic cardiovascular disease and history of hemorrhagic stroke..  Moderate intensity statins are recommended.  Moderate intensity statins are atorvastatin 10 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40 mg, lovastatin 40 mg, fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class90016$*--><b>-   Rosuvastatin-asian warning</b>  <i>Primary_Recommendation</i> : %#Warning when prescribing rosuvastatin to Asians:  there is a 2-fold elevation in median exposure (AUC and Cmax) to rosuvastatin in Asian subjects when compared with a Caucasian control group.#% </p><p><!--Message$athena_hypertension_272142$*--><b>-   recently refilled; expired warning</b>  <i>Primary_Recommendation</i> : %#Prescriptions for <drug_name> has(have) EXPIRED, although the patient has recently filled the medication(s).#% </p><p><!--Message$athena_hypertension_272143$*--><b>-   active and not refilled warning</b>  <i>Primary_Recommendation</i> : %#Prescription(s) for <drug_name> has(have) NOT BEEN FILLED RECENTLY.#% </p><p><!--Message$athena_hypertension_429434$*--><b>-   Primary: use ARB and ACE for non diabetic renal disease</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of non diabetic kidney disease, use of combined therapy with ARB and ACE may offer more renal protection than either alone.#% </p><p><!--Message$athena_hypertension_59854$*--><b>-   adr to ACE</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67708$*--><b>-   ADR to non DHP CCB</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67710$*--><b>-   ADR to alpha beta blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67712$*--><b>-   ADR to alpha blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67714$*--><b>-   ADR to Angiotensin II Receptor Blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_67716$*--><b>-   ADR to Cardioselective Beta Blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68067$*--><b>-   ADR to DHP Calcium channel blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68069$*--><b>-   ADR to non-cardioselective beta blocker</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_hypertension_68071$*--><b>-   ADR to thiazides</b>  <i>Recommendation</i> : %#Use clinical judgment to determine its relevance in this patient.#% </p><p><!--Message$athena_runtime_INSTANCE_00123$*--><b>-   presence of medication with adverse reaction</b>  <i>Recommendation</i> : %# #% </p><p><!--Message$ATHENA_CKD_Class190355$*--><b>-   4+ BP meds refer msg</b>  <i>Recommendation</i> : %#Patient is on 4 or more BP medications and his/her blood pressure is greater than 140/90.   Please refer to nephrologist#% </p><p><!--Message$ATHENA_CKD_Class30008$*--><b>-   Out of scope, refer to nephrologist msg</b>  <i>Primary_Recommendation</i> : %#Patient has eGFR<30 or eGFR<45 and ACR>=30 or eGFR<60 and ACR>300 or on 4 or more BP meds or has Stage 4 or 5 CKD.  These conditions are out of scope.  Please refer to a nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40028$*--><b>-   Msg to immunize for flu, pneumonia, hep B</b>  <i>Recommendation</i> : %#Consider immunizing patients againts the flu, pneumonia and hepatitis B.#% </p><p><!--Message$ATHENA_CKD_Class40029$*--><b>-   Msg for low salt diet</b>  <i>Recommendation</i> : %#Patients with CKD need to be on a low salt diet; <2 gm Na per day or <5gm NaCl per day.#% </p><p><!--Message$ATHENA_CKD_Class50017$*--><b>-   Low protein diet DM</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults with diabetes (2C).#% </p><p><!--Message$ATHENA_CKD_Class50018$*--><b>-   Low protein dient nonDM and eGFR<30</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults without diabetes and GFR <30 (2B)#% </p><p><!--Message$ATHENA_CKD_Class50021$*--><b>-   Prim msg: ACR>=30 have target BP 130/80</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR>=30 have their blood pressure <130/80#% </p><p><!--Message$ATHENA_CKD_Class50024$*--><b>-   Prim msg: ACR<30 have target BP 140/90</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR<30 have their blood pressure <140/90.#% </p><p><!--Message$ATHENA_CKD_Class50034$*--><b>-   Prim msg:  missing BP in past year</b>  <i>Primary_Recommendation</i> : %#Patient is missing BP measurement in past year.   For CKD patients with ACR>=30, BP target is 130/80.  For CKD patients with ACR<30, BP target is 140/90.#% </p><p><!--Message$ATHENA_CKD_Instance_20001$*--><b>-   Order microalbumin/creatinine ratio 3 months from last one</b>  <i>Recommendation</i> : %#The patient has abnormal microalbumin/creatinine ratio; Please order another test at least 3 months from the last one.#% </p><p><!--Message$ATHENA_CKD_Instance_30013$*--><b>-   Order creatinine</b>  <i>Primary_Recommendation</i> : %#No record of serum creatinine within a year, Please order the test.#% </p><p><!--Message$ATHENA_CKD_Instance_50015$*--><b>-   Order microalbumin/creatinine ratio</b>  <i>Recommendation</i> : %#Absence of microalbumin/creatinine ratio within a year; please order it now.#% </p><p><!--Message$ATHENA_CKD_Instance_50016$*--><b>-   Order Cr and microalbumin/creatinine ratio</b>  <i>Recommendation</i> : %#Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.#% </p><p><!--Message$ATHENA_CKD_Instance_50021$*--><b>-   Order serum creatinine 3 months from last one</b>  <i>Recommendation</i> : %#The patient has abnormal creatinine test  result; Please order another test at least 3 months from the last one.#% </p><p><!--Message$ATHENA_CKD_Instance_50034$*--><b>-   Achieve and maintain Hb A1C goal</b>  <i>Recommendation</i> : %#Important to achieve and maintain Hb A1C goal#% </p><p><!--Message$ATHENA_CKD_Instance_50035$*--><b>-   Important to use ACE or ARB</b>  <i>Recommendation</i> : %#Important to use ACE or ARB#% </p><p><!--Message$ATHENA_CKD_Instance_50039$*--><b>-   achieve/maintain blood pressure goal</b>  <i>Recommendation</i> : %#It is important to achieve/maintain blood pressure goal#% </p><p><!--Message$ATHENA_CKD_Instance_60003$*--><b>-   Add CKD to record</b>  <i>Recommendation</i> : %#Please add chronic kidney disease to the patient's problem list.#% </p><p><!--Message$ATHENA_CKD_Instance_60040$*--><b>-   ?label</b>  <i>Recommendation</i> : %#This is branch 60#% </p><p><!--Message$ATHENA_CKD_Instance_60041$*--><b>-   -56</b>  <i>Recommendation</i> : %#This is branch -56#% </p><p><!--Message$ATHENA_CKD_Instance_70057$*--><b>-   Order confirmatory mALB/Cr</b>  <i>Primary_Recommendation</i> : %#There is a normal mALB/Cr more than 3 months after an abnormal mALB/Cr, order another mALB/Cr to confirm#% </p><p><!--Message$ATHENA_GlycemicControl_Class150023$*--><b>-   Absence of ACEI/ARB message</b>  <i>Recommendation</i> : %#Many DM practitioners add ACE inhibitorsor ARBs  to patient’s regimen regardless of kidney function.#% </p><p><!--Message$ATHENA_GlycemicControl_Class150028$*--><b>-   Set target HbA1c old</b>  <i>Recommendation</i> : %#Some patients need tighter control of their HbA1c.  Consider setting an alternate target HbA1c; initial target ranges can be found in VA DM Guidelines#% </p><p><!--Message$ATHENA_GlycemicControl_Class210017$*--><b>-   HbA1c <= 9</b>  <i>Primary_Recommendation</i> : %#Latest HbA1c <=9, meets dashboard goal. CDS does not give recommendations for HbA1c values between 6 and 9 because target HbA1c goal not available.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210018$*--><b>-   Severe hyperglycemia message</b>  <i>Primary_Recommendation</i> : %#If patient has severe hyperglycemia or excessive symptoms, consider starting insulin and a referral to Diabetic Management Team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210036$*--><b>-   Follow up in 3 months</b>  <i>Follow_Up</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class210046$*--><b>-   dDM Type I out of scope message</b>  <i>Primary_Recommendation</i> : %#Recommendations for DM Type I is out of scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class240013$*--><b>-   dAlert lor HbA1c or Glycohem</b>  <i>Primary_Recommendation</i> : %#ALERT:  patient has low HbA1c or low GlycoHemoglobin, at high risk for cardiovascular event and hypoglycemia.#% </p><p><!--Message$ATHENA_GlycemicControl_Class240044$*--><b>-   Insulin only management out of scope</b>  <i>Primary_Recommendation</i> : %#Management of insulin is beyond scope of this system.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260026$*--><b>-   message that ACE-I and ARB contraindicated</b>  <i>Recommendation</i> : %#ACE-I and ARB are both contraindicated.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260039$*--><b>-   ALERT:  high creatinine or low eGFR</b>  <i>Primary_Recommendation</i> : %#ALERT:  high creatinine (>2.5 male or >2.4 female) or low eGFR (<30)#% </p><p><!--Message$ATHENA_GlycemicControl_Class260042$*--><b>-   Management of insulin is outside the scope of this CDS</b>  <i>Primary_Recommendation</i> : %#Management of insulin is outside the scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class260043$*--><b>-   CDS does not issue rec when 6<=HbA1c<=9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class260051$*--><b>-   ALERT: there exists active and not refilled medication</b>  <i>Primary_Recommendation</i> : %#Placeholder:  ALERT: there exists active and not refilled medication.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260059$*--><b>-   ALERT:  SGOT or SGPT > 2.5*normal</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT > 2.5*normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330001$*--><b>-   Recommendation for pregnant women out of scope</b>  <i>Primary_Recommendation</i> : %#Warning:  These recommendations do not apply to women who are pregnant.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330022$*--><b>-   Liver Enzyme ALERT</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT greater than 3*Upper Limit of Normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class350011$*--><b>-   Low bicarb alert</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate levels are less than or equal to 21.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class410006$*--><b>-   eGFR  missing</b>  <i>Recommendation</i> : %#Cannot evaluate recommendation for adding ACE-I or ARB without eGFR lab within last month..#% </p><p><!--Message$ATHENA_GlycemicControl_Class420001$*--><b>-   K missing</b>  <i>Recommendation</i> : %#Cannot evaluate recommendation for adding ACE-I or ARB without K lab within last month..#% </p><p><!--Message$ATHENA_GlycemicControl_Class460111$*--><b>-   no SBP measurement during the last month</b>  <i>Recommendation</i> : %#Most recent blood pressure is older than 1 month.  Please measure BP, to evaluate usage of  ACE Inhibitor or ARB.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470007$*--><b>-   on 3+ agents</b>  <i>Recommendation</i> : %#Patient HbA1c is >9 and is on 3 oral agents.  Please refer to endocrinologist and specialized DM care team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470014$*--><b>-   DM-1 aand DM-2 message</b>  <i>Recommendation</i> : %#Diagnoses of both DM-1 and DM-2 detected.  Debug not clear.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480000$*--><b>-   Set target HbA1c</b>  <i>Recommendation</i> : %#Although the VA performance measure is to attain an HbA1c<9%, this is usually not the true target for an individual patient. The  <a href="http://@AUTOPMWEBSERVER@/DM/VA_GL_DiabetesMellitus_2010.pdf#page=49"> Table G1 from VA DM Guidelines </a> can be used as a reference to decide an individual patient’s target.#% </p><p><!--Message$ATHENA_GlycemicControl_Class490005$*--><b>-   Add ARB despite kidney function</b>  <i>Recommendation</i> : %#Patients with diabetes should be considered for use of ACE inhibitor or ARB in order to provide renal protection#% </p><p><!--Message$ATHENA_GlycemicControl_Class510002$*--><b>-   Presence of DM-1 and DM-2 message</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of both DM-1 and DM-2.  We have made recommendations ASSUMING that the patient has only DM-2.  If this is not the case, these recommendations are not appropriate#% </p><p><!--Message$ATHENA_GlycemicControl_Class590001$*--><b>-   Blocked MF message</b>  <i>Primary_Recommendation</i> : %#We would normally recommend Biguanide but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600175$*--><b>-   Start Aspirin message old</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy, if not contraindicated,  to reduce the risk of cardiovascular fatal events.#% </p><p><!--Message$ATHENA_GlycemicControl_Class620004$*--><b>-   Presence of drugs that affect blood glucse levels.</b>  <i>Primary_Recommendation</i> : %#Warning:  patient is taking either bromocriptine or colesevelam that has hypoglycemic properties#% </p><p><!--Message$ATHENA_GlycemicControl_Class660000$*--><b>-   Start Aspirin message</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy.  Additional information available <a href="http://@AUTOPMWEBSERVER@/DM/AdditionalAspirinTherapyInfo.pdf"> here </a>.#% </p><p><!--Message$ATHENA_GlycemicControl_Class660593$*--><b>-   ACEi and ARB both contraindicated no rule in</b>  <i>Recommendation</i> : %#ACE Inhibitors and ARBs are both contraindicated and cannot be used for renal protection#% </p><p><!--Message$ATHENA_GlycemicControl_Class730013$*--><b>-   Age > 65 and missing creatinine msg</b>  <i>Recommendation</i> : %#We would normally recommend glyburide, but patient's age is >= 65 and is missing creatinine lab in past month#% </p><p><!--Message$ATHENA_GlycemicControl_Class741056$*--><b>-   Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#We would normally be recommending adding metformin, but we are missing creatinine and eGFR in the past month#% </p><p><!--Message$ATHENA_GlycemicControl_Class750000$*--><b>-   Request confirmation of target goal</b>  <i>Recommendation</i> : %#Request confirmation of target goal#% </p><p><!--Message$ATHENA_GlycemicControl_Class80007$*--><b>-   Start Aspirin</b>  <i>Recommendation</i> : %#Consider aspirin therapy to reduce the risk of cardiovascular fatal events.#% </p><p><!--Message$ATHENA_GlycemicControl_Class80019$*--><b>-   Add ACE despite kidney function</b>  <i>Recommendation</i> : %#Patients with diabetes should be considered for use of ACE inhibitor or ARB in order to provide renal protection.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820003$*--><b>-   UGT inducers and canaglifozin warning</b>  <i>Primary_Recommendation</i> : %#If patient is on UGT induces (e.g. rifampin, pheytoin, phenobarbitol, ritonovir) and 45<eGFR<60, do not prescribe canafligozin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class830001$*--><b>-   Gen msg all patients re ACE/ARB</b>  <i>Primary_Recommendation</i> : %#Consider ACE or ARB for renal protection if eGFR and K are within acceptable levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class850569$*--><b>-   Bad drug partner message</b>  <i>Primary_Recommendation</i> : %#Patient is taking two DM medications that would normally not be taken together.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120110$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140145$*--><b>-   dose - rec add chlorpropamide</b>  <i>Recommendation</i> : %#100mg/day-125mg/day for elderly patients; 250mg/day in the mild-to-moderately severe, middle aged, stable patient#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140146$*--><b>-   dose - rec add piolgitazone</b>  <i>Recommendation</i> : %#15 - 45mg administered once daily.

May be given without regard to meals
Dosage adjustment is not required for renal insufficiency; however, there is insufficient data to recommend use in endstage renal disease.
Slow onset of action.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140147$*--><b>-   dose - rec add Repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140148$*--><b>-   dose - rec add Tolazamide</b>  <i>Recommendation</i> : %#1000 mg given once daily or divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140149$*--><b>-   dose - rec add micronized gliburide</b>  <i>Recommendation</i> : %#0.75 - 12mg given once daily or divided into 2 doses; doses >6mg when divided, may provide a better response

If the response to a single daily dose does not achieve treatment goals, dividing the dose may be effective.
In general, the hypoglycemic effects of glyburide and glipizide tend to plateau at 10mg and 20mg, respectively.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140150$*--><b>-   dose - rec add Tolbutamide</b>  <i>Recommendation</i> : %#250-2000mg divided into 2-3 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140154$*--><b>-   dose - rec add acarbose</b>  <i>Recommendation</i> : %#For acarbose or miglitol begin with 25 mg TID or initiate gradually:
25 mg QD x 1-2 weeks followed by 
25 mg BID for 1-2 weeks followed by
25 mg TID. Once a 25mg TID dosing regimen is reached, further increases may be made at a 4-8 week interval.

The usual maintenance dose is 50 mg TID. Maximum dose for acarbose is 100mg TID (50 mg TID if weight <60 kg) and 100mg tid for miglitol.

Dose is to be taken with the first bite of each main meal.

If the patient misses or adds a meal, they should omit or add the dose.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140155$*--><b>-   dose - rec add rosiglitazone</b>  <i>Recommendation</i> : %#4 - 8mg/day, given once daily or divided into 2 doses.

May be given without regard to meals
Dosage adjustment is not required for renal insufficiency; however, there is insufficient data to recommend use in endstage renal disease.
Slow onset of action.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140156$*--><b>-   dose - rec add miglitol</b>  <i>Recommendation</i> : %#For acarbose or miglitol begin with 25 mg TID or initiate gradually:
25 mg QD x 1-2 weeks followed by 
25 mg BID for 1-2 weeks followed by
25 mg TID. Once a 25mg TID dosing regimen is reached, further increases may be made at a 4-8 week interval.

The usual maintenance dose is 50 mg TID. Maximum dose for acarbose is 100mg TID (50 mg TID if weight <60 kg) and 100mg tid for miglitol.

Dose is to be taken with the first bite of each main meal.

If the patient misses or adds a meal, they should omit or add the dose.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140157$*--><b>-   dose - rec add nateglinide</b>  <i>Recommendation</i> : %#120mg before each meal.

Take 1 - 30 minutes before a meal.
If the patient misses or adds a meal, they should omit or add the dose#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140159$*--><b>-   dose - rec add repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140160$*--><b>-   dose - rec add Repaglinide</b>  <i>Recommendation</i> : %#Starting dose is 0.5mg in patients with HbA1c <8%. If the HbA1c is >8%, a dose of 1 or 2mg may be initiated. Maximum dose is 4mg per meal.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_90005$*--><b>-   Continue therapy- HbA1c under control</b>  <i>Recommendation</i> : %#Latest HbA1c under control.  Continue therapy and periodically reevaluate appropriateness of target.#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p><p><!--Message$KB_390055_Class1$*--><b>-   dose - rec add metformin ER</b>  <i>Recommendation</i> : %#Begin with 500mg daily with the evening meal. Dose may be increased by 500mg per week to a maximum of 2000mg once daily. If glycemic control is not achieved, consider dividing into 2 doses.#% </p><p><!--Message$KB_707783_Class7$*--><b>-   Elderly on meds hypoglycemia risk</b>  <i>Recommendation</i> : %#Elderly patients are at a higher risk for drug-associated hypoglycemia, due to altered metabolism and excretion rates, impaired symptom recognition, and potentially attenuated counter-regulatory responses. Instruct patient and family  to recognize signs and symptoms of hypoglycemia and its management.#% </p><p><!--Message$ATHENA_HF_Class110355$*--><b>-   meet target dose, not max dose lisinopril</b>  <i>Recommendation</i> : %#The target dose for lisinopril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.#% </p><p><!--Message$ATHENA_HF_Class110357$*--><b>-   target dose enalapril</b>  <i>Recommendation</i> : %#The target dose for enalapril in heart failure management is 20mg/day. There were no demonstrated benefits using higher doses.#% </p><p><!--Message$ATHENA_HF_Class110379$*--><b>-   rec add ace: dose adjustent based on kidney functio</b>  <i>Recommendation</i> : %#Refer to specific ACE Inhibitor dose adjustments based on kidney function.#% </p><p><!--Message$ATHENA_HF_Class110380$*--><b>-   monitoring renal function and K for ACEI</b>  <i>Recommendation</i> : %#Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with preexisting hypotension, hyponatremia, diabetes
mellitus, or azotemia or in those taking potassium
supplements.#% </p><p><!--Message$ATHENA_HF_Class110383$*--><b>-   rec add hydralazine and nitrates- dose suggsetions</b>  <i>Recommendation</i> : %#Recommend starting with hydralazine 25mg tid and nitrates 10mg tid. Would not go much above hydralazine 50mg tid and nitrates 40mg tid. Titrate after a month. Beta blockers can avoid the tachycardia caused by hydralazine and nitrates.#% </p><p><!--Message$ATHENA_HF_Class110392$*--><b>-   BNP monitoring</b>  <i>Recommendation</i> : %#There is somewhat more evidence, and home self bnp monitoring is in development.   While I don’t do it, I think that it wouldn’t be bad to get a baseline BNP on a newly diagnosed patient.  Very high ones mean something and woulde make me more aggressive.  I prefer history and PE, but there may be value for PCP who may have less time for history and less skill with PE.#% </p><p><!--Message$ATHENA_HF_Class110414$*--><b>-   not use nutritional supplements</b>  <i>Class III</i> : %#Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class132286$*--><b>-   Digoxin StageC Class IIA 4</b>  <i>Recommendation</i> : %#Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced LVEF to decrease hospitalizations for HF (Level of Evidence: B).  ADD ADDL INFO from HF experts to help guide choice of when to add dig#% </p><p><!--Message$ATHENA_HF_Class160000$*--><b>-   NYHA classification</b>  <i>Recommendation</i> : %#Functional Capacity .....................................................Objective Assessment
Class I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.	A. No objective evidence of cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.	B. Objective evidence of minimal cardiovascular disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.	C. Objective evidence of moderately severe cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	D. Objective evidence of severe cardiovascular disease.#% </p><p><!--Message$ATHENA_HF_Class170329$*--><b>-   rec add hyralazine_nitrates IF symptoms</b>  <i>Class I</i> : %#Class I Recommendation for hydralazine and nitrates for patients who are African American, have an active prescription of an ACE inhibitor and beta blocker and diuretics and an ASSUMMPTION that patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation#% </p><p><!--Message$ATHENA_HF_Class170330$*--><b>-   rec add aldosterone antagonist IF symptoms</b>  <i>Class I</i> : %#Class I recommendation for aldosterone antagonist for patietst with HF, LVEF<=35, (creatinine <=2.5 and male) or (creatine <=2 and femalel) and an ASSUMPTiON that  patient is experiencing moderate or severe HF symptoms.  Presence/absence of HF symptoms data not available for this recommendation.#% </p><p><!--Message$ATHENA_HF_Class190000$*--><b>-   elevated BNP</b>  <i>Recommendation</i> : %#Although lower values of BNP or NT-proBNP exclude the presence of HF and higher values have
reasonably high positive predictive value to diagnose HF, elevated plasma levels
for both natriuretic peptides have been associated with a wide variety of cardiac (ACS, heart muscle disease, valvular heart disease, pericardial disease, atrial fibrilation, myocarditis, cardiac surgery, cardioverion) and noncardiac causes (advancing age, anemia, renal failure, obstuctive sleep apnea, severe pnemonia, pumonary hypertension, critical illness, bacterial sepsis, severe burns, toxic-metablic insults, including cancer chemotherapy and envenomation)..#% </p><p><!--Message$ATHENA_HF_Class200016$*--><b>-   Order BNP or NTproBNP lab</b>  <i>Recommendation</i> : %#BNP and NTproBNP lab values absent.  Either of these measurements is useful in clinical decision making in HF.  Please order BNP or NTproBNP. [Level of Evidence A]#% </p><p><!--Message$ATHENA_HF_Class240000$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p><p><!--Message$ATHENA_HF_Class240016$*--><b>-   rec add hyralazine_nitrates Astronaut II</b>  <i>Class I</i> : %#The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III or IIV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (423, 424). (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class340251$*--><b>-   Absence of ACE-I, add ACE-I</b>  <i>Primary_Recommendation</i> : %#Patient is not taking ACE-I; add ACE-I.#% </p><p><!--Message$ATHENA_HF_Class370002$*--><b>-   ICD primary prev rec Stage C Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for more than 1 year (355, 593). (Level of Evidence:  A)#% </p><p><!--Message$ATHENA_HF_Class370004$*--><b>-   ICD primary prev rec Stage C stage I Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#ICD therapy is recommended for primary prevention of SCD to reduce total mortality in selected patients at least 40 days post-MI with LVEF of30% or less, and NYHA class I symptoms while receiving GDMT, who have reasonable expectation of meaningful survival for more than 1 year (362, 597, 598). (Level of Evidence:  B)*#% </p><p><!--Message$ATHENA_HF_Class370006$*--><b>-   CRT Astronaut II msg</b>  <i>Primary_Recommendation</i> : %#CRT is indicated for patients who have LVEF of 35% or less, sinus rhythm, left bundle-branch block (LBBB) with a QRS duration of 150 ms or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. (Level of Evidence: A for NYHA class III/IV; Level of Evidence: B for NYHA class II).  ALERT:  we assumed the presence of sinus rhythm, LBBB with QRS duration of >150ms.  If these assumptions are incorrect, a CRT is not indicated.#% </p><p><!--Message$ATHENA_HF_Class400002$*--><b>-   Missing creatinine/eGFR might rec ACEi/ARB</b>  <i>Primary_Recommendation</i> : %#ATHENA Heart Failure CDS may have recommended ACE inhibitor/ARB but lab values for creatinine/eGFR are missing. Please order creatinine.#% </p><p><!--Message$ATHENA_HF_Class50061$*--><b>-   nutritional supplements</b>  <i>Class III</i> : %#Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.#% </p><p><!--Message$ATHENA_HF_Class50078$*--><b>-   Fluid management</b>  <i>Recommendation</i> : %#?messagebody#% </p><p><!--Message$ATHENA_HF_Class50081$*--><b>-   Assess activities of daily living</b>  <i>Recommendation</i> : %#Assess ability of patient to perform routine and desired activities of daily living. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50082$*--><b>-   Assess volume status</b>  <i>Recommendation</i> : %#Assess volume status and weight. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50083$*--><b>-   Assess use cardiotoxic drugs and behaviors</b>  <i>Recommendation</i> : %#Assess current use of alcohol, tobacco, illicit drugs, “alternative therapies,” and chemotherapy drugs, as well as diet and sodium intake. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50086$*--><b>-   Repeat Echocardiogram</b>  <i>Recommendation</i> : %#Repeat echocardiogram can provide useful information in patients with HF who have had a change in clinical status or who have experienced or recovered from a clinical event or received treatment that might have had a significant effect on cardiac function. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50091$*--><b>-   Fluid management</b>  <i>Class I</i> : %#Diuretics and salt restriction are indicated if there is evidence of fluid retention. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class50096$*--><b>-   Exercise</b>  <i>Class I</i> : %#Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70020$*--><b>-   Hypertension control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporaryguidelines. (Level of Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70021$*--><b>-   Lipid disorder control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)#% </p><p><!--Message$ATHENA_HF_Class70022$*--><b>-   Blood sugar control message</b>  <i>Class I</i> : %#For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70023$*--><b>-   behavior  control message</b>  <i>Class I</i> : %#Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70024$*--><b>-   Ventricular rate/sinus rhythm  control message</b>  <i>Class I</i> : %#Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)#% </p><p><!--Message$ATHENA_HF_Class70025$*--><b>-   Thyroid disorder  control message</b>  <i>Class I</i> : %#Thyroid disorders should be treated in accordance with contemporary
guidelines in patients at high risk for developing HF. (Level
of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70026$*--><b>-   Periodic evaluation message</b>  <i>Class I</i> : %#Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70027$*--><b>-   atherosclerotic vascular disease control message</b>  <i>Class I</i> : %#In patients at high risk for developing HF who have known
atherosclerotic vascular disease, healthcare providers should
follow current guidelines for secondary prevention. (Level of
Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70028$*--><b>-   LV function evaluation message</b>  <i>Class I</i> : %#Healthcare providers should perform a noninvasive evaluation of
LV function (i.e., LVEF) in patients with a strong family history of
cardiomyopathy or in those receiving cardiotoxic interventions.
(Level of Evidence: C)#% </p><p><!--Message$ATHENA_HF_Class70167$*--><b>-   Aldosterone antagonist warning</b>  <i>Recommendation</i> : %#Addition of an aldosterone antagonist is recommended in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who CAN BE CAREFULLY MONITORED for PRESERVED RENAL FUNCTION and NORMAL POTASSIUM concentration. Creatinine should be 2.5 mg per dL or less in men or 2.0 mg per dL or less in women and potassium should be less than 5.0 mEq per liter. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone anatgonists.#% </p><p><!--Message$ATHENA_HF_Class70173$*--><b>-   Maximal exercise testing</b>  <i>Class II a</i> : %#Maximal exercise testing with or without measurement of respiratory gas exchange is reasonable to facilitate prescription of an appropriate exercise program for patients presenting with HF. (Level of Evidence: C)#% </p><p><!--Message$KB_048666_Class5$*--><b>-   Prim msg hydralazine and nitrates together are beneficial</b>  <i>Primary_Recommendation</i> : %#Hydralazine and nitrates TOGETHER are beneficial to patients with HF.#% </p><p><!--Message$KB_104117_Class1$*--><b>-   Presence of ACE good message</b>  <i>Recommendation</i> : %#Patient is on ACE Inhibitor. Good!#% </p><p><!--Message$KB_234689_Class0$*--><b>-   diuretcs out of scope</b>  <i>Primary_Recommendation</i> : %#HF with reduced EF with fluid retention is an indication for diuretic therapy, but is beyond the scope of this project recommendations.#% </p><p><!--Message$KB_243202_Class1$*--><b>-   Out of scope message</b>  <i>Primary_Recommendation</i> : %#HF patients with preserved EJ function, LVEF>40) or without an LVEF value are out of scope of this CDS.#% </p><p><!--Message$KB_261275_Class13$*--><b>-   BB substitution</b>  <i>Recommendation</i> : %#Patient is taking a beta blocker that is not one of the recommeded beta blockers for heart failure patients. Evaluate susbtitution with carvedilol, bisoprolol or sustained release metoprolol succinate.#% </p><p><!--Message$KB_313397_Class1$*--><b>-   ?label</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of chronic kidney disease stage 3 or 4, or eGFR between 15 and 60); evaluate clinical significance and impact of prescription for ACEi and frequency of monitoring labs#% </p><p><!--Message$KB_899077_Class2$*--><b>-   rec add ACE-I dose based on 2013 ACCF/AHA Guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific ACE-I starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.#% </p><p><!--Message$KB_899077_Class4$*--><b>-   rec add ARB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below)  for specific ARB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
candesartan starting dose 4-8 mg/once; max dose 32 mg once
losartan starting dose 25-50 once; max dose 50-150 mg once
valsartan 20-40 mg twice; max dose 160 mg twice#% </p><p><!--Message$KB_899077_Class5$*--><b>-   rec add AA based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific AA starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
spironolactone starting dose 12.5 0 25.0 once; max dose 25 mg once or twice
eplerenone starting dose 25 mg once; max dose 50 mg once#% </p><p><!--Message$KB_899077_Class6$*--><b>-   rec add BB based on 2013 ACCF/AHA guidelines</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline (reproduced below) for specific BB starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
bisoprolol starting dose 1.25 mg once; max dose 10 mg once
carvedilol starting dose 3.125 mg twice; max dose 50 mg twice
carvedilol CR starting dose 10 mg once; max dose 80 mg once
metoprolol succinate ER starting dose 12.5 - 25 mg once; 200 mg once#% </p><p><!--Message$KB_899077_Class7$*--><b>-   rec add hydralazine and nitrates based on 2013 ACCF/AHA guideline</b>  <i>Recommendation</i> : %#Refer to 2013 ACCF/AHA Guideline for specific hydraline and nitrates starting dose and maximum dose.  In this application, we do not know what particular dosage can be tolerated by the patient.
fixed dose combination starting dose 37.5 mg hydralazine + 20 mg isosorbide dintrate/ 3x; max dose 75 mg hydralazine + 40 mg isosorbide dinitrate 3x dialy
hydralazine and isosorbide dinitrate sstarting dose hydralazine 25-50 mg 3 or 4 x daily and isosorbide dintrate 20 to 30 mg 3 or 4 x dialy; max dose hydralazine 300 mg daily in divided doses and isosorbide dintrate 120 mg daily in divided doses#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class10048$*--><b>-   Above Dashboard Target below JNC8 Target</b>  <i>Primary_Recommendation</i> : %#NEED TO DECIDE WHAT MESSAGE TO GIVE....

NEED TO DECIDE IF WILL DO SUBSTITUTIONS#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class60000$*--><b>-   preferred drug:max dose or contraindication Refer</b>  <i>Recommendation</i> : %#Refer to hypertension specialist or explore drug options other than ACE inhibitor, ARB, calcium channel blocker or thiazides.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80010$*--><b>-   >4 active anti-hypertensive meds (broad) AND BP<220/110 AND absence IIHD AND DBP>=60</b>  <i>Recommendation</i> : %#Patient on more than 4 antihypertensive drugs. Refer to hypertension specialist.#% </p><p><!--Message$ATHENA_HTN_Dashboard_Class80017$*--><b>-   BP below Dashboard and JNC target</b>  <i>Recommendation</i> : %#Maintain current drug choices and  continue to encourage patient adherence to his/her current regimen.#% </p><p><!--Message$athena_hypertension_00099$*--><b>-   beta blocker and diltiazem</b>  <i>Recommendation</i> : %#Use caution if combining a beta blocker with diltiazem.#% </p><p><!--Message$athena_hypertension_00101$*--><b>-   Beta blocker and diabetes</b>  <i>Recommendation</i> : %#Beta blockers may mask symptoms of hypoglycemia and should be used with caution.#% </p><p><!--Message$athena_hypertension_00115$*--><b>-   Beta blocker and PVD</b>  <i>Recommendation</i> : %#Beta blockers may exacerbate symptoms of peripheral vascular disease.  It is important to ask about this potential side effect in your treated patient. #% </p><p><!--Message$athena_hypertension_00129$*--><b>-   beta blocker and verapamil</b>  <i>Recommendation</i> : %#Ordinarily we would have recommended a beta blocker as a first line agent in patients with hypertension.  However, the patient is taking verapamil, which is a contraindication to beta blocker therapy.  contraindication.#% </p><p><!--Message$athena_hypertension_00206$*--><b>-   On furosemide no CHF or RF</b>  <i>Recommendation</i> : %#Patient is taking furosemide or a loop diuretic and appears to have neither CHF nor renal insufficiency. Hydrochlorothiazide is generally a more efficacious diuretic in the management of hypertension.#% </p><p><!--Message$athena_hypertension_00223$*--><b>-   assumption Female between 50 and 60</b>  <i>Assumption</i> : %#We assume women older than 50 years are postmenopausal. If this is not the case for your patient, be alert for the possibility of pregnancy. These recommendations DO NOT apply to women who are pregnant.  Please make sure this patient is not pregnant before acting on recommendations.#% </p><p><!--Message$athena_hypertension_00244$*--><b>-   Low K. Consider hyperaldosteronism</b>  <i>Recommendation</i> : %#This patient's most recent potassium is below normal limits. Use care if initiating or continuing diuretic therapy. Hyperaldosteronism may be a consideration in this patient's hypokalemia.#% </p><p><!--Message$athena_hypertension_00451$*--><b>-   on beta blocker plus verapamil</b>  <i>Recommendation</i> : %#This patient has prescriptions for both verapamil and beta blocker.  Please re-evaluate this combination, which can increase risk of heart block.#% </p><p><!--Message$athena_hypertension_00518$*--><b>-   ISH Message</b>  <i>Recommendation</i> : %#Both thiazide diuretics and dihydropyridine calcium channel blockers are effective in lowering the risk of stroke in ISH,  but there have been no head to head comparisons. Thiazides are far less expensive.#% </p><p><!--Message$athena_hypertension_00569$*--><b>-   Central Alphas and Depression</b>  <i>Recommendation</i> : %#Central alpha-agonists (e.g., clonidine or methlydopa) may cause or exacerbate the symptoms of depression and should be used with caution.#% </p><p><!--Message$athena_hypertension_00570$*--><b>-   Reserpine and depression</b>  <i>Recommendation</i> : %#Reserpine may cause or exacerbate the symptoms of depression and should be used with caution.#% </p><p><!--Message$athena_hypertension_00641$*--><b>-   Labetalol and Liver Disease</b>  <i>Recommendation</i> : %#Labetalol has extensive first pass clearance and the rate of metabolism is sensitive to hepatic blood flow. Liver disease is a relative contraindication.#% </p><p><!--Message$athena_hypertension_00654$*--><b>-   Liver Disease and methyldopa</b>  <i>Recommendation</i> : %#Methyldopa can induce hepatitis; it is advisable to avoid its use in patients with liver disease.#% </p><p><!--Message$athena_hypertension_01936$*--><b>-   On clonidine</b>  <i>Recommendation</i> : %#National and VA Guidelines DO NOT recommend CLONIDINE as a preferred drug, either for uncomplicated hypertension or for specific comorbidities.#% </p><p><!--Message$athena_hypertension_04834$*--><b>-   assumption No ADE current drug</b>  <i>Assumption</i> : %#Current antihypertensive drugs have no adverse reactions listed.  If the patient has had an adverse reaction/allergy please enter it in "Orders" tab in CPRS under  "Allergies/Adverse Reactions".#% </p><p><!--Message$athena_hypertension_04852$*--><b>-   NO ADE recommended drug</b>  <i>Recommendation</i> : %#No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".#% </p><p><!--Message$athena_hypertension_04863$*--><b>-   assumption No BPH </b>  <i>Assumption</i> : %#We assume that patients do not have benign prostatic hyperplasia unless it is listed as a diagnosis. If this patient does have benign prostatic hyperplasia, please enter that diagnosis on the problem list. This can be done using the "problem list" tab in CPRS or mark "add" for the diagnosis in the encounter form. #% </p><p><!--Message$athena_hypertension_04884$*--><b>-   alpha blocker orthostasis</b>  <i>Recommendation</i> : %#This patient has an active prescription for an alpha adrenergic antagonist. We assume that you have checked the patient's standing blood pressure and that the patient does not have orthostasis (for example, SBP drop >20 mmHg).#% </p><p><!--Message$athena_hypertension_05575$*--><b>-   on clonidine, warning side effects</b>  <i>Recommendation</i> : %#Inquire about  the presence of side effects of clonidine such as dry mouth, postural hypotension and alterations in mental state. Evaluate clinical benefits versus harm.#% </p><p><!--Message$athena_hypertension_05580$*--><b>-   on clonidine, has compelling indication for BB</b>  <i>Recommendation</i> : %#This patient has a compelling indication for a beta adrenoreceptor antagonist. When blood pressure is controlled consider tapering off clonidine and initiating a beta adrenergic receptor blocker.#% </p><p><!--Message$athena_hypertension_09865$*--><b>-   ADE to Recommened Drug</b>  <i>Recommendation</i> : %#There is an allergy or adverse drug reaction reported for a drug that is recommended below. Consult the Patient History for a listing of the reported event and use clinical judgment to determine whether to disgard the recommendation.#% </p><p><!--Message$athena_hypertension_100871$*--><b>-   Clonidine withdrawal</b>  <i>Recommendation</i> : %#Use caution when discontinuing clonidine. Gradual dosage reduction may be necessary to avoid serious rebound hypertension.  This risk is increased when clonidine dose is greater than 0.6mg/day or diastolic is greater then 105mmHg.#% </p><p><!--Message$athena_hypertension_104229$*--><b>-   Susbtituting away fom alpha blocker, no BPH?</b>  <i>Recommendation</i> : %#We could not find a diagnosis of BPH. If there is a diagnosis of BPH please update the problem list and ignore this recommendation to substitute away from the alpha blocker.#% </p><p><!--Message$athena_hypertension_110155$*--><b>-   Heart failure and NOT on beta blocker</b>  <i>Recommendation</i> : %#While beta blockers are indicated in certain patients with CHF, managing patients with CHF on beta blockers is complex and beyond the scope of the Hypertension Guidelines.#% </p><p><!--Message$athena_hypertension_14109$*--><b>-   No BP in database, assumption target achieved</b>  <i>Primary_Recommendation</i> : %#NO blood pressure in database, please UPDATE BP in "Today's Decision BP": ASSUMPTION TARGET BP ACHIEVED.#% </p><p><!--Message$athena_hypertension_14130$*--><b>-   Lack of drug recommendation</b>  <i>Primary_Recommendation</i> : %#We are recommending INTENSIFY therapy but have not generated a drug recommendation. Consider consultation.#% </p><p><!--Message$athena_hypertension_144351$*--><b>-   ALPHA BLOCKER MONOTHERAPY NO  BPH</b>  <i>Primary_Recommendation</i> : %#ALPHA BLOCKER MONOTHERAPY for hypertension is currently NOT recommended, consider adding a drug independent of blood pressure control. If patient has BPH, please add diagnosis to CPRS.#% </p><p><!--Message$athena_hypertension_148449$*--><b>-   Alpha blocker and dose titration</b>  <i>Recommendation</i> : %#To decrease the likelihood of syncope or excessive hypotension treatment should usually be initiated with a dose of 1 or 2 mgs at bedtime. The dose should be increased in a stepwise fashion. Blood pressures should be measured to check for postural drop.#% </p><p><!--Message$athena_hypertension_149465$*--><b>-   SBP<100</b>  <i>Primary_Recommendation</i> : %#Most recent SBP<100mmHg, use clinical judgement to evaluate therapeutic strategy.#% </p><p><!--Message$athena_hypertension_15045$*--><b>-   no default drug to substitute with, absolute contraindication</b>  <i>Recommendation</i> : %#We are recommending SUBSTITUTING AWAY from a drug due to a strong contraindication but have not generated a drug recommendation. Consider consultation.#% </p><p><!--Message$athena_hypertension_15048$*--><b>-   No BP in database, assumption target not achieved</b>  <i>Primary_Recommendation</i> : %#NO blood pressure in database, please UPDATE BP in "Today's Decision BP": ASSUMPTION TARGET BP NOT ACHIEVED.#% </p><p><!--Message$athena_hypertension_154824$*--><b>-   alpha blocker monotherapy</b>  <i>Recommendation</i> : %#Treating the hypertensive man with BPH with alpha blocker MONOTHERAPY is currently not recommended.#% </p><p><!--Message$athena_hypertension_160438$*--><b>-   on clonidine</b>  <i>Recommendation</i> : %#Very little is known about the efficacy of clonidine in reducing morbidity associated with hypertension.#% </p><p><!--Message$athena_hypertension_166907$*--><b>-   ARB II-check K and Cr</b>  <i>Recommendation</i> : %#Check the patient's plasma creatinine and potassium concentrations when prescribing or increasing dose of  angiotensin II receptor blockers.#% </p><p><!--Message$athena_hypertension_168639$*--><b>-   assumption Women aged 60+ and menopause</b>  <i>Assumption</i> : %#We assume women older than 60 years are postmenopausal. #% </p><p><!--Message$athena_hypertension_174120$*--><b>-   SBP<100</b>  <i>Primary_Recommendation</i> : %#Most recent SBP<100mmHg, use clinical judgement to evaluate therapeutic strategy.#% </p><p><!--Message$athena_hypertension_178163$*--><b>-   DBP<60 and SBP<goal</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed with repeat BPs, evaluate benefit:risk of continuing present doses.#% </p><p><!--Message$athena_hypertension_179265$*--><b>-   PM BP not controlled, DBP<70</b>  <i>Primary_Recommendation</i> : %#We are recommending treatment to lower SBP. Use clinical judgment to evaluate the degree of DBP lowering that is acceptable.#% </p><p><!--Message$athena_hypertension_181132$*--><b>-   PM: MI on clonidine, no beta blocker</b>  <i>Primary_Recommendation</i> : %#Beta blockers are recommended for patients post MI but these drugs are not
generally advisable in conjunction with clonidine.#% </p><p><!--Message$athena_hypertension_185078$*--><b>-   assumption Dx on encounter form or problem list</b>  <i>Recommendation</i> : %#Diagnosis from encounter forms and problem list are used in the reasoning for this advisory. If patient has a relevant diagnosis not listed please update CPRS.#% </p><p><!--Message$athena_hypertension_185439$*--><b>-   Primary: Active prescription for BB and verapamil</b>  <i>Primary_Recommendation</i> : %#There is a risk of HEART BLOCK from combining verapamil and beta blocker.#% </p><p><!--Message$athena_hypertension_185968$*--><b>-   Assumption: Home BP Target Goal</b>  <i>Assumption</i> : %#When using home blood pressures to assess adequacy of blood pressure
control, remember that the targets are different.  There is no universally 
agreed-on upper limit of normal home blood pressure, but readings 
of  135/85 mmHg or greater should be considered elevated if the patient's 
clinic blood pressure target is 140/90 mmHg.  If the patient's clinic target BP 
is lower, for example 140/80 mmHg because of diabetes, the home blood pressure 
targets should be correspondingly lower.#% </p><p><!--Message$athena_hypertension_185971$*--><b>-   assumption: Absence Lab values</b>  <i>Assumption</i> : %#If there are no data for laboratory results (sodium, creatinine,
potasium, uric acid, etc.) Athena Hypertension Advisory assumes these values
are within the normal limits.  This may not be a correct 
assumption.  Please keep this in mind when you evaluate the recommendations 
made here.#% </p><p><!--Message$athena_hypertension_188555$*--><b>-   Active prescription for Clonidine and BB</b>  <i>Recommendation</i> : %#It is generally not desirable to combine clonidine and beta blocker because of their overlapping capacity to slow heart rate.#% </p><p><!--Message$athena_hypertension_192997$*--><b>-   Primary Msg: Add ACE I and dx renal disease</b>  <i>Primary_Recommendation</i> : %#Benefit of ADDING ACEI versus risk of HYPERKALEMIA requires clinical judgement in presence of renal disease.
#% </p><p><!--Message$athena_hypertension_206788$*--><b>-   assumption drug dose </b>  <i>Assumption</i> : %#Daily dosage calculation is based on the following formula:  [(strength of dosage form) x (number of dosage forms)]/days supply. If extra dosage forms (tablets) are dispensed there may be an overestimation of actual daily dose.  The calculated daily dose is displayed in the patient summary.#% </p><p><!--Message$athena_hypertension_222400$*--><b>-   substitution explanation metoprolol+felodipine</b>  <i>Recommendation</i> : %#This patient will benefit from metoprolol (secondary prevention of MI).  Because blood pressure elevation is significant we recommend substituting with felodipine and adding metoprolol. Recheck BP in 4-6 weeks.#% </p><p><!--Message$athena_hypertension_223693$*--><b>-   Assumption about secondary prevention MI</b>  <i>Assumption</i> : %#The evidence for benefits of secondary prevention of myocardial infarct is when beta adrenergic receptor antagonists are started within 2-4 weeks of the event. This program is limited in identifying this interval and therefore we recommend beta adrenergic receptor antagonists to patients with a history of MI.#% </p><p><!--Message$athena_hypertension_23973$*--><b>-   On ACE inhibitor and K sparing diuretic, hyperkalemia warning</b>  <i>Recommendation</i> : %#Patient has a current prescription for ACE inhibitor and a potassium sparing diuretic; this  may increase risk of hyperkalemia.#% </p><p><!--Message$athena_hypertension_253466$*--><b>-   HF and MI, using diltiazem</b>  <i>Recommendation</i> : %#Felodipine is the preferred calcium channel blocker because it has less myocardial depressant effects than diltiazem.#% </p><p><!--Message$athena_hypertension_254903$*--><b>-   compelling if symptomatic BPH</b>  <i>Recommendation</i> : %#Compellingly indicated if the patient has symptomatic BPH.#% </p><p><!--Message$athena_hypertension_259472$*--><b>-   BPH and use of alpha blocker</b>  <i>Recommendation</i> : %#Patient may benefit from using an alpha blocker. Evaluate adding an alpha blocker to this patient's therapy and adjusting other drug doses accordingly.#% </p><p><!--Message$athena_hypertension_260886$*--><b>-   Primary: On clonidine ADD Alpha blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotension before adding alpha blocker to clonidine.#% </p><p><!--Message$athena_hypertension_260890$*--><b>-   Primary: On clonidine INCREASE DOSE Alpha blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotension before increasing dose of alpha blocker in patient on clonidine.#% </p><p><!--Message$athena_hypertension_260895$*--><b>-   Primary: Not on clonidine Increase dose Alpha Blocker</b>  <i>Primary_Recommendation</i> : %#Check for orthostatic hypotenstion before increasing dose of alpha blocker.#% </p><p><!--Message$athena_hypertension_262501$*--><b>-   ADR ACE (DM or HF), not rec ARB risk cross reactivity</b>  <i>Recommendation</i> : %#This patient had an adverse drug reaction to ACE inhibitor. ARB's are not recommended due to the risk of cross reactivity.#% </p><p><!--Message$athena_hypertension_264390$*--><b>-   high K (>5.5)</b>  <i>Recommendation</i> : %#Greatly elevated K, requires immediate intervention.#% </p><p><!--Message$athena_hypertension_268571$*--><b>-   No BB and CAD</b>  <i>Recommendation</i> : %#VA Hypertension guidelines recommend beta blockers for patients with coronary artery disease. Current evidence strongly supports beta blockers for secondary prevention of myocardial infarction however for primary prevention it remains unclear if they are superior to thiazide diuretics.#% </p><p><!--Message$athena_hypertension_269219$*--><b>-   Na<=125 and on thiazide</b>  <i>Recommendation</i> : %#A recent sodium was below 125 mEq/l. Consider reducing dose or discontinuing diuretic therapy based on current value.#% </p><p><!--Message$athena_hypertension_269228$*--><b>-   sinoatrial node dysfunction, no pacemaker, on BB</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction, no pacemaker and a prescription for beta blocker and is therefore at increased risk for heart block. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269231$*--><b>-   on BB, depression caution</b>  <i>Recommendation</i> : %#Use caution as beta blockers may cause or exacerbate symptoms of depression; however, many patients tolerate them without difficulty.#% </p><p><!--Message$athena_hypertension_269233$*--><b>-   on amiodarone and BB</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and beta adrenergic receptor antagonist may result in excessive lowering of heart rate.#% </p><p><!--Message$athena_hypertension_269237$*--><b>-   sinoatrial node dysfunction, no pacemaker, on diltiazem or verapamil</b>  <i>Recommendation</i> : %#Our records indicate this patient has sinoatrial node dysfunction, no pacemaker and a prescription for diltiazem or verapamil and is therefore at increased risk for heart block. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269239$*--><b>-   on amiodarone and diltiazem (or verapamil)</b>  <i>Recommendation</i> : %#Concurrent use of amiodarone and diltiazem or verapamil may result in excessive lowering of heart rate. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269243$*--><b>-   gout and thiazides</b>  <i>Recommendation</i> : %#Thiazides may increase uric acid levels and induce an acute gout attack. Evaluate clinically.#% </p><p><!--Message$athena_hypertension_269249$*--><b>-   low K and on thiazide primary msg</b>  <i>Primary_Recommendation</i> : %#Hypokalemia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_269253$*--><b>-   high uric acid, on thiazides</b>  <i>Recommendation</i> : %#This patient has a prescription for a thiazide diuretic, and the most recent uric acid is above normal limits.  We recommend that you check uric acid.#% </p><p><!--Message$athena_hypertension_269261$*--><b>-   assumption no dx hypertension</b>  <i>Assumption</i> : %#If this patient does not have hypertension, or if this patient already has a diagnosis of secondary hypertension on the problem list, please take a moment to tell us that, using the "comment" box at the bottom of the recommendations screen.  You can also send us an email, if you like, in DHCP (VA Palo Alto): Susana Martins (Susana.Martins@med.va). You can open DHCP to send email without closing your CPRS-GUI window.#% </p><p><!--Message$athena_hypertension_269263$*--><b>-   assumption exclusion </b>  <i>Assumption</i> : %#This program does NOT provide recommendations for patients with SECONDARY HYPERTENSION, NARCOLEPSY, ASCITES, SPINAL-CORD INJURY , or IDIOPATHIC HYPERTHROPHIC SUBAORTIC STENOSIS. If this patient has one or more of these diagnoses, please ADD it to the patient's PROBLEM LIST.#% </p><p><!--Message$athena_hypertension_269598$*--><b>-   ACE and high K (>5.5), on thiazides</b>  <i>Recommendation</i> : %#Patient's MOST RECENT K>5.5mEq/L. Recheck and follow K+ closely, consider decreasing dose of ACE inhibitor.#% </p><p><!--Message$athena_hypertension_272593$*--><b>-   Carvedilol+MI+BPH, no HF</b>  <i>Recommendation</i> : %#Patient has a diagnosis of myocardial infarction and benign prostatic hyperplasia and NO heart failure. Use of metoprolol (secondary prevention of myocardial infarction) and terazosin may provide more benefits than carvedilol. If patient has heart failure please update the problem list.#% </p><p><!--Message$athena_hypertension_272595$*--><b>-   Combination therapy</b>  <i>Recommendation</i> : %#There is not much information on combination therapy for hypertension. If BP is not controlled after 3 months at maximum tolerated dose we suggest substituting one or more drugs.#% </p><p><!--Message$athena_hypertension_295517$*--><b>-   DBP<60 on NO meds, REC add med</b>  <i>Primary_Recommendation</i> : %#Most recent DBP < 60. If confirmed 
with repeat BPs, evaluate benefit:risk of adding recommended drugs.#% </p><p><!--Message$athena_hypertension_29761$*--><b>-   disclaimer about procedure reports delete</b>  <i>Recommendation</i> : %#Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.#% </p><p><!--Message$athena_hypertension_29764$*--><b>-   disclaimer for EKG reports</b>  <i>Recommendation</i> : %#Diagnosis from EKG reports are not extracted. If patient has an arrythmia that is not included in the problem list please update it.#% </p><p><!--Message$athena_hypertension_29771$*--><b>-   assumption disclaimer about procedure reports</b>  <i>Assumption</i> : %#Diagnoses from procedure reports (EKG, X-ray, etc.) are not recognizable to ATHENA DSS.  ATHENA pulls diagnoses from the problem list and the list of diagnoses for each visit on the encounter forms.  The Patient Summary in ATHENA shows the diagnoses for this patient that are known to the program. If patient has a diagnosis that is not included in the Patient Summary, please update the problem list, or include the diagnosis on today's encounter form.#% </p><p><!--Message$athena_hypertension_308494$*--><b>-   labetolol substitution- primary message</b>  <i>Primary_Recommendation</i> : %#Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred#% </p><p><!--Message$athena_hypertension_31097$*--><b>-   Cr>2.0 and HCTZ dosing message</b>  <i>Recommendation</i> : %#While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.#% </p><p><!--Message$athena_hypertension_31112$*--><b>-   unspecified heart block, on BB</b>  <i>Recommendation</i> : %#This patient has a diagnosis of unspecified heart block. Second or third degree heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug. Update problem list.#% </p><p><!--Message$athena_hypertension_32502$*--><b>-   pregnancy and on ACE primary msg</b>  <i>Primary_Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for ACE inhibitors. Discontinue ACE inhibitor.#% </p><p><!--Message$athena_hypertension_32514$*--><b>-   PRECAUTION, ON HCTZ AND Na<=125 primary msg</b>  <i>Primary_Recommendation</i> : %#Hyponatremia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_325595$*--><b>-   On high dose hctz</b>  <i>Primary_Recommendation</i> : %#HCTZ DOSE ABOVE 25 mg DOES NOT ADD TO BP CONTROL for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_hypertension_331482$*--><b>-   3 drugs, increasing dose, no HCTZ</b>  <i>Recommendation</i> : %#In general, multidrug regimens should include a thiazide diuretic unless contraindicated. However, since that would add a 4th antihypertensive drug to this patient's regimen, we recommend consultation.#% </p><p><!--Message$athena_hypertension_33446$*--><b>-   ADR ACE inhibitor and ON ACE</b>  <i>Primary_Recommendation</i> : %#An ADVERSE DRUG EVENT has been listed for ACE inhibitor.  EVALUATE THE CLINICAL SIGNIFICANCE.#% </p><p><!--Message$athena_hypertension_37144$*--><b>-   ADE to ACE precaution msg</b>  <i>Recommendation</i> : %#An adverse drug event has been listed for ACE inhibitor.  Analyzing the significance of the adverse event is beyond the scope of this program.  Evaluate the clinical significance of the reported adverse event.#% </p><p><!--Message$athena_hypertension_37146$*--><b>-   unspecified heart block primary msg</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of unspecified heart block. Second or third degree heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers.#% </p><p><!--Message$athena_hypertension_37150$*--><b>-   pregnancy and on ACE precaution msg</b>  <i>Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for ACE inhibitors. Discontinue ACE inhibitor.#% </p><p><!--Message$athena_hypertension_37152$*--><b>-   PRECAUTION, ON HCTZ AND Na<=125 precaution msg</b>  <i>Recommendation</i> : %#Hyponatremia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_37154$*--><b>-   on BB presence of bronchospasm precaution msg</b>  <i>Recommendation</i> : %#Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist. Please monitor patient carefully if maintaining beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_37155$*--><b>-   presence gout complicated and on thiazides precaution msg</b>  <i>Recommendation</i> : %#Presence of tophaceous gout is a STRONG CONTRAINDICATION for use of thiazides. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_37156$*--><b>-   heart block without pacemaker, on beta blocker precaution msg</b>  <i>Recommendation</i> : %#Presence of heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_37157$*--><b>-   low K and on thiazide precaution msg</b>  <i>Recommendation</i> : %#Hypokalemia is a STRONG CONTRAINDICATION for use of thiazide diuretics. Discontinue use of thiazide diuretics.#% </p><p><!--Message$athena_hypertension_372688$*--><b>-   Ischemic Heart disease and DBP<60 and BP not at target</b>  <i>Primary_Recommendation</i> : %#Patient has a diagnosis of ischemic heart disease and the most recent DBP<60mmHg. Patient at high risk for cardiovascular events.#% </p><p><!--Message$athena_hypertension_375576$*--><b>-   add BB & dislipidemia</b>  <i>Recommendation</i> : %#Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.#% </p><p><!--Message$athena_hypertension_382799$*--><b>-   Home BP  for Target</b>  <i>Primary_Recommendation</i> : %#A HOME BP is used to determine if patient met BP TARGET (see assumptions for detailed description).#% </p><p><!--Message$athena_hypertension_394087$*--><b>-   Hyponatremia in the past, Rec add Thiazide</b>  <i>Primary_Recommendation</i> : %#Patient had SEVERE HYPONATREMIA in the past, monitor introduction of thiazide therapy closely.#% </p><p><!--Message$athena_hypertension_397722$*--><b>-   PM: Sinoatrial node dysfunction , no pacemaker on a BB</b>  <i>Primary_Recommendation</i> : %#Presence of Sinoatrial node dysfunction without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_406825$*--><b>-   Risk Group C and DM</b>  <i>Recommendation</i> : %#This patient has hypertension and diabetes (Risk Group C per JNC6) and should be considered for prompt and intensive pharmacologic therapy.  Aggressive lowering of blood pressure in people with diabetes and hypertension reduces cardiovascular morbidity and mortality, therefore recommended BP goal is less than 130/85.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_hypertension_407232$*--><b>-   assumption Disclaimer</b>  <i>Assumption</i> : %#Recommendations of the ATHENA DSS must be considered in the context of full information about the patient and the clinician-patient interaction.  The final responsibility for medical management rests with the prescribing/treating clinician (physician or nurse practitioner).  While we have made every effort to ensure that the recommendations generated by ATHENA DSS reflect the current evidence for management of hypertension, we cannot guarantee that the program will generate a recommendation for the best treatment in all cases.  Please use your clinical judgment in evaluating recommendations from ATHENA DSS.  If you see recommendations that you believe represent errors in the program, please call them to our attention.#% </p><p><!--Message$athena_hypertension_407235$*--><b>-   assumption Update BP</b>  <i>Assumption</i> : %#A BP entered into the ATHENA system today will not be entered into the patient's electronic medical record.  The program will use the BP to update the recommendations on the screen, but it will not write the BP to VistA, so the BP will not show up in   CPRS-GUI.  You can enter additional BP's into the patient's permanent medical record by clicking 'BP' in the Vitals box on the CPRS-GUI main screen.  Click 'Enter Vitals' in the top left of the screen, select the appropriate appointment location, and then enter the new blood pressure at the prompt.  Any BP you add to the patient's medical record today will be available to this program at the patient's next visit. The ATHENA system will have a write-back feature implemented in the near future that will allow you to write BP's you enter in ATHENA to CPRS.#% </p><p><!--Message$athena_hypertension_409238$*--><b>-   Ischemic heart disease and nitrates</b>  <i>Assumption</i> : %#Recommending nitrates for management of hypertension in patients with ischemic heart disease is beyond the scope of this program.#% </p><p><!--Message$athena_hypertension_40932$*--><b>-   primary msg Warning pregnancy female<50yrs</b>  <i>Primary_Recommendation</i> : %#RECOMMENDATIONS DO NOT APPLY TO PREGNANT WOMEN (or women likely to become pregnant or nursing mother).#% </p><p><!--Message$athena_hypertension_410347$*--><b>-   assumption about targets for home BP</b>  <i>Assumption</i> : %#Consensus of Expert Team (Mary Goldstein, Brian Hoffman, Gene Oddone, Paul, ... Cushman, David Simel,...) defined the following targets for home BP's: Absence of Diabetes or CKD: 135/85mmHg; Presence of Diabetes or CKD: 135/80mmHg and presence of proteinuria >1g/day: 125/75mmHg. If patient has multiple conditions ATHENA uses the lowest target.#% </p><p><!--Message$athena_hypertension_412235$*--><b>-   Assumption about eGFR</b>  <i>Assumption</i> : %#The eGFR is calculated based on the most recent serum creatinine.#% </p><p><!--Message$athena_hypertension_43300$*--><b>-   SBP>=220 or DBP>=115, etiology message</b>  <i>Primary_Recommendation</i> : %#Marked elevations of BP have many possible explanations, for example: non-adherence to therapy, inadequate diuretic treatment or renal dysfunction.#% </p><p><!--Message$athena_hypertension_43301$*--><b>-   SBP>=220 or DBP>=115, urgent attention</b>  <i>Primary_Recommendation</i> : %#SBP>220 or DBP>115 so treatment recommendations are beyond the scope of this program. If MARKED BP ELEVATION is confirmed, then the patient needs further TREATMENT and EARLY FOLLOW-UP to MONITOR THERAPEUTIC EFFICACY. #% </p><p><!--Message$athena_hypertension_44146$*--><b>-   Risk group C, no meds and high normal BP</b>  <i>Primary_Recommendation</i> : %#Some patients with HIGH NORMAL BP (per JNC6) and a diagnosis of renal insufficiency, heart failure or diabetes should be considered for PROMPT pharmacologic therapy.#% </p><p><!--Message$athena_hypertension_464777$*--><b>-   low Na and on thiazides precaution msg</b>  <i>Recommendation</i> : %#This patient has a prescription for a diuretic, and the most recent sodium is below normal limits.  We recommend that you recheck the sodium.#% </p><p><!--Message$athena_hypertension_467644$*--><b>-   minimum dose ACE and secondary prevention DM</b>  <i>Recommendation</i> : %#Clinical trials showing the efficacy of ACE-Inhibitors in patients with diabetes mellitus for secondary prevention have used minimum daily dosage equivalent to approximately 5-10 mg of lisinopril, so it is not known if lower doses are effective.  However, it is often prudent to start at a lower dosage and titrate upward slowly.#% </p><p><!--Message$athena_hypertension_468867$*--><b>-   assumption about prescriptions</b>  <i>Assumption</i> : %#If a prescription expires, it will not appear on the active medication list though the patient may still be taking the medication.  This will be reflected correctly in the prescription graph (see BP-Prescription Graphs tab).  #% </p><p><!--Message$athena_hypertension_484968$*--><b>-   primary: Cough as ADR to ACE, no angioedema, rec add ARB</b>  <i>Primary_Recommendation</i> : %#Patient has cough as an ADR to ACE and there is no record of angioedema, please exclude possibility of other serious adverse reactions before prescribing ARB.#% </p><p><!--Message$athena_hypertension_492203$*--><b>-   heart block without pacemaker, on beta blocker primary msg</b>  <i>Primary_Recommendation</i> : %#Presence of heart block without a pacemaker is a STRONG CONTRAINDICATION for use of beta adrenergic receptor blockers. Use caution if maintaining prescription of this drug.#% </p><p><!--Message$athena_hypertension_492207$*--><b>-   presence gout complicated and on thiazides</b>  <i>Primary_Recommendation</i> : %#Presence of tophaceous gout is a STRONG CONTRAINDICATION for use of thiazides. Use caution if maintaining prescription of this drug.
#% </p><p><!--Message$athena_hypertension_493229$*--><b>-   assumption: Medication calculations</b>  <i>Assumption</i> : %#Medication information used by ATHENA is based on the "fill date"  (or reflll or partial fill) from the VA pharmacy database.  the "fill date" indicates that the prescription was filled by the pharmacy, but it does not necessarily mean that the patient picked up the medication. We also use information from the pharmacy database about how many pills/tablets the patient picked up.  We use this information, together with the "days supplied" (to take account of tablet-splitting), in estimating how many days of coverage for the medication the patient has.#% </p><p><!--Message$athena_hypertension_504686$*--><b>-   Presence of phosphodiasterase-5 enzyme inhibitors  and alpha blocker</b>  <i>Primary_Recommendation</i> : %#Patient has an active prescription for an alpha blocker and a phosphodiasterase-5 enzyme inhibitors.  Increased risk of hypotension when taking both drugs.#% </p><p><!--Message$athena_hypertension_508280$*--><b>-   ATHENA HTN Disclaimer</b>  <i>Recommendation</i> : %#The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.#% </p><p><!--Message$athena_hypertension_508281$*--><b>-   Pointer to ATHENA HTN Disclaimer</b>  <i>Primary_Recommendation</i> : %#Please see the Precautions tab for the disclaimer on the ATHENA HTN demo system.#% </p><p><!--Message$athena_hypertension_510168$*--><b>-   Using 2 ACE's</b>  <i>Primary_Recommendation</i> : %#USING 2 ACE#% </p><p><!--Message$athena_hypertension_510604$*--><b>-   bronchospasm, rec increase BB</b>  <i>Recommendation</i> : %#Bronchospasm is a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist.#% </p><p><!--Message$athena_hypertension_522476$*--><b>-   LDL disclaimer</b>  <i>Assumption</i> : %#LDL laboratory values are coded differently at different medical centers. In some cases complete information may not be available to the ATHENA System. Clinican decision regarding LDL should be based on CPRS information.
#% </p><p><!--Message$athena_hypertension_524500$*--><b>-   creatinine>uln females</b>  <i>Recommendation</i> : %#Warning: creatinine value is greater than 1.3 mg/dL, upper limit of normal for females.#% </p><p><!--Message$athena_hypertension_69873$*--><b>-   primary ARB and pregnancy</b>  <i>Primary_Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for Angiotensin II Receptor Blocker (ARB). Discontinue ARB.#% </p><p><!--Message$athena_hypertension_69874$*--><b>-   precaution ARB and pregnancy</b>  <i>Recommendation</i> : %#Pregnancy is a STRONG CONTRAINDICATION for Angiotensin II Receptor Blocker (ARB). Discontinue ARB.#% </p><p><!--Message$athena_hypertension_81529$*--><b>-   primary message: on HCTZ; 3.0<K<3.5</b>  <i>Primary_Recommendation</i> : %#Most recent serum Potassium relatively low. Thiazides can contribute to hypokalemia.#% </p><p><!--Message$athena_hypertension_81530$*--><b>-   precautions: on HCTZ; 3.0<K<3.5</b>  <i>Recommendation</i> : %#Most recent serum Potassium relatively low. Thiazides can contribute to hypokalemia.#% </p><p><!--Message$athena_hypertension_81532$*--><b>-   USING HCTZ, K<3.5</b>  <i>Recommendation</i> : %#Low dose diuretics may unmask hyperaldosteronism, manifesting as hypokalemia.#% </p><p><!--Message$athena_hypertension_82821$*--><b>-   ALPHA BLOCKER MONOTHERAPY w BPH</b>  <i>Primary_Recommendation</i> : %#ALPHA BLOCKER MONOTHERAPY for hypertension is currently NOT recommended, consider adding a drug independent of blood pressure control.#% </p><p><!--Message$athena_hypertension_84361$*--><b>-   CCB and Angina collateral action message</b>  <i>Recommendation</i> : %#If indicated, the patient should be warned about the possibility of chest pain after discontinuing a calcium channel blocker. Some patients experience angina that is 'unmasked' when a calcium channel blocker is discontinued.#% </p><p><!--Message$athena_hypertension_INSTANCE_00056$*--><b>-   creatinine > uln warning males</b>  <i>Recommendation</i> : %#Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.#% </p><p><!--Message$athena_hypertension_INSTANCE_00062$*--><b>-   assumption no creatinine message</b>  <i>Assumption</i> : %#We use the most recent creatinine in the patient's record. If there is no creatinine listed, our recommendations are based on the assumption creatinine is within normal limits.#% </p><p><!--Message$athena_hypertension_INSTANCE_00063$*--><b>-   assumption no systolic or diastolic BP message</b>  <i>Assumption</i> : %#We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.#% </p><p><!--Message$athena_hypertension_INSTANCE_00130$*--><b>-   heart failure beta blocker message</b>  <i>Recommendation</i> : %#Beta blockers have a strong mortality benefit for persons with heart failure from LV dysfunction. Because the initiation and titration of beta blockers requires careful monitoring, consider referring patient to a special program for heart failure patients.#% </p><p><!--Message$athena_hypertension_INSTANCE_00537$*--><b>-   continue life style change w/o drug message</b>  <i>Primary_Recommendation</i> : %#Blood pressure appears to be adequately controlled based on the most recent available BP. Continue to follow patient and encourage healthy lifestyle.#% </p><p><!--Message$athena_hypertension_INSTANCE_00552$*--><b>-   check compliance</b>  <i>Recommendation</i> : %#Patient's blood pressure is not adequately controlled.  Check that the patient is taking the drugs that have been prescribed.#% </p><p><!--Message$athena_hypertension_INSTANCE_00600$*--><b>-   HCTZ dosing message</b>  <i>Recommendation</i> : %#HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.#% </p><p><!--Message$athena_runtime_14973$*--><b>-   Beta blocker secondary prevention</b>  <i>Recommendation</i> : %#Beta blockers may reduce the risk for subsequent MI and sudden cardiac death and should be considered for this patient.#% </p><p><!--Message$athena_runtime_15058$*--><b>-   CAD and CHF No beta blocker</b>  <i>Recommendation</i> : %#Beta blockers have not been recommended because their use in patients with CHF is outside the scope of this guideline.#% </p><p><!--Message$athena_runtime_15104$*--><b>-   Multiple dose increase</b>  <i>Recommendation</i> : %#When modifying the dosage of multiple drugs, doses should be carefully titrated one medication at a time to minimize the potential of dose related adverse events.#% </p><p><!--Message$athena_runtime_77285$*--><b>-   stepping down message</b>  <i>Primary_Recommendation</i> : %#Consider stopping antihypertensive medication.#% </p><p><!--Message$athena_runtime_77286$*--><b>-   substitution message</b>  <i>Primary_Recommendation</i> : %#Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.#% </p><p><!--Message$athena_runtime_INSTANCE_00019$*--><b>-   encourage smoking cessation</b>  <i>Recommendation</i> : %#If patient is still smoking, please encourage smoking cessation#% </p><p><!--Message$athena_runtime_INSTANCE_00051$*--><b>-   interim SBP goal</b>  <i>Recommendation</i> : %#For elderly patients with marked systolic hypertension (SBP>160), an interim goal of SBP below 160 mmHg may be necessary.#% </p><p><!--Message$athena_runtime_INSTANCE_00054$*--><b>-   risk group B message</b>  <i>Recommendation</i> : %#This patient has one or more risk factors for clinical cardiovascular disease (Risk Group B per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt and intensive pharmacologic therapy.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_runtime_INSTANCE_00074$*--><b>-   risk group C message, no DM</b>  <i>Recommendation</i> : %#This patient has clinically manifest cardiovascular disease or target organ damage (Risk Group C per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt pharmacologic therapy, even if the BP is in the high-normal range.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.#% </p><p><!--Message$athena_runtime_INSTANCE_00303$*--><b>-   betablocker dyslipidemia warning message</b>  <i>Recommendation</i> : %#Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.#% </p><p><!--Message$Lipid_dashboard_Class100010$*--><b>-   Pres hem stroke msg, risk/benefit of increasing dose</b>  <i>Primary_Recommendation</i> : %#Patient has history of hemorrhagic stroke but is not at goal..  Consider risk/benefit of increasing statin dose or intensity.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100011$*--><b>-   Increase dose to moderate intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has DM.  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.#% </p><p><!--Message$Lipid_dashboard_Class100012$*--><b>-   Increase dose to high intensity msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider increasing dose to high intensity dose.#% </p><p><!--Message$Lipid_dashboard_Class100013$*--><b>-   Substitute high intensity statin msg</b>  <i>Primary_Recommendation</i> : %#Patient has history of ASCVD.  Consider substituting high intensity atorvastatin or rosuvastatin in place of existing statin#% </p><p><!--Message$Lipid_dashboard_Class100014$*--><b>-   Intolerance to increase statin dose msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of statns, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>#% </p><p><!--Message$Lipid_dashboard_Class100015$*--><b>-   Refusal or intolerance to statin</b>  <i>Recommendation</i> : %#If patient refuses statins or cannot tolerate statins, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class100019$*--><b>-   Monitor liver function as appropriate</b>  <i>Recommendation</i> : %#Monitor liver function as appropriate.#% </p><p><!--Message$Lipid_dashboard_Class100031$*--><b>-   ADR to statin msg</b>  <i>Primary_Recommendation</i> : %#If patient has an ADR to a statin or cannot tolerate current dose, consider decreasing dose, substituting a different statin or stopping statin.  If stopping statin or if patient refuses to continue statins, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class110003$*--><b>-   Women ages 18-50:  pregnant women</b>  <i>Primary_Recommendation</i> : %#Pregnant women and nursing mothers are out of scope for this CDS.#% </p><p><!--Message$Lipid_dashboard_Class110008$*--><b>-   Treat hi TG mgs</b>  <i>Primary_Recommendation</i> : %#Triglycerides are >=500 mg/dL.  Evaluate and treat.#% </p><p><!--Message$Lipid_dashboard_Class110011$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Consider therapeutic life style changes <link to TLC>#% </p><p><!--Message$Lipid_dashboard_Class120001$*--><b>-   Order baseline CK?</b>  <i>Recommendation</i> : %#Baseline measurement of creatinine kinase (CK) is reasonable for those individuals believed to be at increased risk for adverse muscle events based upon personal or family history of statin intolerance or muscle disease or concomitant drug therapy that might increase the risk for myopathy.#% </p><p><!--Message$Lipid_dashboard_Class180005$*--><b>-   Goals achieved</b>  <i>Primary_Recommendation</i> : %#Patient is on moderate or high dose statin or LDL<100.  Goal achieved#% </p><p><!--Message$Lipid_dashboard_Class210027$*--><b>-   Contraindicated statin AND statin interacting drug</b>  <i>Recommendation</i> : %#Patient is on a statin that is contraindicated and is taking a <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>. that increases the rist of myopathy.   Please make a decision of which statin and what dose to prescribe or consult your local pharmacist <link to statin interacting drugs>#% </p><p><!--Message$Lipid_dashboard_Class210037$*--><b>-   No contraindication AND statin interacting drug</b>  <i>Recommendation</i> : %#Patient is on  a statin AND a<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>. that increases the rist of myopathy.   Please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class220010$*--><b>-   Statin at maximum dosage level</b>  <i>Recommendation</i> : %#Statin at maximum dosage level.  should not be here.#% </p><p><!--Message$Lipid_dashboard_Class220027$*--><b>-   ASCVD msg high intensity statins contraindicated</b>  <i>Recommendation</i> : %#High intensity statins contraindicated.  Recommended moderate intensity formulatry statins.#% </p><p><!--Message$Lipid_dashboard_Class230001$*--><b>-   No statin rec for add statin</b>  <i>Primary_Recommendation</i> : %#No statin can be recommended..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class240017$*--><b>-   Absence of DM and ASDVD out of scope msg</b>  <i>Primary_Recommendation</i> : %#Patient does not have DM or ASCVD and is out of scope of this CDS.#% </p><p><!--Message$Lipid_dashboard_Class240022$*--><b>-   > 1 statin cannot generate recommendations msg</b>  <i>Primary_Recommendation</i> : %#We are unable to generate recommendations because patient is taking more than 1 statin, which is generally not recommended.#% </p><p><!--Message$Lipid_dashboard_Class250010$*--><b>-   Follow up in 4-12 weeks</b>  <i>Recommendation</i> : %#Follow up in 4-12 weeks#% </p><p><!--Message$Lipid_dashboard_Class250011$*--><b>-   Cannot tolerate high dose formulary statin msg</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity formulary statin, consider non-formulary statin or moderate dose statin#% </p><p><!--Message$Lipid_dashboard_Class250023$*--><b>-   Rsik/benefit msg for frail, abnormal liver/renal, Asian</b>  <i>Primary_Recommendation</i> : %#Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian#% </p><p><!--Message$Lipid_dashboard_Class260003$*--><b>-   Msg Check adherence and response to therapy</b>  <i>Recommendation</i> : %#Check for patient medication adherence and response to therapy.#% </p><p><!--Message$Lipid_dashboard_Class260010$*--><b>-   Stop contraindicated statin</b>  <i>Primary_Recommendation</i> : %#Presence of contraindication to statin.  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class260011$*--><b>-   Prim msg:  statin DDI do not increase dose</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class270009$*--><b>-   Intolerance to increase high intensity statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate increasing dose of atrovastatin or rosuvastatin statns, consider  <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class280004$*--><b>-   Dose level high intensity statins</b>  <i>Recommendation</i> : %#High intensity statins are recommended for patients with ASCVD.  Thie means atorvastatin (formulary) 40-80/day mg or rosuvastatin (non-formulatry) 20 mg/day.#% </p><p><!--Message$Lipid_dashboard_Class280007$*--><b>-   Dose level moderate intensity statins</b>  <i>Recommendation</i> : %#Formulary moderate intensity statins are atorvastatin 10 mg/day; simvastatin 20-40 mg/day; pravastatin 40 mg/day; lovastatin 40 mg/day.  Non-formulary moderate intensity statins are  rosuvastatin 5 mg/day; fluvastatin 80 mg/day.#% </p><p><!--Message$Lipid_dashboard_Class300117$*--><b>-   Prim msg:  statin DDI pres of statin</b>  <i>Primary_Recommendation</i> : %#Presence of drug that interacts with statin. <a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>.  Consult your local pharmacy about continuing use of statin or increasing dose in the presence of an interacting drug.#% </p><p><!--Message$Lipid_dashboard_Class30038$*--><b>-   Dose level high intensity atorvastatin</b>  <i>Recommendation</i> : %#High dose for atorvastatin is  40 mg/day or greater#% </p><p><!--Message$Lipid_dashboard_Class30040$*--><b>-   Dose level high intensity rosuvastatin</b>  <i>Recommendation</i> : %#High dose rosuvastastin is 20 mg/day or greater#% </p><p><!--Message$Lipid_dashboard_Class30059$*--><b>-   Dose level moderate intensity atorvastatin</b>  <i>Recommendation</i> : %#Moderate dose for atorvastatin is >=20 mg/day but <40 mg/day#% </p><p><!--Message$Lipid_dashboard_Class330001$*--><b>-   Increase dose to moderate intensity ASCVD</b>  <i>Primary_Recommendation</i> : %#Patient has ASCVD and is over age 75..  Consider increasing dose of statin to moderate intensity. Moderate intensity daily dose:   atorvastatin 10 mg, rosuvastatin 5 mg; simvastatin 20-40 mg; pravastatin 40 mg; lovastatin 40 mg; fluvastatin 80 mg.  If patient cannot tolerate increaseing dose, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>..#% </p><p><!--Message$Lipid_dashboard_Class380000$*--><b>-   No incr dose statin msg</b>  <i>Recommendation</i> : %#We cannot recommend increasing intensity of statin.   Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class410212$*--><b>-   ASCVD Prim Msg to start high dose statin (not conditional)</b>  <i>Primary_Recommendation</i> : %#High intensity statins are recommended for patients with atherosclerotic cardiovascular disease.   Formulary high intensity statin is atorvastatin 40-80 mg.  Non-formulary high intensity statin is rosuvastatin 20 mg#% </p><p><!--Message$Lipid_dashboard_Class420000$*--><b>-   Statin rec DM patients if not 40<=age<=75</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75  (inclusinve) derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range.
Consider risk/benefit of higher dose statins for those who are frail, have abnormal renal or liver function, or who are Asian.#% </p><p><!--Message$Lipid_dashboard_Class430000$*--><b>-   Substitute high intensity statin for low dose statin</b>  <i>Recommendation</i> : %#If patient cannot tolerate high intensity statns (atorvastatin>=40mg, rosuvastatin>=20mg), consider increasing dose to moderate intensity (atorvastatin >=10mg, rosuvastatin >=5 mg, simvastatin >=20 mg, lovastatin >=40 mg, fluvastatin >=80 mg.)  or<a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class70046$*--><b>-   Patient on drug that interacts w statin</b>  <i>Primary_Recommendation</i> : %#Patient is on a 
<a href="http://@AUTOPMWEBSERVER@/Lipid/statinDDIdrugsU.pdf">  drug that interacts with statins </a>  that increases the risk of myopathy; please make a decision of which statin and what dose to prescribe or consult your local pharmacist.#% </p><p><!--Message$Lipid_dashboard_Class70047$*--><b>-   Patient refuses statin</b>  <i>Recommendation</i> : %#If patient refuses statin or cannot tolerate statin, consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class80030$*--><b>-   Statin rec DM patients if not 18<=Age<40</b>  <i>Primary_Recommendation</i> : %#Currently the VA Office of Analytics and Business Intelligencer ecommends DM patients, age> 18 to be on moderate dose statins.  According to the ACC/AHA guidelines (Nov 2013, Stone et al), DM patients ages 40 through 75 derive the maximum benefit from statins.  Please use clinical judgment for patients outside that age range..#% </p><p><!--Message$Lipid_dashboard_Class80044$*--><b>-   No statin recommended for Substitution msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking statin that is contraindicated AND we cannot find another statin that is not contraindicated..  Consider <a href="http://@AUTOPMWEBSERVER@/Lipid/Non_statin_drugs.pdf">  non-statin drugs </a>.#% </p><p><!--Message$Lipid_dashboard_Class90071$*--><b>-   test</b>  <i>Recommendation</i> : %#test#% </p>
 <b>Message: HTN Parameterized collateral messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: CKD Dashboard consultation on-screen messages</b>
 Message Type: Fixed Messsages
 Message: 
 <b>Message: CKD Parameterized Consultation Messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: CKD algorithm on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_CKD_Class100006$*--><b>-   PTH elevated, not normal Ca or phosphate or vitamin D labs</b>  <i>Primary_Recommendation</i> : %#PTH is elevated and Ca or phosphate or vitamin D labs are not within normal range.  Please assess.#% </p><p><!--Message$ATHENA_CKD_Class110001$*--><b>-   Msg to order vitamin D lab when PTH elevated</b>  <i>Recommendation</i> : %#PTH is elevated and vitamin D levels need to be assessed but lab is missing.  Please order vitamin D lab.#% </p><p><!--Message$ATHENA_CKD_Class170261$*--><b>-   ACR>300 refer</b>  <i>Primary_Recommendation</i> : %#ACR>300.  Please refer to nephrologist.#% </p><p><!--Message$ATHENA_CKD_Class40030$*--><b>-   Pres of ASCVD msg to consider antiplatelet</b>  <i>Recommendation</i> : %#Consider antiplatelet therapy for patients with CKD and atherosclerotic vascular disease.#% </p><p><!--Message$ATHENA_CKD_Class40032$*--><b>-   Pres JNC8 BP meds msg</b>  <i>Recommendation</i> : %#Patients with CKD and on BP medications need to be aware of the possiblity of postural hypotension/#% </p><p><!--Message$ATHENA_CKD_Class40034$*--><b>-   Age>75 warning msg</b>  <i>Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_CKD_Class60014$*--><b>-   ALERT:  Calcium outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Calcium level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60016$*--><b>-   ALERT:  Phosphate outside normal range</b>  <i>Primary_Recommendation</i> : %#ALERT:  Phosphate level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class60018$*--><b>-   ALERT: Alk Phos outside normal range</b>  <i>Recommendation</i> : %#ALERT: Alkaline Phosphatase level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class70011$*--><b>-   Msg to order HGB annually</b>  <i>Recommendation</i> : %#Patients with CKD and 30<=eGFR<60 are recommended to have their HGB checked annually.#% </p><p><!--Message$ATHENA_CKD_Class70012$*--><b>-   Msg to order HGB lab as clinically appropriate</b>  <i>Recommendation</i> : %#Missing HGB lab.  Order as clinically appropriate for CKD patients with eGFR>=60.#% </p><p><!--Message$ATHENA_CKD_Class70016$*--><b>-   Dx of anemia</b>  <i>Primary_Recommendation</i> : %#ALERT:  Patient has anemia:   HGB<13 (male) or HGB<12 (femiale).#% </p><p><!--Message$ATHENA_CKD_Class90000$*--><b>-   ALERT:  bicarb outside normal range</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate values (CO2) are outside the normal range#% </p><p><!--Message$ATHENA_CKD_Class90006$*--><b>-   ALERT:  PTH values outside normal range</b>  <i>Recommendation</i> : %#ALERT:  PTH  level is outside normal range.#% </p><p><!--Message$ATHENA_CKD_Class190355$*--><b>-   4+ BP meds refer msg</b>  <i>Recommendation</i> : %#Patient is on 4 or more BP medications and his/her blood pressure is greater than 140/90.   Please refer to nephrologist#% </p><p><!--Message$ATHENA_CKD_Class40028$*--><b>-   Msg to immunize for flu, pneumonia, hep B</b>  <i>Recommendation</i> : %#Consider immunizing patients againts the flu, pneumonia and hepatitis B.#% </p><p><!--Message$ATHENA_CKD_Class40029$*--><b>-   Msg for low salt diet</b>  <i>Recommendation</i> : %#Patients with CKD need to be on a low salt diet; <2 gm Na per day or <5gm NaCl per day.#% </p><p><!--Message$ATHENA_CKD_Class50017$*--><b>-   Low protein diet DM</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults with diabetes (2C).#% </p><p><!--Message$ATHENA_CKD_Class50018$*--><b>-   Low protein dient nonDM and eGFR<30</b>  <i>Recommendation</i> : %#We suggest lowering protein intake to 0.8 g/kg/day in adults without diabetes and GFR <30 (2B)#% </p><p><!--Message$ATHENA_CKD_Class50021$*--><b>-   Prim msg: ACR>=30 have target BP 130/80</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR>=30 have their blood pressure <130/80#% </p><p><!--Message$ATHENA_CKD_Class50024$*--><b>-   Prim msg: ACR<30 have target BP 140/90</b>  <i>Primary_Recommendation</i> : %#We suggest that CKD patients with ACR<30 have their blood pressure <140/90.#% </p><p><!--Message$ATHENA_CKD_Class50034$*--><b>-   Prim msg:  missing BP in past year</b>  <i>Primary_Recommendation</i> : %#Patient is missing BP measurement in past year.   For CKD patients with ACR>=30, BP target is 130/80.  For CKD patients with ACR<30, BP target is 140/90.#% </p>
 <b>Message: CKD Parameterized Algorithm Messages</b>
 Message Type: Parameterized Messages
 Message:  <p><!--Parameterized_Message$ATHENA_CKD_Class180009$*--><b>-   out of scope conditions</b>%#Patient has ?out_of_scope.  This condition is out of scope.  Please refer to a nephrologist.#%</p>    <p><!--Parameterized_Message$ATHENA_CKD_Class60036$*--><b>-   Missing CKD labs</b>%#CKD patients with eGFR<45 would normally have ?missingLab but this/these lab value(s) are missing.#%</p>   
 <b>Message: CKD collateral on-screen messages</b>
 Message Type: Fixed Messsages
 Message: 
 <b>Message: CKD Parameterized collateral messages</b>
 Message Type: Parameterized Messages
 Message: 
 <b>Message: Glycemic control algorithm on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_GlycemicControl_Class310002$*--><b>-   Msg to order HbA1c</b>  <i>Recommendation</i> : %#HbA1c is either missing or older than 1 year; CDS cannot give recommendations.  Please order HbA1c.#% </p><p><!--Message$ATHENA_GlycemicControl_Class540025$*--><b>-   Follow up in 3 months if rec add drug</b>  <i>Recommendation</i> : %#Follow up in 3 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class850006$*--><b>-   Presence of gemfibrozil and thiazolidinedione bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking gemfibrozil and thiazolidinedione, which are contraindciated.  Please evaluate#% </p><p><!--Message$ATHENA_GlycemicControl_Class850007$*--><b>-   Presence of SGLT2 inhibitor and UGT2 inducer bad drug partner msg</b>  <i>Primary_Recommendation</i> : %#Patient is taking an SGLT2 inhibitor (canaglifozin or empaflifozin) and a UDG2 inducer which are contraindciated.  Please evaluate.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210017$*--><b>-   HbA1c <= 9</b>  <i>Primary_Recommendation</i> : %#Latest HbA1c <=9, meets dashboard goal. CDS does not give recommendations for HbA1c values between 6 and 9 because target HbA1c goal not available.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210018$*--><b>-   Severe hyperglycemia message</b>  <i>Primary_Recommendation</i> : %#If patient has severe hyperglycemia or excessive symptoms, consider starting insulin and a referral to Diabetic Management Team.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210046$*--><b>-   dDM Type I out of scope message</b>  <i>Primary_Recommendation</i> : %#Recommendations for DM Type I is out of scope of this CDS#% </p><p><!--Message$ATHENA_GlycemicControl_Class240013$*--><b>-   dAlert lor HbA1c or Glycohem</b>  <i>Primary_Recommendation</i> : %#ALERT:  patient has low HbA1c or low GlycoHemoglobin, at high risk for cardiovascular event and hypoglycemia.#% </p><p><!--Message$ATHENA_GlycemicControl_Class240044$*--><b>-   Insulin only management out of scope</b>  <i>Primary_Recommendation</i> : %#Management of insulin is beyond scope of this system.#% </p><p><!--Message$ATHENA_GlycemicControl_Class470007$*--><b>-   on 3+ agents</b>  <i>Recommendation</i> : %#Patient HbA1c is >9 and is on 3 oral agents.  Please refer to endocrinologist and specialized DM care team.#% </p>
 <b>Message: Glycemic Control Parameterized Algorithm Messages</b>
 Message Type: Parameterized Messages
 Message:  <p><!--Parameterized_Message$library_Class160004$*--><b>-   Give warning when There exists medication whose daily dose is greater than the upper limit of maximum recommended dose range</b>%#The daily dose of medications ?meds is above the maximum recommended dose. Please review.#%</p>    <p><!--Parameterized_Message$ATHENA_GlycemicControl_Class850168$*--><b>-   Param msg for bad drug partners</b>%#Patient is on ?bad_drug_partners that are usually not prescribed together.#%</p>   
 <b>Message: Glycemic control consultation on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_GlycemicControl_Class150033$*--><b>-   On metformin check serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class290002$*--><b>-   Age>75 message</b>  <i>Primary_Recommendation</i> : %#Patient is over age 75; these patients need special attention in terms of drug dosing because of age relatec changes in pharmacodyniamics and phrmacokinetics.  Please use clinical judgement.#% </p><p><!--Message$ATHENA_GlycemicControl_Class300002$*--><b>-   Glyburide serum creatinine</b>  <i>Recommendation</i> : %#It is recommended that patients on Glyburide have a serum creatinine checked at least every 12 months#% </p><p><!--Message$ATHENA_GlycemicControl_Class360002$*--><b>-   Disclaimer HbA1c btwn 6 and 9</b>  <i>Primary_Recommendation</i> : %#This CDS does not issue recommendations when 6<=HbA1c<=9 
because patient target HbA1c not known.#% </p><p><!--Message$ATHENA_GlycemicControl_Class50002$*--><b>-   On Metformin check serum B12 level</b>  <i>Recommendation</i> : %#It is recommended that patients on Metformin have a serum B12 checked at least every 2 years.#% </p><p><!--Message$ATHENA_GlycemicControl_Class260039$*--><b>-   ALERT:  high creatinine or low eGFR</b>  <i>Primary_Recommendation</i> : %#ALERT:  high creatinine (>2.5 male or >2.4 female) or low eGFR (<30)#% </p><p><!--Message$ATHENA_GlycemicControl_Class260051$*--><b>-   ALERT: there exists active and not refilled medication</b>  <i>Primary_Recommendation</i> : %#Placeholder:  ALERT: there exists active and not refilled medication.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330001$*--><b>-   Recommendation for pregnant women out of scope</b>  <i>Primary_Recommendation</i> : %#Warning:  These recommendations do not apply to women who are pregnant.#% </p><p><!--Message$ATHENA_GlycemicControl_Class330022$*--><b>-   Liver Enzyme ALERT</b>  <i>Primary_Recommendation</i> : %#ALERT:  SGOT or SGPT greater than 3*Upper Limit of Normal#% </p><p><!--Message$ATHENA_GlycemicControl_Class350011$*--><b>-   Low bicarb alert</b>  <i>Recommendation</i> : %#ALERT:  bicarbonate levels are less than or equal to 21.#% </p><p><!--Message$ATHENA_GlycemicControl_Class480000$*--><b>-   Set target HbA1c</b>  <i>Recommendation</i> : %#Although the VA performance measure is to attain an HbA1c<9%, this is usually not the true target for an individual patient. The  <a href="http://@AUTOPMWEBSERVER@/DM/VA_GL_DiabetesMellitus_2010.pdf#page=49"> Table G1 from VA DM Guidelines </a> can be used as a reference to decide an individual patient’s target.#% </p><p><!--Message$ATHENA_GlycemicControl_Class510002$*--><b>-   Presence of DM-1 and DM-2 message</b>  <i>Primary_Recommendation</i> : %#Patient has diagnosis of both DM-1 and DM-2.  We have made recommendations ASSUMING that the patient has only DM-2.  If this is not the case, these recommendations are not appropriate#% </p><p><!--Message$ATHENA_GlycemicControl_Class620004$*--><b>-   Presence of drugs that affect blood glucse levels.</b>  <i>Primary_Recommendation</i> : %#Warning:  patient is taking either bromocriptine or colesevelam that has hypoglycemic properties#% </p><p><!--Message$ATHENA_GlycemicControl_Class660000$*--><b>-   Start Aspirin message</b>  <i>Primary_Recommendation</i> : %#Consider aspirin therapy.  Additional information available <a href="http://@AUTOPMWEBSERVER@/DM/AdditionalAspirinTherapyInfo.pdf"> here </a>.#% </p><p><!--Message$ATHENA_GlycemicControl_Class830001$*--><b>-   Gen msg all patients re ACE/ARB</b>  <i>Primary_Recommendation</i> : %#Consider ACE or ARB for renal protection if eGFR and K are within acceptable levels.#% </p>
 <b>Message: Glycemic Control Parameterized Consultation Messages</b>
 Message Type: Parameterized Messages
 Message:  <p><!--Parameterized_Message$ATHENA_GlycemicControl_Class380017$*--><b>-   drug mpr<0.9 message</b>%#Patient appears not to be adhering to ?drugName (MPR= ?mpr %). Confirm and evaluate clinical strategy.#%</p>   
 <b>Message: Glycemic Control collateral on-screen messages</b>
 Message Type: Fixed Messsages
 Message: <p><!--Message$ATHENA_GlycemicControl_Class350014$*--><b>-   ALERT:  eGFR<30</b>  <i>Primary_Recommendation</i> : %#ALERT:  Impared renal function exists; eGFR<30; consider when prescribing this drug#% </p><p><!--Message$ATHENA_GlycemicControl_Class500005$*--><b>-   Absence of eGFR and creatinine cannot add DM drug</b>  <i>Primary_Recommendation</i> : %#Consider addingrepaglinide.  Current eGFR and creatinine labs are older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Class60009$*--><b>-   add biguanide age >80</b>  <i>Recommendation</i> : %#For patients 80 years and over only add biguanides if they have normal creatinine clearance, and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class790000$*--><b>-   Conditional: Missing eGFR/creatinine, cannotadd metformin</b>  <i>Primary_Recommendation</i> : %#Consider adding Biguanide (metformin), after evaluating a more recent creatinine/eGFR lab.#% </p><p><!--Message$ATHENA_GlycemicControl_Class900001$*--><b>-   Conditional: Missing eGFR/creatinine, canno tadd glyburide</b>  <i>Recommendation</i> : %#Consider adding Glyburide..  Current eGFR/creatinine lab is older than 1 month.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120002$*--><b>-   Monitor creatinine level closely if age > 80</b>  <i>Recommendation</i> : %#Monitor creatinine level closely if age > 80 and the dose should not be escalated to the maximum in elderly patients due to increased susceptibility to lactic acidosis.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_120010$*--><b>-   Biguanide info general</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a 1.0 - 2.0%
•	The major blood glucose lowering effect is through decreasing hepatic glucose                           production with some decrease in peripheral insulin resistance 
•	May restore ovulation in premenopausal anovulatory females.
•	Monitor renal function prior to drug initiation and at least annually thereafter.
•	Inexpensive when using generic.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140144$*--><b>-   Sulfonylurea general info when prescribing</b>  <i>Recommendation</i> : %#•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive#% </p><p><!--Message$KB_308520_Class14$*--><b>-   Thiazolidinedions and ovulation warning message</b>  <i>Recommendation</i> : %#Thiazolidinediones may restore ovulation in premenopausal anovulatory females.#% </p><p><!--Message$KB_308520_Class6$*--><b>-   Warning for intravascular iodinated radiocontrast studies</b>  <i>Recommendation</i> : %#Temporarily discontinue metformin use at the time of or prior to intravascular iodinated radiocontrast studies and withhold for 48 hours after the procedure. Reinstitute only after renal function has been reevaluated and found to be normal.#% </p><p><!--Message$ATHENA_GlycemicControl_Class210049$*--><b>-   Consider if insulin refused</b>  <i>Recommendation</i> : %#Consider this alternative therapy if insulin is refused.#% </p><p><!--Message$ATHENA_GlycemicControl_Class220000$*--><b>-   Refer to Diabetes Management Team msg</b>  <i>Recommendation</i> : %#Refer to Diabetes Care Management Team#% </p><p><!--Message$ATHENA_GlycemicControl_Class220001$*--><b>-   Night-time use of insulin</b>  <i>Recommendation</i> : %#Preference for night-time use of insulin#% </p><p><!--Message$ATHENA_GlycemicControl_Class260046$*--><b>-   TLC</b>  <i>Recommendation</i> : %#Lifestyle changes to control of DM#% </p><p><!--Message$ATHENA_GlycemicControl_Class30003$*--><b>-   Add biguanide, alert hipoxemia, dehydration or sepsis</b>  <i>Recommendation</i> : %#Withhold metformin in the presence of any condition associated with hipoxemia, dehydration or sepsis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class40001$*--><b>-   Metformin and B12</b>  <i>Recommendation</i> : %#Check B12 levels every 2 years when a patient is using Metformin.#% </p><p><!--Message$ATHENA_GlycemicControl_Class600004$*--><b>-   blocked alpha glucosidase inhibitor</b>  <i>Primary_Recommendation</i> : %#We would normally recommend alpha-glucosidase inhibitor but are not able to do so because we are missing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600006$*--><b>-   blocked glp-1</b>  <i>Primary_Recommendation</i> : %#Consider adding GLP-1 agonist aftering evaluating miissing data (labs or vitals).#% </p><p><!--Message$ATHENA_GlycemicControl_Class600008$*--><b>-   blocked nateglinide</b>  <i>Primary_Recommendation</i> : %#Consider adding nateglinide.  Current SGOT and SGPT labs are older than 1 year.#% </p><p><!--Message$ATHENA_GlycemicControl_Class820001$*--><b>-   Canaglifzin and K levels msg</b>  <i>Recommendation</i> : %#Canaglifozin can lead to hyperkalemia.  Please monitor K levels.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90047$*--><b>-   Reasons to not use TZDs</b>  <i>Recommendation</i> : %#Thiazolidinediones are less effective in lowering HbA1C, have a higher cost, and are non formulary.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90048$*--><b>-   Warning about liver enzymes check in 1st year</b>  <i>Recommendation</i> : %#Check liver enzymes every 2-3 months during first year of thiazolidinedione therapy to evaluate for potential hepatitis.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90050$*--><b>-   Cons of starting insulin</b>  <i>Recommendation</i> : %#Staring insulin therapy requires closer monitoring by patient and clinician, has a higher risk of hypoglycemic events and requires injections.#% </p><p><!--Message$ATHENA_GlycemicControl_Class90057$*--><b>-   liver enzyme check</b>  <i>Recommendation</i> : %#Monitor serum levels of AST/ALT every 3 months during first year of therapy, specially if dose >50mg TID.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140151$*--><b>-   dose - rec add gliburide</b>  <i>Recommendation</i> : %#1.25 - 20mg given once daily or divided into 2 doses#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140152$*--><b>-   dose - rec add Glimepiride</b>  <i>Recommendation</i> : %#1-4 mg once daily#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140153$*--><b>-   dose - rec add glipizide</b>  <i>Recommendation</i> : %#2.5 - 40 mg given once daily or divided into 2 doses taken 30 minutes before a meal.  Doses > 15 mgs should be divided into 2 doses.#% </p><p><!--Message$ATHENA_GlycemicControl_Instance_140158$*--><b>-   dose - rec add metformin</b>  <i>Recommendation</i> : %#Starting dosage is either 500mg BID or 850mg q am:

If on 500mg BID, dosage increase may be made by 500mg increments weekly up to 1000mg BID

If on 850mg q am, dosage increase of 850mg may be made every other week (given as 850mg BID)

The usual maintenance dose is 850 mg BID with meals.

Maximum dose: 2550 mg/day (850mg TID); the dose response curve usually plateaus after 2000mg/day.

Take with food to avoid possible GI symptoms#% </p><p><!--Message$KB_308520_Class5$*--><b>-   Thiazolidinediones warning about liver lab values</b>  <i>Recommendation</i> : %#Liver function tests and bilirubin should be tested every 2 months for 1 year, then periodically therafter.  If ALT is >3x u.l.n., recheck another level as soon as possible.  If ALT remains >3x the upper limit, discontinue use.#% </p>
 <b>Message: Glycemic Control Parameterized collateral messages</b>
 Message Type: Parameterized Messages
 Message: 
</pre>
<br><br>